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We shall not cease from exploration 
And the end of all our exploring 
Will be to arrive where we started 
And know the place for the first time. 
T. S. Eliot, Little Gidding 
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Abstract 
The ocular lens is bathed by a cocktail of growth factors, such as fibroblast growth factor 
(FGF), bone morphogenetic protein (BMP), insulin-like growth factor (IGF), epidermal growth 
factor (EGF) and transforming growth factor-beta (TGFβ) that differentially influence cellular 
behaviour. While some growth factors such as FGF, BMP and EGF facilitate normal 
physiological lens processes, TGFβ is unique in that it is a potent inducer of lens cell pathology, 
namely, epithelial-mesenchymal transition (EMT) leading to fibrotic cataract formation. The 
studies in this thesis primarily explore the intracellular signalling pathways regulating TGFβ2-
induced EMT in the ocular lens using an established rat lens epithelial explant system. We first 
investigate the role of BMP-7 in antagonising TGFβ2-driven EMT through differential 
activation of the canonical Smad signalling pathway. We then explore the role of TGFβ-
signalling leading to the transactivation of EGF receptor (EGFR) signalling and show how 
EGFR-signalling forms an integrated network with ERK1/2/MAPK- and Smad-signalling. 
This led us to examine the role of EGF in augmenting the TGFβ-induced EMT response, 
through a shift in the activation profiles of TGFβ-induced EGFR-, ERK1/2/MAPK- and Smad-
signalling. We conclude by characterising a human anterior subcapsular cataract specimen, and 
applying a human lens epithelial explant system to translate some of the findings from the 
rodent model to human. By culturing the normally discarded anterior lens capsulorhexis 
material obtained during human cataract surgery, we showcase a human model for TGFβ-
induced EMT that presents with a striking morphological and biochemical resemblance to our 
established rodent model. By characterising the roles of downstream intracellular TGFβ-
signalling pathways and how they go on to form an integrated network, we endeavour to better 
understand lens EMT and thus develop effective pharmaceutical alternatives for cataract 
prevention. 
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Mounting tensions: stress fibres take shape 
During epithelial-mesenchymal transition (EMT), epithelial cells lose their 
polarity and transdifferentiate into motile and contractile mesenchymal cells. 
This process involves a re-organisation of the actin cytoskeleton into 
dynamic stress fibres enabling cells to transmit contractile forces. Here we 
see human lens epithelial cells that have undergone EMT following 
treatment with TGFβ. The cells exhibit strong immunoreactivity for the 
mesenchymal marker, α-smooth muscle actin (red), localising to stress fibre 
bundles and a concomitant translocation of the epithelial marker, β-catenin 
(green) from the membrane to the peri-nuclear region. The nucleus is stained 
with Hoechst (blue). Taken on a Zeiss LSM-5Pa confocal microscope.  
Finalist, Bosch Institute Advanced Microscopy Facility Micrograph of the 
Year (2017) Competition, The University of Sydney 
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Chapter One General Introduction1 
Eukaryotic cells are constantly bombarded by signals from the external environment. These 
signals can vary from exposure to extracellular molecules, to changes in temperature, pH or 
mechanical trauma. Regardless of the type of signal, cells have evolved a complex network of 
signalling pathways to respond accordingly. While there are signals that activate normal 
signalling pathways and promote normal cell biology, others induce pathological cell responses 
and activate aberrant signalling pathways leading to disease. 
This thesis narrows its focus to one cell type and one disease derived from these cells, namely 
lens epithelial cells (LECs) and fibrotic cataract. A cocktail of extracellular molecules called 
growth factors exist in the ocular media that bathes the ocular lens. Each growth factor induces 
differing effects on lens cell behaviour by activating a unique set of signalling molecules inside 
the cell. The aim of this project is to better understand how different growth factors, 
specifically, transforming growth factor-beta (TGFβ), bone morphogenetic protein (BMP) and 
epidermal growth factor (EGF) play distinct roles in modulating LEC behaviour in the context 
of cataract development. Through a series of experiments, we explore the downstream 
signalling pathways activated by these growth factors and unravel how these pathways 
crosstalk to form a complex and integrated network of cellular communication. 
1 The Ocular Lens 
1.1 Anatomy of the ocular lens 
The ocular lens (also known as the crystalline lens) is a transparent, biconvex structure that sits 
suspended inside the eye, just behind the iris. Much like the role of the lens of a camera, the 
ocular lens serves to focus light sharply onto the retina. The lens consists of two cell types: the 
LECs and lens fibre cells. Despite this apparent simplicity, the highly ordered architecture of 
these two cell types is established and maintained by a complex network of growth factors and 
signalling molecules. The LECs form an anterior monolayer and the elongated lens fibre cells 
comprise the bulk of the lens, all of which is encapsulated within a thickened basement 
membrane, the lens capsule (Lovicu and McAvoy, 2005). Since all the lens cells remain 
                                                     
1 This chapter contains text adapted from the review article: Shu DY, Lovicu FJ. Myofibroblast 
transdifferentiation: the dark force in ocular wound healing and fibrosis. Progress in Retina and Eye Research 
2017; 60: 44-65. 
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enclosed within the lens capsule, they are segregated from other ocular tissues and thought to 
be protected from external pathogens (Beyer et al., 1984). The mature lens has neither a blood 
supply nor a nerve supply and relies on the cells’ passive exchange of nutrients and removal of 
waste products from the aqueous humour anteriorly and the vitreous humour posteriorly 
(Friedenwald, 1930). 
 
Figure 1. Anatomy of the ocular lens 
 
The lens is the one of the few tissues in the body that continues to grow throughout life. New 
epithelial and fibre cells are continuously added as the older maturing lens fibre cells become 
more densely packed to the centre of the lens forming the lens nucleus. Since no fibre cells are 
lost, the lens holds a chronological record of its growth and development throughout life 
(Pierscionek et al., 2015). Given this set of characteristics, the lens serves as a unique model 
system for studying organ morphogenesis and cell differentiation (Reza and Yasuda, 2004). 
Indeed, it was through the study of lens development in 1901 by Hans Spemann where the 
concept of embryonic induction was first introduced (Spemann, 1901). Since Spemann’s 
classical studies, developmental biologists have continued to use the lens to elucidate the 
general molecular mechanisms underlying inductive interactions and cell specification, 
extending this knowledge to the patterning of other tissues and organs (Gunhaga, 2011). 
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1.2 Normal lens development 
Embryonic development involves a hierarchy of inductive interactions and progressive 
restriction of cell fate (Chang and Hemmati-Brivanlou, 1998). During gastrulation, three 
primary germ layers (ectoderm, mesoderm and endoderm) contain the progenitor cells that 
differentiate into all the adult tissues and organs (Solnica-Krezel and Sepich, 2012). The 
ectoderm is the most exterior layer and can be divided into the surface ectoderm and 
neuroectoderm. The ocular lens is derived from the surface ectoderm alongside other structures 
including the corneal epithelium, epidermis of the skin, hair, nails and tooth enamel, while the 
neuroectoderm gives rise to the nervous system including the retina, optic nerve and brain 
(Solnica-Krezel and Sepich, 2012). 
Lens development is morphologically first seen when the surface ectodermal cells overlying 
the developing optic vesicle are induced to thicken into the lens placode (Gunhaga, 2011). As 
the optic vesicle folds inward to form the optic cup, the lens placode invaginates towards the 
prospective optic cup to form the lens pit that subsequently deepens until it pinches off from 
the surface ectoderm (the prospective cornea) to form a hollow, inverted lens vesicle (Ogino 
and Yasuda, 2000). 
The cells lining the posterior wall of the lens vesicle elongate and differentiate into primary 
lens fibres to fill the vesicle lumen (Ogino and Yasuda, 2000). Cells at the anterior side of the 
lens vesicle form a monolayer of LECs. A distinctive polarity is thus established in the lens. 
Postnatally, proliferation and differentiation of LECs into secondary lens fibres is confined to 
a region known as the “germinative zone” located just anterior to the equator (Ogino and 
Yasuda, 2000). The secondary lens fibre cells span the centre of the anterior face of the lens to 
the centre of the posterior face and as such, appear crescent shaped (Augusteyn, 2010). The 
process of lens fibre differentiation continues throughout life, forming an ever-expanding 
cortex surrounding a dense central nucleus of mature primary fibres (Boswell et al., 2008). 
Pairs of fibres abut and overlap each other to form “sutures” at both the anterior and posterior 
ends (Kuszak et al., 1984). 
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Figure 2. Ocular lens development 
 
Despite the dense packing of cells, the lens remains exquisitely transparent. This is attributable, 
in part, to the programmed degradation of all intracellular membrane-bound organelles within 
the lens fibre cells (Bassnett and Mataic, 1997). Light scatter is also minimised by the close 
apposition of lens fibre cells by specific gap junctions and adhesive proteins (Bassnett et al., 
2011). Furthermore, the remarkably high concentration of crystallin proteins in the cytoplasm 
of lens fibre cells ensures lens transparency (Delaye and Tardieu, 1983). 
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1.3 Lens pathology: cataract development 
Cataract is the pathological state of the lens, characterised by reduced transparency and is the 
leading cause of reversible blindness and visual impairment worldwide (Foster and Resnikoff, 
2005). While there are many types of cataract based on age-of-onset, aetiology and location 
(Table 1), this thesis is focused on understanding the pathogenesis of fibrotic forms of cataract 
such as anterior subscapular cataract (ASC). Another fibrotic lens event is a post-operative 
complication known as posterior capsular opacification (PCO) that follows many cataract 
surgeries. 
Anterior subcapsular cataract, a characteristically dense, white opacity directly beneath the 
anterior lens capsule, is often associated with atopic dermatitis, uveitis, and mechanical or 
chemical ocular trauma (Marcantonio et al., 2003). The prevalence of anterior subcapsular 
cataract is relatively uncommon in Europe and North America at 2-3% of cataract (Marcantonio 
et al., 2003) compared to 4.8% in Asian countries (Johar et al., 2007; Kim and Joo, 2008). 
Unlike more common forms of cataract such as nuclear or cortical, ASC appears to be more 
prevalent in younger populations; 74% of patients with anterior subcapsular cataract are 
younger than 60 years of age with an average age at diagnosis of 51.9 years (Kim and Joo, 
2008). 
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Figure 3. Schematic of an anterior subcapsular cataract with the plaque highlighted in green. 
 
Table 1. Classification of cataract. 
Cataract types based on age-of-onset and aetiology 
Childhood Congenital (present at birth) 
Juvenile (develops after birth) 
Typically caused by genetic disorders, intrauterine infections, 
malnutrition 
Age-related cataract Most common 
Typically develops after 50 years of age 
Nuclear or cortical 
Secondary cataract Following ocular injury 
Caused by other ocular diseases (e.g. glaucoma) 
Caused by use of certain drugs (e.g. corticosteroids) 
Caused by radiation exposure (e.g. following cancer therapy) 
Associated with systemic conditions (diabetes mellitus) 
Cataract types based on morphology 
Nuclear Typically presents as a yellow-brown opacity in the lens 
nucleus 
Cortical Wedge-shaped opacities that form around the edge of the 
lens nucleus 
Subcapsular Opacity that forms beneath the lens capsule, often along the 
visual axis 
Can be anterior or posterior 
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1.4 Cataract surgery and its complications 
Currently, the only means of treatment for cataract is through surgery. Modern cataract surgery 
involves a small self-sealing, suture-less corneal incision followed by removal of the anterior 
lens capsule by continuous curvilinear capsulorhexis (Allen and Vasavada, 2006). The 
cataractous lens fibre mass is then removed by phacoemulsification whereby the lens content 
is emulsified using an ultrasonic probe and simultaneously aspirated from the eye. This process 
generates a capsular bag comprising the equatorial portion of the anterior capsule and the entire 
posterior capsule. A foldable intraocular lens (IOL) is typically inserted into the capsular bag 
to correct refractive error (Allen and Vasavada, 2006). 
Modern cataract surgery is a safe and successful procedure in over 95% of patients with no 
ocular co-pathologies, and 91% of patients achieve a post-operative visual acuity of 6/12 or 
better (Jaycock et al., 2009); however, as with all surgical procedures, there is the risk of 
complications (Chan et al., 2010). Intraoperative complications include posterior capsule 
rupture, vitreous loss, corneal oedema, zonular dehiscence and supra-choroidal haemorrhage. 
Acute post-operative complications such as endophthalmitis present within one month. At 
three months and beyond, post-operative complications include retinal detachment, cystoid 
macular oedema (CMO), dislocated IOL and posterior capsular opacification (PCO) (Chan et 
al., 2010). 
PCO, aptly referred to as “secondary cataract” or “after cataract”, is the most common post-
operative complication affecting 5-50% of adult patients within 5 years of cataract surgery and 
100% of paediatric patients within 2 years (Linebarger et al., 1999; Maltzman et al., 1989). 
Patients younger than 40 years have a higher prevalence of PCO (70%) compared to those 
older than 40 years (37%) (Moisseiev et al., 1989). PCO occurs when the remnant lens cells 
proliferate and migrate centrally to form an opaque plaque on the posterior capsule, thereby 
reducing vision (Wormstone et al., 2009).  
There are two types of PCO: fibrous and pearl (McDonnell et al., 1983). A combination of 
these two morphologic forms can also occur. Fibrous PCO occurs when the anterior LECs 
undergo epithelial-mesenchymal transition (EMT) and presents clinically as a fibrous plaque 
and wrinkling of the capsular bag. The pearl-type PCO occurs when equatorial LECs are 
induced to migrate and differentiate into lens fibre cells and presents clinically as clusters of 
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large, round epithelial cells or “pearls” on the posterior capsule. The remnant LECs can also 
be trapped at the lens equator and as they undergo lens fibre differentiation, a ring of cortical 
fibres is formed, known as Soemmering’s ring (Kappelhof et al., 1987). Treatment for PCO is 
by laser capsulotomy and involves using a neodymium:yttrium-aluminium-garnet (Nd:YAG) 
laser to create a central opening in the opacified posterior capsule, thus clearing the visual axis 
(Ficker and Steele, 1985). 
 
Figure 4. Schematic of posterior capsular opacification (depicted in green) following cataract 
surgery with intraocular lens implantation. 
 
Several surgical approaches have been taken to reduce or delay the incidence of PCO (Nibourg 
et al., 2015). Careful and thorough removal of cortical lens cell remnants during 
phacoemulsification and fixation of the IOL in the capsular bag reduce PCO formation (Ram 
et al., 2001). A slightly smaller diameter capsulorhexis compared to the IOL optic is reported 
to be more effective than a larger capsulorhexis (Ravalico et al., 1996). IOL material and design 
are contributing factors in minimising PCO. Sharp-edge optics using an angulated haptic IOL 
design creates a mechanical barrier against migrating LECs (Nishi and Nishi, 1999). The 
benefit of a square-edge design was further highlighted in a 9-year-long prospective, 
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randomized clinical trial showing that squared optic edge polymethyl methacrylate (PMMA) 
IOLs were more effective in reducing PCO compared to the typical round edge design 
(Haripriya et al., 2017). Koshy et al., (2018) showed no difference in superiority between 
AcrySof and the hydrophilic intraocular lens Superflex over a two-year study. In contrast, in a 
three-year study, Ursell et al., (2018) showed that PCO rates were significantly lower for 
acrylic AcrySof IOLs compared to other hydrophobic and hydrophilic acrylic monofocal IOLs 
including Superflex. The superiority of the AcrySof IOL was further demonstrated in a 
retrospective analysis of patients showing that the hydrophilic SeeLens IOL required laser 
capsulotomy to treat PCO significantly sooner than patients with the hydrophobic AcrySof IOL 
(Sharon et al., 2017). Evidently, there are several studies investigating different materials and 
IOL lens designs on patients; however, there are currently no approved pharmacological 
therapies to prevent, delay or treat PCO. 
1.5 Significance of the research 
The volume of cataract surgery has increased dramatically over the past few decades. Over 10 
years, it increased fourfold in both the United Sates and Denmark since the 1980s and threefold 
in the United Kingdom and Australia (Keeffe and Taylor, 1996; Nørregaard et al., 1996; Stark 
et al., 1989; Williams and Seward, 1993). Cataract surgery comprises over half of all 
ophthalmic surgeries and has become the most common elective surgical procedure in the 
world (Taylor, 2000). The annual global treatment cost of cataract is estimated to be US$573 
million (Armstrong et al., 2012; Foreman et al., 2017). In 2001, an estimated 1.7 million 
Australians had clinically significant cataract in either eye and 320 000 underwent cataract 
surgery (Rochtchina et al., 2003). Given the ageing population in Australia, the prevalence of 
cataract is expected to rise sharply to 2.7 million by 2021 with over 500 000 requiring cataract 
surgery (Rochtchina et al., 2003). Given that the number of Australians with cataract will grow 
by two-thirds in the next 20 years, it is important that our health care delivery systems develop 
better methods to handle the expected increased demand for treatment. 
While cataract surgery carries a significant financial burden, this is not the end of the cost. 
Treatment for PCO currently costs $250 million per year in the United States (Steinberg et al., 
1993). While this statistic is outdated and specific to the United States, it still highlights the 
immense economic burden of secondary cataract and warrants more epidemiological studies 
in the current health cost of PCO as well as a comparison of the costs in different countries. 
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Laser capsulotomy is a simple, quick and effective treatment for PCO; however, there are still 
complications including damage to the IOL, cystoid macular oedema, retinal detachment, 
increased intraocular pressure, iris haemorrhage, corneal oedema, IOL subluxation and 
exacerbation of localised endophthalmitis (Apple et al., 1992). In addition to the substantial 
medical costs, both cataract surgery and laser capsulotomy place a significant physical, social 
and emotional burden on patients, families and caregivers. 
Thus, there is growing interest in improving the success of cataract surgery by finding 
alternative pharmacological therapies for eradicating PCO. This thesis addresses unanswered 
questions regarding the cellular and molecular mechanisms underlying the pathogenesis of 
PCO-like cellular changes, with the aim of discovering novel drug targets to prevent the 
development of PCO. There is currently an intense focus of research on the role of transforming 
growth factor-beta (TGFβ) in inducing EMT in LECs, leading to PCO and ASC. The goal of 
this current project is to explore how other growth factors found in the ocular media, including 
BMP-7 and EGF, impact on TGFβ-induced EMT and, in doing so, unravel the complex 
network of signalling pathways downstream of TGFβ. This thesis provides fundamental 
insights into the fibrotic EMT response in cataract formation and will inform the design of 
therapies to combat ASC, as well as PCO, potentially enabling improved visual outcomes 
following cataract surgery. 
2 Growth factors and the ocular lens 
2.1 A historical perspective 
The lens is bathed in ocular media that influences its cellular behaviour. This was first 
demonstrated by the classical lens inversion experiments of Coulombre and Coulombre in the 
1960s (Coulombre and Coulombre, 1963). For example, in one of their classic experiments, 
these researchers disturbed the normal ocular environment of the lens by turning the lens of an 
embryonic chick 180 degrees, so that its lens epithelium faced the vitreous and presumptive 
retina, instead of the developing aqueous and cornea. In this new orientation, after 5 days, the 
LECs elongated and differentiated into a new mass of lens fibre cells, and a new epithelial 
monolayer formed on the anterior surface of the original lens fibres now facing the cornea. A 
similar response was observed when a 6-day-old mouse lens was implanted in an inverted 
configuration after 2 months (Yamamoto, 1976). 
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Pioneering work using rat LEC explants showed that fibroblast growth factor (FGF) induced a 
differential response in LECs depending on its concentration (McAvoy and Chamberlain, 
1989). Exposure to a low dose of FGF induced LECs to proliferate. As the concentration of 
FGF increased, cells acquired the ability to migrate and at even higher concentrations, these 
cells were shown to elongate and accumulate β-crystallin, a key marker of lens fibre cell 
differentiation. This discovery, coupled with the finding that FGF was found in lower 
concentrations in the aqueous humour compared to higher concentrations in the vitreous 
humour, lead to the theory that lens cell proliferation and fibre differentiation were regulated 
by an ocular “FGF gradient” in vivo. This theory was later validated by culturing rat LEC 
explants in aqueous or vitreous medium (Lovicu et al., 1995), and by altering the FGF gradient 
in the eye using a transgenic approach (Lovicu and Overbeek, 1998). While vitreous induced 
elongation of LECs, aqueous did not, highlighting that the factors responsible for lens fibre cell 
differentiation were present in the vitreous humour. Fractionation of the vitreous showed that 
the majority of its fibre-differentiating ability was due to FGFs (Schulz et al., 1993). Inhibition 
of FGF receptor signalling using SU5402 effectively blocked vitreous-induced lens fibre 
differentiation (Wang et al., 2010); however, the addition of FGF-1 or FGF-2 neutralising 
antibodies did not completely block the fibre-differentiating ability of the vitreous, suggesting 
that while FGF plays a key role, other growth factors may also be involved (Schulz et al., 
1993). 
These experiments demonstrated that the lens is highly sensitive to the growth factors present 
in the ocular environment. Research has since been dedicated to understanding how different 
growth factors influence lens cell behaviour and this has extended to exploring lens pathology, 
namely ASC and PCO. This growing interest, coupled with our growing understanding of 
growth factors and their respective signalling pathways in other systems, has inspired the 
following series of experiments exploring the roles of TGFβ, BMP-7 and EGF, and their 
downstream signalling pathways in the pathogenesis of fibrotic cataract. 
2.2 Growth factors and their signalling pathways 
Growth factors are proteins that regulate many aspects of cellular function, including 
proliferation, migration, differentiation and survival (Sicard, 1986). Like hormones, growth 
factors bind to and activate specific, high-affinity receptor proteins on the cell surface, inducing 
a cascade of intracellular signalling pathways. Unlike hormones that are produced specifically 
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by endocrine tissues and exert their effects on remote cells, growth factors are synthesised and 
secreted by virtually all cells in our body and can act on both local and remote targets 
(Carpenter and Cohen, 1990). 
A plethora of growth factors regulate lens cell behaviour. These include FGF (Le and Musil, 
2001; McAvoy and Chamberlain, 1989), EGF (Iyengar et al., 2009), BMP (Belecky-Adams et 
al., 2002; B. A. Boswell et al., 2008; Faber et al., 2002), platelet-derived growth factor (PDGF) 
(Kok et al., 2002), insulin-like growth factor (IGF) (Klok et al., 1998), hepatocyte growth factor 
(HGF) (Choi et al., 2004; Wormstone et al., 2000), transforming growth factor-alpha (TGFα) 
(Wickström and Madsen, 1993), TGFβ (Boswell et al., 2017; de Iongh et al., 2001; Liu et al., 
1994; Saika, 2002; Wormstone et al., 2002), ephrin (Cheng and Gong, 2011), vascular 
endothelial growth factor (VEGF) (Saint-Geniez et al., 2009) and Wnts (Chen et al., 2006). 
While TGFβ is a potent inducer of EMT in LECs, BMP and EGF are important for normal lens 
cellular processes such as proliferation and differentiation. The following sections will detail 
the specific roles of these growth factors in the lens with an emphasis on the extensive literature 
exploring TGFβ-induced EMT in fibrotic cataract. 
2.3 Transforming growth factor-beta (TGFβ) 
TGF belongs to a large family of structurally related cytokines known as the TGF 
superfamily (Nawshad et al., 2005). In vertebrates, this family consists of over 30 ligand 
proteins, including activins, nodal, anti-Müllerian hormone (AMH, also known as Müllerian 
inhibiting substance or MIS), growth and differentiation factors (GDFs) and bone 
morphogenetic proteins (BMPs) (Miyazawa et al., 2002). Members of the TGF superfamily 
consist of a dimer linked by a disulphide bridge. Each monomer comprises several -sheet 
strands and six conserved cysteine residues interlocked by disulphide bonds giving rise to a 
tight structure known as the “cysteine knot” (Kingsley, 1994; Shi and Massagué, 2003; Sun 
and Davies, 1995). This knot provides considerable stability and resistance to heat, denaturants 
and extremes of pH (Kingsley, 1994; Sun and Davies, 1995). Members of the TGF 
superfamily have pleiotropic functions in the regulation of fundamental cell processes 
including proliferation, differentiation, apoptosis and EMT (Miyazawa et al., 2002; Zhu and 
Burgess, 2001). 
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Among all the superfamily members, TGF has been studied most thoroughly. TGF is 
synthesised and secreted as a biologically inactive precursor protein consisting of a large 
amino-terminal pro-domain known as the latency-associated peptide (LAP) and a mature 
TGF protein at the carboxy-terminal region (Massague and Chen, 2000; Weiss and Attisano, 
2013). The LAP and mature TGF are linked by a single disulphide bond and associate 
noncovalently to form a complex called the small latent complex (SLC). The LAP is usually 
disulphide-bound to a high molecular weight protein known as latent TGF-binding protein 
(LTBP) and this trimolecular aggregate is called the large latent complex (LLC) and retains 
TGF in an inactive form (de Iongh et al., 2005; Rifkin, 2005). LTBPs are not required for the 
maintenance of the latency of TGF but may instead facilitate the secretion and storage of the 
LLC by anchoring the latent TGF within the extracellular matrix (ECM) (Fleisch et al., 2006; 
Lebrun, 2012; Massague and Chen, 2000). Activation of the TGF precursor is essential for 
the regulation of its functions in vivo and is controlled by multiple mechanisms including 
proteolytic enzymatic activity and heated or acidic environments (de Iongh et al., 2005; Lebrun, 
2012). Biologically active TGF, a 25-kDa dimer, is liberated from the LLC by cleavage of 
the LAP (Annes, 2003; Sun and Davies, 1995). 
Members of the TGFβ superfamily bind to two types of serine/threonine kinase receptors (type 
I and type II receptors) (Miyazono et al., 2010). Both type I and type II TGFβ receptors share 
similar structural properties, comprised of a short extracellular domain that contains 10-12 
cysteine residues, a transmembrane domain and a cytosolic serine/threonine kinase domain 
(Bragdon et al., 2011). The intracellular domains of type I receptors, but not type II receptors, 
have a characteristic glycine and serine-rich domain (GS domain) located on the N-terminal 
side of the serine/threonine kinase domains (Miyazono et al., 2010). Both types of receptors 
are required to form a functional complex to propagate downstream signalling events 
(Wordinger and Clark, 2007). Once activated, the TGFβ ligand binds to the extracellular 
domain of the type II TGFβ receptor (TβRII), an autophosphorylated serine/threonine kinase 
receptor (Shi and Massagué, 2003). The activated TβRII transphosphorylates and activates the 
serine and threonine residues in the intracellular glycine-serine rich domain of the type I TGFβ 
receptor (TβRI) (Lebrun, 2012). 
Five isoforms of TGF have been isolated to date from different species and share 64-82% 
homology (Roberts and Sporn, 1992; Sun and Davies, 1995). Of these isoforms, TGF-1, -2 
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and -3 have been identified in mammalian species (Roberts and Sporn, 1992). These three 
isoforms are abundant in the ocular media and the lens itself expresses TGF1 and TGF2 
(Cousins et al., 1991; Gordon-Thomson et al., 1998). TGF2 has been widely used in lens 
research as it is 10 times more potent compared to TGF1 (Gordon-Thomson et al., 1998). 
2.3.1 TGFβ induces epithelial-mesenchymal transition (EMT) 
TGF is a potent inducer of epithelial-mesenchymal transition (EMT). During EMT, polarised 
epithelial cells undergo several morphologic and molecular changes to give rise to motile, 
extracellular matrix-producing mesenchymal cells (Kalluri and Weinberg, 2009). The process 
of EMT occurs in three distinct biological settings, namely types 1, 2 and 3, with different 
functional consequences. EMT that is activated during implantation, embryogenesis and tissue 
morphogenesis constitutes the type I EMT. Type 2 EMT is normally activated during tissue 
regeneration, wound healing and repair, but can be abnormally activated during organ fibrosis 
due to dysregulated inflammatory responses (Taylor et al., 2010). In the context of organ 
fibrosis, type 2 EMT can continue to respond to unabated inflammation, ultimately leading to 
organ destruction (Kalluri, 2009). Lastly, type 3 EMT is activated by cancer cells during 
metastasis (Kalluri and Weinberg, 2009). TGFβ-induced EMT of LECs in fibrotic cataract falls 
under the type 2 EMT category as it involves the transition of epithelial cells into fibrogenic 
myofibroblasts. (Zeisberg and Neilson, 2009). 
EMT is characterised by a cascade of genetic and epigenetic events that culminate in epithelial 
cells relinquishing their regular cuboidal morphology and transdifferentiating into spindle-
shaped myofibroblasts (Taylor et al., 2010). Myofibroblasts possess similar ultrastructural and 
physiological characteristics to smooth muscle cells (Darby et al., 2014). The prominent 
microfilament bundles of myofibroblasts form stress fibres that permit contraction of the cell 
and hence, remodelling of the adjacent ECM (Darby et al., 2014). One key feature of the 
myofibroblast is neo-expression of alpha-smooth muscle actin (α-SMA), the actin isoform 
typically seen in vascular smooth muscle cells (Darby et al., 1990). Incorporation of α-SMA 
into the cellular stress fibres augments the contractile activity of myofibroblasts and represents 
a key marker of the myofibroblastic phenotype (Hinz et al., 2001). Tropomyosin, a protein 
integral to the actin cytoskeleton, precedes the upregulation of α-SMA and facilitates the stable 
incorporation of α-SMA into stress fibres (Prunotto et al., 2015). The actin bundles that 
comprise the stress fibres terminate at the surface of the myofibroblast and form specialised 
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cell-matrix junctions known as “fibronexus junctions” in vivo (Dugina et al., 2001), and “large 
mature focal adhesions” in vitro (Hinz et al., 2003). This creates a mechano-transduction 
system that enables the force generated by stress fibres to be transmitted to the surrounding 
ECM. Moreover, this mechano-transduction system also enables extracellular mechanical 
signals to be transduced into intracellular signalling (Geiger and Bershadsky, 2001). 
The expression of -SMA is regulated by the combined activity of growth factors/cytokines 
such as TGFβ, specialised ECM proteins such as fibronectin, and the surrounding mechanical 
microenvironment (Darby et al., 2014). Under normal physiological conditions, the 
maintenance and turnover of ECM molecules is tightly regulated to maintain a dynamic 
balance between ECM synthesis and degradation. During EMT, myofibroblasts synthesise and 
secrete copious amounts of ECM proteins including collagens type I, III, IV and V, fibronectin 
and tenascin-C, to facilitate tissue remodelling (Zhang et al., 1994). These extraneous ECM 
deposits alter the composition, organisation and mechanical properties of the existing ECM, 
hence distorting normal tissue structure and function (Hinz and Gabbiani, 2003). The force 
generated by the myofibroblast is stabilised by the accumulation of newly synthesised ECM 
molecules (Tomasek et al., 2002). Active ECM remodelling and deposition of excess ECM 
results in matrix stiffening, thereby increasing global cellular stress, and facilitating the 
induction of stress fibres critical for enabling myofibroblast contractility (Tomasek et al., 
2002). Myofibroblasts themselves can release latent TGFβ complexed with LAP that bind to 
ECM proteins, forming a sustained reservoir of TGFβ (Darby et al., 2014). Hence, increased 
mechanical stress and contraction can induce further release of TGFβ, resulting in greater 
myofibroblastic activity. Under normal physiological conditions, myofibroblasts disappear by 
apoptosis with wound healing; however, in pathological conditions, myofibroblast activity can 
persist, leading to chronic contractile activity and subsequent tissue contracture and 
hypertrophic scarring (Darby et al., 2014). 
In undertaking this phenotypic and morphologic transformation in the myofibroblast, there is 
an associated upregulation of mesenchymal markers with the downregulation of epithelial 
markers. Epithelial cells first experience a loss of tight junctional complexes including zonular 
occludins (ZO)-1, followed by the loss of E-cadherin expression at the cell membrane. This 
results in the dissociation of β-catenin from the membrane and subsequent translocation to the 
nucleus (Kalluri and Weinberg, 2009). The loss of E-cadherin facilitates the EMT process and 
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is accompanied by a “cadherin switch” from E-cadherin to N-cadherin, a typical mesenchymal 
marker (Zeisberg and Neilson, 2009). Other mesenchymal markers upregulated during EMT 
include the intermediate filament, vimentin; the fibroblast marker, fibroblast-specific protein 1 
(FSP-1); ECM proteins such as collagens type I, III, IV and V, fibronectin and tenascin-C; and 
matrix metalloproteinases (MMPs) including MMP2 and MMP9 (Kalluri and Neilson, 2003; 
Zeisberg and Neilson, 2009). While there is an increase in ECM deposition during EMT, there 
is also an associated upregulation of ECM degradation by matrix metalloproteinases (MMPs) 
that remodel the ECM and cleave cell-ECM adhesion proteins and cell-cell contacts, enabling 
the release and migration of individual epithelial cells from epithelial sheets over the basement 
membrane (Kalluri and Neilson, 2003). 
Many transcription factors are involved in controlling the EMT response. Snail transcription 
factors are zinc finger proteins, of which, Snai1 and Snai2 (formerly known as Slug) play 
prominent roles in EMT as repressors of E-cadherin expression (Bolós et al., 2003). Twist, a 
basic helix-loop-helix (bHLH) protein is also upregulated during EMT and can repress E-
cadherin independently of Snail (Yang et al., 2004). Another member of the bHLH family, 
E47, has also been identified as a repressor of E-cadherin and potent inducer of EMT (Cubillo 
et al., 2013). The zinc finger E-box-binding homeobox (ZEB)1 and ZEB2 are also 
transcriptional repressors of E-cadherin and play a key role in fibrotic EMT (Xiong et al., 
2012). 
 
Figure 5. Schematic of epithelial-mesenchymal transition (EMT) whereby epithelial cells lose 
their cell-cell adhesions and cell-basement membrane adhesions as they transdifferentiate into 
spindle-shaped myofibroblastic cells that can secrete their own aberrant extracellular matrix 
proteins. 
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2.3.2 Role of TGFβ-induced EMT in fibrotic cataract 
There is a compelling body of evidence implicating EMT in the pathogenesis of fibrotic forms 
of cataract, characterised by an opaque plaque of transdifferentiated myofibroblastic cells 
surrounded by aberrant ECM (de Iongh et al., 2005). TGFβ is known to potently induce LECs 
to undergo EMT and transdifferentiate into myofibroblastic cells bearing morphological and 
biochemical resemblance to human ASC and PCO (de Iongh et al., 2005). Both TGFβ1 and 
TGFβ2 isoforms are constitutively expressed by LECs and exist in the aqueous humour in their 
latent, inactive forms (Gordon-Thomson et al., 1998). 
Following ocular trauma (e.g. surgery), active levels of TGFβ isoforms become dramatically 
elevated (Eldred et al., 2011). Treatment of LECs with TGFβ induces EMT in both rat lens 
epithelial explants (Liu et al., 1994) and human capsular bag models (Wormstone et al., 2002). 
In vivo models including intravitreal injection of active TGFβ into rodent eyes (Hales et al., 
1999), ectopic overexpression of mature TGFβ in transgenic mouse lenses (Lovicu et al., 2002; 
Srinivasan et al., 1998) and adenoviral gene delivery of TGFβ into the mouse anterior chamber 
(Robertson et al., 2007), all induce ASC-like plaques with characteristic EMT features. 
ASC has been associated with several conditions involving altered levels of TGFβ expression 
and/or activation, including trauma (Tang et al., 2003), ocular inflammation, such as atopic 
dermatitis (Brandonisio et al., 2001; Sasaki et al., 1998) and iritis (Marcantonio et al., 2003). 
Human ASC plaques have been shown to consist of myofibroblastic cells surrounded by 
accumulations of ECM proteins including fibronectin, laminin, collagen type I and type IV, 
directly beneath the anterior capsule (Joo et al., 1999). 
Several features of TGFβ-induced EMT have also been identified in PCO. Residual LECs, that 
remain on the anterior capsule following cataract surgery, have been found to proliferate, 
migrate and transdifferentiate to form fibrotic plaques (Wormstone et al., 2002). An in vitro 
human capsular bag model that involves performing sham cataract operations on human donor 
lenses, has been used to investigate the pathogenesis of PCO (Liu et al., 1996; Saxby et al., 
1998; Wormstone et al., 1997). The transdifferentiated cells in this model have been found to 
express α-SMA as well as aberrant ECM similar to that of human ASC (Marcantonio et al., 
2003). 
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2.4 Bone-morphogenetic proteins (BMPs) 
Bone morphogenetic proteins (BMPs) are also members of the TGFβ superfamily (R. Wang et 
al., 2014). BMPs are 30-38kDa homodimer proteins, synthesised as large precursor molecules 
of approximately 400-525 amino acids in length with an amino (N)-terminal secretory signal 
peptide, a pro-domain for folding and a carboxyl (C)-terminal mature peptide with seven 
cysteine residues (R. Wang et al., 2014; Xiao et al., 2007). Precursor molecules are synthesised 
in the cytoplasm and undergo many post-translational modifications before the mature form is 
secreted. Following cleavage of the signal peptide, the precursor protein undergoes 
glycosylation and dimerisation (Jain et al., 2013). 
The C-terminal segment contains the mature dimeric BMP protein with the cysteine knot 
(Yadin et al., 2015). The mature dimeric BMP proteins can either be disulfide-linked 
homodimers comprising two similar BMPs (e.g. BMP-4/BMP-4) or disulfide-linked 
heterodimers comprising two different BMPs (e.g. BMP-2/BMP-4) (Wordinger and Clark, 
2007). This flexible oligomerisation pattern broadens the range of BMP interactions with its 
receptors, resulting in the activation of numerous signalling pathways and cellular functions 
(Wordinger and Clark, 2007). 
To date, over 20 BMPs have been identified and shown to play important roles in 
embryogenesis, organogenesis and maintenance of adult tissue homeostasis (Lee et al., 2010). 
BMPs are intricately involved in many vital physiological processes including proliferation, 
differentiation, growth inhibition and arrest of maturation in various cell types, depending on 
the cellular microenvironment. As a result, the term “body morphogenetic protein” may be 
more apt given our current knowledge (Reddi, 2005). 
Based on amino acid sequences and functional differences, the BMP subfamily is divided into 
BMP-2/4, BMP-5/6/7/8, BMP-12/13/14 (GDF-5/6/7), GDF-8/11, BMP-9 (GDF-2)/BMP-10, 
GDF-1/3 and the GDF-10/BMP-3 subgroups (Mueller and Nickel, 2012; Yadin et al., 2015). 
It should be noted that BMP-1 does not belong to the TGFβ superfamily as it shares homology 
with a pro-collagen C-proteinase (Karsenty, 1999). Although their monikers imply that all 
members are inducers of bone, some BMPs can act as inhibitors of bone formation (R. Wang 
et al., 2014). For instance, BMP-3 is a negative regulator of bone density (Daluiski et al., 2001) 
and BMP-13 strongly inhibits bone formation (Shen et al., 2009). 
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From gene inactivation studies in mice, it is clear that BMPs are critical for the development 
of various other organ systems beyond bone (Mueller and Nickel, 2012). BMP-2 knockout 
mice die due to amnion/chorion defects, highlighting the importance of BMP-2 for cardiac 
development (Zhang and Bradley, 1996). BMP-4 deficient mice show early defects in limb 
patterning, skeletogenesis (Bandyopadhyay et al., 2006) as well as thymus and parathyroid 
morphogenesis (Gordon et al., 2010). BMP-7 knockout mice display defects in skeletogenesis 
(Luo et al., 1995), neurogenesis (Le Dréau et al., 2012) as well as kidney (Luo et al., 1995), 
eye (Luo et al., 1995) and cardiac development (Kim et al., 2001). In the adult, BMP-7 
expression remains highest in the kidney (Simon et al., 1999) and to a lesser extent in cartilage 
(Chubinskaya et al., 2007), brain (Söderström and Ebendal, 1999) and the eye (Wordinger and 
Clark, 2007). Deletion of BMP-3, BMP-5, BMP-6, BMP-8, GDF-5/6/7, GDF-8, GDF-10, 
GDF-11 do not cause lethality, emphasising the functional redundancy of BMPs in skeletal, 
heart and limb development (Mueller and Nickel, 2012). 
Although some BMP subgroups share overlapping functions, certain individual members 
display unique functions (Mueller and Nickel, 2012). For instance, within the BMP-5/6/7 
subgroup, BMP-5 and BMP-7 share similar functions, but BMP-6 is uniquely involved in iron 
metabolism and stimulates expression of hepcidin, a key regulator of iron absorption (Meynard 
et al., 2009). 
While TGFβ binds exclusively to its type I receptor (TβRI) and type II receptor (TβRII), BMPs 
have five type I receptors and three type II receptors (Nohe, 2004). The BMP type I receptors 
include Acvrl1 (also known as ALK1), ActRI (ALK2), BMPR-IA (ALK3), ActRIb (ALK4) 
and BMPR-IB (ALK6). The three type II receptors consist of BMPR-II, ActRIIa, and ActRIIb 
(Bragdon et al., 2011). BMPR-II is specific for BMPs whereas ActRIIa and ActRIIb are also 
shared by activins and myostatin (Miyazono et al., 2010). BMP molecules have differing 
affinities for the various BMP receptors and thus, form preferred ligand-receptor complexes 
(Miyazono et al., 2010; Yu et al., 2005). 
In general, ligand binding of members of the TGFβ superfamily induces the constitutively 
active serine/threonine domains of type II receptors to transphosphorylate the GS domain of 
the type I receptor, forming a hetero-tetrameric complex (Miyazono et al., 2010). BMP-7 
follows this pattern and binds to type II receptors BMPRII, ActRIIa and ActRIIb that then 
activates type I receptors ActRI, BMPR-IA, BMPR-IB (Weiskirchen et al., 2009). In contrast, 
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the binding of BMP-2 follows a different sequential binding mechanism (Kirsch et al., 2000). 
BMP-2 first binds to the type I BMP receptor (high affinity receptor) that then activates 
recruitment of the type II BMP receptor (low affinity receptor) into a ternary complex (Kirsch 
et al., 2000). Type I and type II BMP receptors can bind BMP-2 independently, but in the 
presence of both receptor types, binding affinity is enhanced (Ichijo, 1996). 
A number of secreted extracellular BMP antagonists modulate the activity of BMP at the cell 
surface by preventing the binding of BMP to its receptor complex (Botchkarev, 2003; 
Massague and Chen, 2000). BMP antagonists possess a cysteine knot structure and, as such, 
have been classified into three subfamilies according to the size of the cysteine knot: the CAN 
family (eight-membered ring); twisted gastrulation protein (nine-membered ring); and chordin 
and noggin (ten-membered ring) (Avsian-Kretchmer and Hsueh, 2004). The CAN family is 
further subdivided into Gremlin/DRM/IHG-2, protein related to DAN and Cerberus (PRDC), 
Cerberus, Coco, DAN, Sclerostin and USAG-1 (Avsian-Kretchmer and Hsueh, 2004). 
2.4.1 Role of BMPs in normal lens biology 
In the ocular lens, BMPs are important in orchestrating fundamental developmental lens 
processes such as lens induction and lens fibre differentiation. BMP-2 and BMP-4 are detected 
at the anterior neural plate border (Chapman et al., 2002; Faure et al., 2002) where both 
prospective lens progenitor cells are located (Bhattacharyya et al., 2004). BMP-7 is present in 
both the optic vesicle and the surface ectoderm at the time of lens placode thickening and is 
crucial in the early lens induction process (Lyons et al., 1995; Wawersik et al., 1999). 
Consistently, targeted deletion of specific components of the BMP pathway have led to 
disturbances in lens induction (Beebe et al., 2004; Furuta and Hogan, 1998; Wawersik et al., 
1999). Using a BMP-4 knockout mouse model, lens induction was absent despite close contact 
between the ectoderm and optic vesicle with concurrent loss of Sox2 expression, a transcription 
factor implicated in the regulation of crystallin genes in early lens fibre differentiation (Furuta 
and Hogan, 1998; Kamachi et al., 1995). 
Although FGF signalling is required for lens fibre differentiation, it appears that FGFs alone 
cannot account for all the fibre differentiation activity in the vitreous humour. There is growing 
evidence that additional growth factors such as BMPs are also capable of enhancing the 
synthesis of fibre-specific proteins (Lovicu and McAvoy, 2005). The addition of BMP-4 and 
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BMP-7 to organ cultures of optic vesicles and lens placodes from chick embryos resulted in 
enhanced lens growth and expression of the lens fibre-specific differentiation marker, δ-
crystallin (Trousse et al., 2001). Similarly, Boswell et al. (2008) found that exogenous addition 
of BMP-2, -4 and -7 upregulated both morphological features and biochemical markers of fibre 
differentiation including δ-crystallin and CP49 in chick cell cultures (Boswell et al., 2008). 
Little is known about the expression levels of BMPs in the aqueous humour. The human 
trabecular meshwork is known to synthesise and secrete BMP-4 (Wordinger et al., 2007); 
however, it is not known whether this BMP-4 enters the aqueous humour. Gremlin, an 
antagonist of BMP-signalling is present in the human aqueous humour (Wordinger et al., 
2007). Future studies that directly measure BMP isoform levels in the aqueous humour is 
warranted. 
2.5 Epidermal growth factor (EGF) 
EGF has long been known to influence eye development since its first discovery by Stanley 
Cohen in 1962 when salivary gland extracts induced early eye opening in mice and accelerated 
eruption of teeth (Cohen, 1962). The precocious eyelid opening and tooth eruption was later 
discovered to be due to enhanced epithelial growth and keratinisation. The protein responsible 
for this phenomenon, originally termed “tooth-lid factor” was isolated and found to be a low 
molecular weight, heat stable, nondialyzable polypeptide now known as EGF (Cohen and 
Elliott, 1963). 
EGF belongs to the EGF family of ligands that bind to and activate the EGF receptor (EGFR) 
family, also known as ErbB family of receptor tyrosine kinases (Riese and Stern, 1998). This 
family can be divided into three distinct groups. The first includes EGF, amphiregulin (AREG) 
and transforming growth factor-α (TGF-α) that all specifically bind to EGFR (Riese and Stern, 
1998). The second includes betacellulin (BTC), heparin-binding EGF-like growth factor (HB-
EGF) and epiregulin (EPR), which bind to both EGFR and ErbB-4 (Riese and Stern, 1998). 
The third group comprises the neuregulins (NRGs, also known as heregulins, HRGs) and can 
be further divided into two subgroups based on their ability to bind both ErbB-3 and ErbB-4 
(NRG-1 and NRG-2) or only ErbB-4 (NRG-3 and NRG-4) (Holbro et al., 2003).  
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EGF family ligands are synthesised as type I transmembrane precursors that typically undergo 
extracellular domain cleavage to release the soluble form of the hormone that then binds to and 
activates the EGFR (Singh et al., 2016). This proteolytic cleavage event is typically mediated 
by members of the ADAM (a disintegrin and metalloprotease) family (Sahin et al., 2004). The 
soluble hormones share a domain of homology that spans approximately 30-40 amino acids 
and comprises six characteristically spaced cysteine residues that form three disulfide bonds 
resulting in a triple-loop secondary structure (Abe et al., 1998). This domain plays a key role 
in ErbB family receptor binding and activation (Riese and Stern, 1998). Although most of the 
EGF family of ligands are biologically active only in their soluble secreted form, some are also 
active as membrane-anchored precursor molecules (e.g. HB-EGF) that can activate EGFR 
through juxtacrine signalling (Singh et al., 2007). 
The ErbB family belongs to subclass I of the superfamily of receptor tyrosine kinases (RTK) 
(Olayioye et al., 2000). It comprises four distinct receptors: EGFR (ErbB-1 or HER1 in 
humans), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4) (Arteaga and Engelman, 
2014). Structurally, these four proteins each have an extracellular N-terminal ligand binding 
domain, a single spanning transmembrane domain and an intracellular cytoplasmic C-terminal 
protein tyrosine kinase domain with several phosphorylation sites (Seshacharyulu et al., 2012). 
The intracellular tyrosine kinase domain of ErbB receptors is highly conserved and therefore, 
the variable extracellular ligand binding domain allows binding to different ligands 
(Seshacharyulu et al., 2012). The extracellular region of EGFR is further subdivided into four 
domains (I-IV also known as the L1, S1, L2 and S3 domains, respectively) (Bajaj et al., 1987). 
Domains I and III are leucine-rich ligand binding domains and domains II and IV are cysteine-
rich domains (Ferguson, 2008). 
Understanding how these ligands are released at the cell surface and trafficked within the cell 
provides new insights into EGFR signalling. While EGF and TGF-α specifically bind and 
activate EGFR, HB-EGF is also able to activate EGFR but through G-protein coupled receptor-
mediated metalloproteinase-dependent cleavage of proHB-EGF (Prenzel et al., 1999). EGF 
ligands also exhibit hormone-like activity through endocrine signalling. For example, EGF is 
produced and secreted by the maternal mammary gland and mammary derived EGF has been 
shown to play a key role in gut development in the neonatal rodent (Fisher and Lakshmanan, 
1990; Mroczkowski and Reich, 1993).  
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2.5.1 Role of EGF/EGFR in normal lens biology  
Epidermal growth factor (EGF) is an important mitogen for LECs, stimulating LEC 
proliferation in rabbit (Hollenberg, 1975; Reddan and Wilson-Dziedzic, 1983), bovine 
(Gospodarowicz et al., 1977), chick (Ireland and Mrock, 2004), rat (Iyengar et al., 2009) and 
human (Ibaraki et al., 1995; K Majima, 1995) lenses. 
The role of EGF and EGFR signalling in lens fibre differentiation appears to be species-
dependent. In cultured human LECs, EGF induced morphological changes characteristic of 
lens fibre differentiation (Ibaraki et al., 1996, 1995). Studies on embryonic chick lenses showed 
increases in EGFR activation in both epithelial cells committed to fibre cell differentiation and 
in fibre cells undergoing the initial stages of terminal differentiation (Ireland and Mrock, 2004). 
Activated EGFR was not observed in central epithelial cells or nuclear fibre cells suggesting 
that activation of EGFR appears to be restricted to post-natal secondary lens fibre 
differentiation (Ireland and Mrock, 2004). While both TGFα and EGF were both able to 
activate EGFR signalling and promote fibre differentiation in chick LECs, TGFα was more 
effective than EGF (Ireland and Mrock, 2000). EGF alone did not induce fibre cell 
differentiation in rat lens epithelial explants; however, a fibre differentiation response was 
elicited when EGF was combined with a low proliferating dose of FGF (Wang et al., 2010). 
EGFR is present in the human lens at both the gene and protein level (Bhuyan et al., 2000). 
Bhuyan et al., (2000) showed that EGFR gene expression does not change in the lens with age; 
however, EGFR protein levels increase with age. The levels of EGFR protein increase 3-fold 
to 4-fold at 48 years and above compared to that observed at age 40. Degradation of EGFR 
protein is evident after age 48. EGFR protein was not detectable in the membranes of lens fibre 
cells. 
There are conflicting reports on the expression levels of EGF in the aqueous humour. van 
Seiten et al., (1996) showed that EGF was unable to be detected in the anterior chamber fluid 
of normal human eyes (ages 21-84 years old) undergoing cataract surgery. The authors used 
an ELISA immunoassay with a detection limit of 0.2 pg/ml. In contrast, Yang et al., (2011) 
showed using multiplex-bead technology that EGF was present in the anterior chamber of 
normal human eyes undergoing cataract surgery (ages not reported) at 3.28 pg/ml. More 
recently, a study by Cheng et al., (2017) compared the levels of EGF in the aqueous humour 
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of patients with retinoblastoma compared to patients with congenital cataracts as controls (ages 
8-32 months). Using an ELISA kit, the authors reported that EGF was present at 0.66 pg/ml in 
controls compared to 3.97 pg/ml in retinoblastoma patients. It appears that the more advanced 
protein analysis techniques developed over time may be enabling the low (previously 
undetectable) levels of EGF in the aqueous humour to now be detected. 
3 Growth factor signalling pathways 
A fundamental question in this thesis concerns the downstream interplay of the molecular 
mechanisms of the three growth factors, TGFβ, BMP and EGF. How do these soluble 
extracellular ligands exert such potent effects on LECs? Here, we introduce the concept of 
cellular signalling and review the current literature regarding the signalling pathways activated 
by each growth factor. 
Growth factors mediate their diverse biological responses by firstly binding to and activating 
specific cell-surface receptors with intrinsic protein kinase activity. Activation of the receptor 
triggers the subsequent phosphorylation of a cascade of downstream intracellular signalling 
pathways. Phosphorylation involves the addition of one or more phosphate groups to the 
primary amino acid sequence of the protein, often resulting in a conformational change in the 
protein (Bourret et al., 1991). While protein kinases catalyse the phosphorylation of proteins, 
a reciprocal group of enzymes called phosphatases perform the opposite action of removing 
phosphate groups, that is, dephosphorylation (Hunter, 1995). 
Broadly speaking, there are two main groups of protein kinases: tyrosine kinases and 
serine/threonine kinases. Tyrosine kinases catalyse the transfer of a phosphate group to tyrosine 
residues while serine/threonine kinases add a phosphate group to serine and/or threonine 
residues. TGFβ and BMPs bind to serine/threonine receptor protein kinases whereas EGF binds 
to a receptor tyrosine kinase (Alexander et al., 2011). These receptors span the plasma 
membrane, comprising of an extracellular ligand-binding domain, a transmembrane region and 
a cytoplasmic domain, thereby enabling extracellular signals to induce intracellular changes. 
The activated ligand/receptor complex activates a chain of signalling molecules that each pass 
the message to the next molecule of the transduction pathway until it reaches the nucleus to 
initiate gene expression. Although each growth factor signalling pathway is distinct and can 
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function independently, some pathways share common elements and feed into one another 
through crosstalk, feedback and/or feed-forward loops (Housden and Perrimon, 2014). Indeed, 
growth factor signalling pathways can be better understood as a complex web of events with 
dynamic modularity, and extensive connectivity evolved to respond efficiently to our changing 
environment. 
3.1 TGFβ signalling pathways 
Once activated, the TGFβ ligand binds to the extracellular domain of the type II TGFβ receptor 
(TβRII), an autophosphorylated serine/threonine kinase receptor (Shi and Massagué, 2003). 
The activated TβRII transphosphorylates and activates the serine and threonine residues in the 
intracellular glycine-serine rich domain of the type I TGFβ receptor (TβRI) (Lebrun, 2012). 
The activated TβRI is subsequently able to control several downstream signalling pathways 
including the canonical Smad-dependent and non-canonical Smad-independent signalling 
pathways (Lebrun, 2012). 
3.1.1 Smad-dependent pathways 
Activated TβRI phosphorylates the cytoplasmic receptor-regulated small mothers against 
decapentaplegic (R-Smads), specifically Smad2 and Smad3 (Yi et al., 2005). The amplitude 
and duration of Smad2/3 signalling is modulated by auxiliary anchoring proteins such as the 
Smad anchor for receptor activation (SARA) that facilitates access of the R-Smads to the type 
I receptors (ten Dijke and Hill, 2004). Activated R-Smads associate with the common Smad 
(Co-Smad, also known as Smad4) to form a heteromeric complex that translocates to the 
nucleus to regulate transcription of TGFβ-responsive genes (Fleisch et al., 2006; Massague and 
Chen, 2000; Miyazono, 2009; Wendt et al., 2009). Smad proteins recognise the palindromic 
DNA sequence (CAGAC), termed the Smad binding element (SBE); however, their affinity 
for DNA binding is relatively low (Denissova and Liu, 2004; Jonk et al., 1998; Massague and 
Chen, 2000). Thus, in order for Smads to achieve high-affinity DNA binding, they need to bind 
synergistically to DNA with cell-specific co-factors (transcriptional co-activators or co-
repressors) to ensure the activation of cell type-specific targeted expression of TGFβ-
responsive genes (Chen et al., 1997; Lebrun, 2012; Miyazono, 2009; Wendt et al., 2009). 
The Smad-dependent pathway is regulated through negative feedback loops (Miyazono, 2009). 
Smad7 is an inhibitory Smad (I-Smad) that represses TGFβ-signalling through multiple 
Chapter One: General Introduction 
26 
mechanisms (Lebrun, 2012). Smad7 acts as an inert decoy by binding to activated TβRI to limit 
the phosphorylation of Smad2/3 through competitive inhibition (Shi et al., 1998). Moreover, 
Smad7 promotes the internalisation and degradation of TβRI (Taylor et al., 2010) and competes 
with R-Smads for receptor binding (Miyazono, 2009). 
3.1.2 Smad-independent pathways 
While the Smad pathway represents the canonical signalling pathway for TGFβ, several non-
Smad intracellular signaling cascades have been implicated in mediating the cellular effects of 
TGFβ (Yi et al., 2005). The stress-activated kinases p38 and JNK are induced by TGFβ and 
synergise with Smad signalling resulting in EMT and apoptosis (Lebrun, 2012). TGFβ also 
signals through other mitogen activated protein kinase (MAPK) pathways by activating the 
extracellular-signal-regulated kinases 1 and 2 (ERK1 and ERK2), leading to the induction of 
EMT (Zhang, 2009). Rho GTPases have been shown to relay TGFβ signals resulting in 
cytoskeletal reorganization, cell motility and invasion through activation of small GTPase 
RhoA, Cdc42 GTPases, Rac1 and the tyrosine kinase Src (Miyazono, 2009; Moustakas and 
Heldin, 2012; Zhang, 2009). TGFβ can also signal through the mTOR and the phosphoinositide 
3-kinase (PI3K)/Akt pathways to regulate cell growth, inhibition and induction of EMT 
(Lebrun, 2012). 
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Figure 6. Canonical and non-canonical signalling pathways downstream of TGFβ. 
3.2 BMP signalling pathways 
BMPs activate different intracellular pathways by signalling through distinct receptor 
complexes (Sieber et al., 2009). Detailed analyses of the intracellular signalling pathway for 
BMP-2 has shown two modes of signal transfer. In the first mode, BMP-2 binds to a preformed 
complex of BMPR-IA and BMPR-II that triggers clathrin-mediated endocytosis and initiates 
the canonical Smad-signalling pathway. In the second mode, BMP-2 binds its high affinity 
receptor BMPR-IA upon which BMPR-II is recruited into the complex, forming a BMP-
induced signalling complex (Hassel et al., 2003). This results in internalisation via caveolae 
and activation of the non-canonical mitogen-activated protein kinase (MAPK) signalling 
pathway (Miyazono et al., 2001). 
3.2.1 Canonical signalling pathway 
Similar to TGFβ, the canonical BMP signalling pathway also involves Smad proteins 
(Gazzerro and Canalis, 2006). The activated receptor complex relays the signal to the 
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cytoplasm by phosphorylating the carboxy-terminus of R-Smads (Guo and Wang, 2009). R-
Smads for the TGFβ/activin pathway include Smad2 and Smad3 whereas Smad1, Smad5 and 
Smad8 participate in BMP signalling (Miyazono et al., 2010). Similar to the SARA cofactor in 
TGFβ signalling that interacts directly with Smad2/3 to recruit Smad2/3 to the TGFβ receptor 
(Tang et al., 2010), endofin acts as a Smad1 anchor for BMP receptor activation and in turn, 
enhances Smad1 phosphorylation and translocation to the nucleus in BMP signalling (Shi et 
al., 2007). 
Phosphorylated R-Smads hetero-oligomerise with Co-Smad, Smad4, which is shared by both 
TGFβ and BMP signalling (Mueller and Nickel, 2012). This complex then translocates into the 
nucleus and binds to DNA at the Smad-binding element (SBE) or BMP-responsive element 
(BRE) to regulate transcription of respective target genes (Gazzerro and Canalis, 2006). Since 
Smads have low intrinsic DNA binding affinity, they cooperate with transcriptional co-
activators or co-repressors and chromatin remodelling factors to facilitate the integration of 
different signalling inputs, accounting for the myriad gene responses generated by the few 
Smad proteins (Mueller and Nickel, 2012). 
I-Smads (Smad6 and Smad7) can interrupt phosphorylation of R-Smads by negatively 
regulating Smad activation (Miyazono et al., 2005). Smad6 and Smad7 lack the SSXS 
phosphorylation site and form a stable association with the activated type I receptors, thus 
preventing phosphorylation of R- and Co-Smads (R. Wang et al., 2014). Smad7 inhibits both 
TGFβ and BMP signalling while Smad6 only inhibits BMP signalling (Hata et al., 1998). 
Smad6 can also inhibit signalling by competing with R-Smads for Co-Smad binding and by 
acting as a transcriptional co-repressor (Miyazono et al., 2001). Moreover, I-Smads have been 
found to mediate the interaction between receptors and E3-ubiquitin ligases, Smad ubiquitin 
regulatory factor (Smurf)1 and Smurf2, which ubiquitinate and degrade R-Smads and BMP 
receptors via Smad6 and Smad7 (Murakami, 2003). The mRNA levels of Smad6 and Smad7 
can be upregulated by TGFβ, activin and BMP, suggesting that I-Smads function in a negative 
feedback loop to turn off both TGFβ and BMP signalling (Miyazono et al., 2001). Additionally, 
TGFβ, activin and nodal pathways can also interact with BMP type I receptor to phosphorylate 
Smad2/3, hence diverting the canonical BMP signalling pathway (Kishigami and Mishina, 
2005). 
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3.2.2 Non-canonical signalling pathway 
In addition to the canonical signalling cascade, BMP can also signal through several non-
canonical, Smad-independent pathways (Miyazono et al., 2001). These include the ERK, p38, 
JNK and nuclear factor kappa beta (NF-κB) pathways (Bragdon et al., 2011). The activation 
of the non-Smad pathways is believed to be through the interaction with BRAM1 (bone 
morphogenetic protein receptor associated molecule 1), XIAP (X-linked inhibitor of apoptosis 
protein) and downstream signalling molecules, TAK1 (TGFβ-activated kinase 1) and TAB1 
(TAK1 binding protein), forming the TAB1-TAK1 complex (Bragdon et al., 2011). Integration 
and cross-talk of diverse Smad and non-Smad pathways broadens the cellular responses elicited 
by BMP and is a key mechanism for the modulation of its downstream responses (Thawani et 
al., 2010). 
3.3 EGF signalling pathways 
Activation of the EGFR stimulates the phosphorylation of a multitude of downstream 
signalling pathways (Oda et al., 2005; Wee and Wang, 2017). The Ras-Raf-MAPK pathway is 
a major downstream signalling route for EGFR (Mendelsohn and Baselga, 2003). Activation 
of Ras and Raf initiates a multistep cascade of phosphorylation events that leads to the 
activation of MAPK and ERK1/2 to regulate various biological responses such as proliferation 
and survival (Lewis et al., 1998). Another route for EGFR signalling is the PI3K/Akt pathway 
that triggers a cascade of responses including cell growth, proliferation, survival and motility 
(Freudlsperger et al., 2011). In cancer studies, the EGFR-PI3K-Akt axis is often dysregulated 
and hyper-activated leading to downregulation of PTEN (phosphatase and tensin homolog), a 
tumour suppressor known to antagonise PI3K activity (Davis et al., 2014). EGFR also signals 
through the stress-activated protein kinase (SAPK) pathway, including protein kinase C (PKC) 
and JAK/STAT (Andl et al., 2004; Denning et al., 1996). The activation of these downstream 
EGFR pathways translates in the nucleus as diverse transcriptional programs that mediate 
wide-ranging cellular behaviours including cell proliferation, growth, differentiation, survival 
and migration (Yarden and Sliwkowski, 2001). 
Once activated, EGFR signalling is terminated by internalisation of receptor-ligand complexes 
(Yarden, 2001). Activated EGFR can either be directed towards a canonical clathrin-dependent 
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pathway for endocytosis or a “fast” clathrin-independent pathway involving an E3 ubiquitin 
ligase Cbl that targets activated receptors for ubiquitination (Sigismund et al., 2005). 
3.4 Inhibition of TGFβ signalling pathways to target fibrotic 
cataract 
Investigating the molecular mechanisms underlying TGFβ-induced EMT in LECs has led to 
the discovery of many potential drug targets to combat fibrotic cataract. In a mouse lens injury 
model of ASC, capsular puncture upregulated the TGFβ/Smad signalling pathway and induced 
myofibroblastic transdifferentiation of LECs (Saika et al., 2004b). Pre-treatment with TGFβ-
neutralising antibodies prior to capsular puncture injury inhibited the nuclear translocation of 
Smad3/4 and subsequent lens fibrosis (Saika et al., 2004b). Moreover, injury-induced EMT 
was inhibited in Smad3 knockout transgenic mice, supporting the role of Smad signalling in 
lens fibrosis (Saika et al., 2004b). Knockdown of Smad3 signalling using siRNA inhibited the 
effect of TGFβ2 on cell proliferation and the production of ECM proteins such as fibronectin 
and collagen type I, whereas siRNA against Smad2 blocked cell migration and the production 
of α-SMA (Li et al., 2011). Silencing both Smad2 and Smad3 effectively blocked the effect of 
TGFβ2-mediated cell proliferation, migration and ECM production, emphasising the 
importance of TGFβ/Smad signalling in mediating EMT in the lens (Li et al., 2011). Moreover, 
adenoviral gene transfer of the inhibitory Smad, Smad7, prevented injury-induced EMT of 
LECs in mice with reduction in TGFβ1 and EMT markers including α-SMA, lumican and 
collagen VI (Saika et al., 2004a). 
Several Smad-independent intracellular signalling cascades have also been implicated in 
regulating EMT in the lens (de Iongh et al., 2005). Chen et al., showed that MAPK/ERK1/2 
was activated in TGFβ2-induced EMT, and inhibition of ERK1/2 signalling with U0126, 
completely prevented TGFβ2-induced expression of α-SMA, fibronectin, collagen types I, IV 
and suppressed the myofibroblastic phenotype (Chen et al., 2014). Further, work in our 
laboratory showed that ERK1/2 is required for the initiation but not the progression of TGFβ2-
induced EMT in rat lens epithelial explants (Wojciechowski et al., 2017). We also showed that 
Sprouty (Spry), an antagonist of receptor tyrosine kinases and ERK1/2 signalling, is a negative 
regulator of TGFβ-signalling in the lens (Lovicu et al., 2015; Shin et al., 2012). Conditional 
knockout of Spry from the lenses of mice induced the formation of ASC, with subpopulations 
of cells expressing α-SMA and a concomitant loss of E-cadherin, highlighting the loss of the 
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epithelial phenotype through an EMT (Shin et al., 2012). Overexpression of Spry in LECs in 
vivo and in vitro rendered the cells less responsive to TGFβ signalling and maintained lens cell 
integrity and transparency (Shin et al., 2012; Zhao et al., 2015). 
The Rho/ROCK pathway has been found to promote TGFβ activity leading to cytoskeletal 
reorganisation, cell motility and invasion in LECs (Maddala et al., 2003). Pre-treatment of cells 
with C3-exoenzyme (an irreversible inhibitor of Rho-GTPase) or the ROCK inhibitor, Y-
27632, inhibited TGFβ-induced EMT by abolishing the formation of actin stress fibres and 
focal adhesions (Maddala et al., 2003). Interestingly, although Smad3 and Rho/ROCK signal 
activation were both required for TGFβ-induced EMT, their activation was found to be 
independent of each other, highlighting the complexity of the network of signalling pathways 
involved in myofibroblastic transdifferentiation in the lens (Cho and Yoo, 2007). 
Oxidative stress also plays a key role in the pathogenesis of fibrotic cataract. Addition of the 
antioxidant glutathione (GSH) abrogated TGFβ-induced EMT and plaque formation in whole 
rat lenses and rat lens epithelial explants (Chamberlain et al., 2009). TGFβ stimulates the 
production of reactive oxygen species (ROS) in numerous cell types and activates many redox-
sensitive signalling pathways including Ras/Raf/MAPK and PI3K/Akt leading to fibrosis (Liu 
and Gaston Pravia, 2010; Manoharan et al., 2018). Work in our laboratory has identified a role 
for the ROS-producing enzyme, Nox4, in mediating TGFβ2-induced EMT in the lens (Das et 
al., 2016). Inhibition of Nox4 expression and its production of ROS using a pan-NADPH 
oxidase inhibitor, VAS2870, suppressed the progression of EMT in rat lens epithelial explants 
(Das et al., 2016).  
4 Aims and hypotheses 
While there is an extensive body of literature dedicated specifically to the role of TGFβ in the 
pathogenesis of fibrotic cataract, there is a paucity of research on how other growth factors 
impact TGFβ activity. In vivo, the lens is exposed to a variety of growth factors found in the 
ocular media that each induce a distinct response on LECs. Inspired by research in organ 
fibrosis and cancer studies outside of the eye, we chose to study the effects of BMP-7 and EGF 
on TGFβ-induced EMT in the lens. We conclude by applying a human lens epithelial explant 
system to test TGFβ-induced EMT translation to human fibrotic cataract progression. 
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4.1 Hypothesis I: BMP-7 blocks TGFβ-induced EMT in the lens 
Although TGFβ and BMPs are members of the same superfamily, they play opposing roles 
during EMT. There is compelling evidence to suggest that BMP-7 can directly counteract 
TGF-induced EMT in various organ systems (Weiskirchen et al., 2009). For example, TGF 
is known to initiate and propagate EMT in the kidney resulting in renal fibrosis with associated 
down-regulation of BMP-7 protein expression (X.-M. Meng et al., 2013). Exogenous 
administration of BMP-7 has been shown to reverse this EMT response by restoration of the 
epithelial phenotype with re-expression of epithelial markers (E-cadherin, ZO-1) and reduction 
in mesenchymal markers (α-SMA, collagen I, fibronectin and connective tissue growth factor) 
(Xu et al., 2009; Zeisberg et al., 2003b). Furthermore, adenoviral-mediated overexpression of 
BMP-7 attenuated TGF-induced fibrogenic activity via upregulation of a downstream target 
gene of BMP-7, inhibitor of differentiation- (Id-)2 in models of both pulmonary (Izumi et al., 
2005) and hepatic (Kinoshita et al., 2007) fibrosis. However, the therapeutic effect of BMP-7 
in pulmonary fibrosis is contentious as there have been studies refuting its capacity to reverse 
or inhibit EMT, suggesting that the protective effects of BMP-7 may be confined to certain 
organs (Hackett et al., 2009; Murray et al., 2008). Currently, BMP-7 has FDA approval for use 
in bone repair; known commercially as osteogenic protein-1 (OP-1) (White et al., 2007). 
Although current animal studies show promising data in the safety and efficacy of systemic 
administration of BMP-7, this has yet to be conducted in human clinical trials. 
In the lens, the protective role of BMP-7 has been explored using in vitro and in vivo models. 
Adenoviral-mediated overexpression of BMP target genes, Id2 and Id3 suppressed TGF-
induced EMT in a murine LEC line with maintenance of ZO-1 levels and reductions in α-SMA 
expression (Kowanetz et al., 2004). Using an in vivo model, Saika et al. (2006) investigated 
the effect of adenoviral-mediated expression of BMP-7, Id2 or Id3 in a mouse lens capsular 
injury-induced model of EMT (Saika et al., 2006). BMP-7 upregulated the expression of Id2 
and Id3 in injured lenses (Saika et al., 2006). Gene transfer of BMP-7, Id2 or Id3 delayed 
injury-induced EMT by maintenance of the epithelial phenotype and reductions in EMT 
markers (α-SMA and collagen type VI) (Saika et al., 2006). Although gene transfer of BMP-
7, Id2 or Id3 attenuated the EMT response, this inhibitory effect did not extend past day 10 
with evidence of elongated fibroblastic cells in these groups despite the persistence of BMP-7, 
Id2 and Id3 expression. 
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Overexpression of BMP-7 in lenses of transgenic mice resulted in widespread apoptosis and 
ablation of the neural retina (Hung et al., 2002). Retinal ablation was correlated to shifting of 
the lens bow region posteriorly until the entire lens was filled with LECs. While this suggests 
that the retina is critical in providing fiber cell differentiation cues to the lens, it also highlights 
a potential role for BMP-7 in maintaining the epithelial phenotype, an important factor in 
preventing EMT. 
Building on the work of Saika et al., (2006), the first results chapter aims to explore the role of 
BMP-7 in blocking TGF-induced lens EMT through exogenous administration of BMP-7. An 
in vitro rat lens epithelial explant system was used for these experiments to understand the 
effect of BMP-7 on TGF activity in isolation from the influence of other growth factors that 
may be present in vivo. We hypothesised that BMP-7 would block TGF-induced lens EMT 
by promoting the BMP-7-responsive Smads (Smad1/5) and the BMP-7 target genes, Id2 and 
Id3. 
4.2 Hypothesis II: EGFR-signalling is involved in TGFβ-induced EMT in the 
lens 
EGFR-signalling has been implicated in the pathogenesis of PCO (Maidment et al., 2004). 
Treatment of human LECs with EGF promoted coverage of the posterior capsular bag and 
selective inhibition of the EGF receptor (EGFR) using AG1478 significantly retarded the 
growth rates of cells (Maidment et al., 2004). Treatment of human anterior lens capsules from 
cataract patients with EGF induced LECs to become multilayered fibroblasts, bearing 
resemblance to human anterior polar cataract and PCO (Majima, 1998). SiRNA-mediated 
knockdown of EGFR expression significantly reduced the proliferative capacity in human 
LECs and progression of PCO in an in vivo rat model (Huang et al., 2011). Similarly, blockade 
of EGFR-signalling using anti-cancer drugs, Erlotinib (Wertheimer et al., 2014, 2013) or 
Gefitinib (Wertheimer et al., 2015), reduced proliferation, migration, matrix contraction and 
cell spreading in human LECs. More recently, EGF was found to induce EMT in human LECs 
with an upregulation of mesenchymal markers (fibronectin and α-SMA) and downregulation 
of the epithelial marker, E-cadherin (Dong et al., 2018). The authors showed that this effect 
was mediated through inhibition of microRNA-26b and recruitment of histone deacetylase 3 
(HDAC3) (Dong et al., 2018). 
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Although several studies have highlighted the anti-proliferative effect of EGFR inhibitors in 
PCO formation, little is known about how it impacts on myofibroblast transdifferentiation, 
another key feature of PCO. Given that TGFβ is a potent inducer of myofibroblast 
transdifferentiation in LECs, the aim of the second results chapter was to explore whether 
EGFR-signalling is involved in TGFβ-induced EMT in a rat lens epithelial explant system. 
Research in the cancer field showed that activation of EGFR promoted invasion by inducing 
an EMT in breast cancer (Thomas et al., 2012), squamous cell carcinoma (Zuo et al., 2011) 
and non-small cell lung cancer (Bae et al., 2013). Further, EGFR inhibitors such as Erlotinib 
and Gefitinib have been approved for treatment of these cancers (Rocha-Lima et al., 2007). 
Hence, we hypothesised that EGFR-signalling is involved in TGFβ-induced EMT in rat lens 
epithelial explants and that inhibition of EGFR-signalling blocks lens EMT. 
4.3 Hypothesis III: Enhanced EGF receptor-signalling augments TGFβ-
induced EMT in the lens 
EGF has been reported to augment or block aspects of TGF activity in different cancer studies. 
Several studies show that EGF, when combined with TGF, can enhance the EMT response; 
EGF and TGF1 synergistically enhanced tumour invasiveness in lung epithelial cells (Saha 
et al., 1999), pig thyroid epithelial cells (Grände et al., 2002) and epithelial ovarian cancer cells 
(Xu et al., 2010). In contrast to the above, there are reports whereby EGF blocks TGF activity. 
Carmona-Cuenca et al., (2006) showed that EGF blocked TGF-induced production of ROS 
and upregulation of Nox4 in fetal rat hepatocytes (Carmona-Cuenca et al., 2006). Blocking the 
EGF pathway enhanced TGF-induced apoptosis in rat hepatoma cells, with an associated 
increase in oxidative stress through elevated Nox4 and ROS production (Sancho et al., 2009). 
The pro-survival effect of EGF was also observed in renal HK-2 cells where adding EGF 
blocked TGF-induced apoptosis during EMT in a PI3K/Akt-dependent manner (Docherty et 
al., 2006). 
Evidently, the impact of EGF on TGF varies in different cell types. The aim of the third results 
chapter was to determine how the addition of EGF impacts on TGF-induced EMT in rat LEC 
explants. We hypothesised that adding EGF to our rat lens epithelial explants would potentiate 
the activity of TGF to promote EMT. Since EGF is known to activate both EGFR-signalling 
and the ERK1/2-signaling pathway, we proposed that the combined treatment of EGF and 
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TGF would lead to a more pronounced and integrated activation network of Smad, ERK1/2 
and EGFR-signalling, thus leading to an exacerbated EMT response. 
4.4 Hypothesis IV: TGFβ induces EMT in a human lens epithelial explant 
model 
Numerous animal models including rat lens epithelial explants, whole rat lens culture, 
transgenic mice, capsular puncture mouse model and cultured embryonic chick lens have been 
used to model the pathogenesis of fibrotic cataract; however, there has been a relative paucity 
of research using human tissue (Wormstone and Eldred, 2015). The fourth and final results 
chapter of this thesis explores the in vitro EMT response in human LECs, a fundamental step 
in translating animal studies to human. The first part describes the histopathological features 
of a human lens capsulorhexis with an anterior subscapular cataract obtained during cataract 
surgery. The second part describes the application of a human lens epithelial explant model to 
validate our established rat lens explant model. We hypothesised that the ASC plaque would 
display key features of EMT including upregulation of mesenchymal markers and 
downregulation epithelial makers. Further, we hypothesised that TGF would induce human 
LECs in explants to undergo EMT, bearing similarities to the rat explant model. 
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Chapter Two General Methods 
1 Tissue culture 
1.1 Experimental conduct 
Experimental procedures adhered to the National Health and Medical Research Council 
(Australia) guidelines, the Association for Research in Vision and Ophthalmology (ARVO) 
Statement for the Use of Animals in Ophthalmic and Vision Research (USA), the National 
Health and Medical Research Council (NHMRC) Australian Code of Practice for the Care and 
Use of Animals for Scientific Purposes (Australia) and the tenets of the Declaration of Helsinki. 
Experimental procedures were approved by the Animal Ethics Review Committee and Human 
Ethics Committee of the University of Sydney (see Appendix for Patient Consent Form). 
1.2 Animals 
Ocular lenses were obtained from post-natal 21-day-old albino Wistar rats (Rattus norvegicus). 
Animals were housed and bred at the Bosch Animal Facility (University of Sydney) in rooms 
with an alternating 12-hour light-to-dark cycle. 
1.3 Human lens tissue 
Human lens tissues were obtained as anterior capsulorhexis specimens from patients aged 59-
76 years during routine cataract surgery for age-related nuclear and/or cortical cataract 
involving phacoemulsification and intraocular lens implantation by ophthalmologist Dr. Keith 
Ong from Dalcross Adventist Hospital (Killara, NSW, Australia).  
1.4 Preparation of rat lens epithelial explants 
The rat lens epithelial explant system is an established ex vivo/in vitro tool to study ocular lens 
development and cataract (West-Mays et al., 2010). The explant consists of securing a flat 
mount of an intact lens epithelium whilst adherent to its native basement membrane, the lens 
capsule, to the base of a tissue culture dish (Figure 1). 
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Figure 1. Schematic of the lens epithelial explant system (left) and photograph (right) of two 
explants pinned down on a 35mm culture dish. 
 
All tissue collection and culture procedures were performed at 37°C in a humidified 5% CO2 
incubator. Medium 199 with Earle’s salts (Life Technologies, Waltham, MA, USA) 
supplemented with 0.1 μg/ml L-glutamine (Life Technologies), 0.1% bovine serum albumin 
(BSA; Sigma-Aldrich Corp., St. Louis, MO, USA), 2.5 μg/ml Amphostat B (Thermo Fisher 
Scientific, MA, USA) and 100 IU/ml penicillin/100 μg/ml streptomycin (Life Technologies) 
adjusted to a pH of 7.2 and ultra-filtered before being stored in sterile culture bottles at 4oC. 
Culture media was equilibrated at 37oC with 5% CO2 before use. 
Rats were euthanised by carbon dioxide asphyxiation and cervical dislocation. The eyeballs 
were enucleated and immediately placed into a culture dish containing fresh media. To 
maintain aseptic conditions, all tissue culture procedures were performed in a laminar flow 
cabinet. Under an inverted stereo microscope, fine watchmaker’s forceps were used to pinch 
and tear the sclera at the optic nerve. The lens was then removed from the surrounding ocular 
tissues along with any adherent extralenticular tissues such as the ciliary body. 
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Once the lens was cleanly isolated, the lens was orientated such that the anterior epithelium 
was facing the base of the dish. The posterior lens capsule was then torn gently multiple times 
to the lens equator and the fibre cell mass was readily removed. The lens capsule was then 
pinned down to the base of the tissue culture dish by applying pressure to lightly embed the 
capsule into the plastic. Sufficient pinning was required around the circumference of the 
explant to ensure that the epithelial monolayer was secure and flat. Two explants were pinned 
down per each 35mm culture dish (Nunc, Denmark). Explants were cultured for up to 5 days 
and viewed with phase-contrast microscopy (CK2, Olympus, Japan) and photographed (Leica 
DFC-280, Leica Camera, Wetzlar, Germany). 
1.5 Treatment with growth factors 
Growth factors were reconstituted according to the manufacturer’s instructions and added to 
the media of the appropriate culture dishes under a laminar flow cabinet. Table 1 outlines 
details of the growth factors used in this thesis. 
Table 1. Growth factors and their dosages. 
Growth factor Product #/Company Dosages 
Recombinant human transforming growth 
factor beta 2 (TGFβ2) 
302-B2-002 
R&D Systems 
200 pg/ml 
50 pg/ml 
10 ng/ml 
Recombinant human bone morphogenetic 
protein-7 (BMP-7) 
354-B2-010 
R&D Systems 
1, 5, 10, 20 ng/ml 
Recombinant human epidermal growth 
factor (EGF) 
585506 
BioLegend 
5 ng/ml 
 
1.6 Treatment with inhibitors 
Inhibitors were diluted in dimethyl sulfoxide (DMSO) and added to the media of the 
appropriate culture dishes in a laminar flow cabinet 2 hours prior to the start of the experiment. 
An equivalent volume of DMSO was added to all control groups. Table 2 outlines details of 
the inhibitors used in this thesis. 
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Table 2. Inhibitors and their dosages. 
Inhibitor Product #/Company Dosages 
PD153035, EGFR inhibitor 302-B2-002 
R&D Systems 
100 nM 
U0126, MEK1/2 inhibitor 9903S 
Cell Signaling 
50 µM 
SIS3, Smad3 inhibitor sc-253565 
Santa Cruz 
5 µM 
2 Protein analysis 
2.1 Immunofluorescence for rat explants 
Rat lens epithelial explants were fixed in 100% methanol for 45 seconds and rinsed 4 times in 
phosphate buffered saline (PBS). This was followed by rinsing (3 x 5 minutes) in PBS 
supplemented with 0.1% (w/v) BSA (PBS/BSA). Explants were incubated for 1 hour in a 
blocking solution of 10% normal goat serum (NGS) diluted in PBS/BSA. Primary antibodies 
were diluted in PBS/BSA with 1.5% NGS and incubated overnight at 4°C in a humidified 
chamber. Primary antibodies were diluted in PBS/BSA with 1.5% NGS and incubated 
overnight at 4oC in a humidified chamber. The following day, explants were equilibrated to 
room temperature and any unbound primary antibody was removed by rinsing in PBS/BSA (3 
x 5 minutes). The appropriate secondary antibody was diluted 1:1000 in PBS/BSA and applied 
to the explants for 2 hours at room temperature in a dark humidified chamber. Explants were 
rinsed (3 x 5 minutes) in PBS/BSA before counterstaining with 3 µg/ml bisbenzimide (Hoechst 
33342; Sigma-Aldrich Corp.) for 3 minutes. Explants were then rinsed in PBS/BSA (3 x 5 
minutes) and mounted with 10% PBS (v/v) in glycerol, before viewing with a Zeiss LSM-5Pa 
confocal microscope (Carl Zeiss AG, Jena, Germany) and photographed using Zen Blue edition 
(Carl Zeiss AG). All primary and secondary antibodies used and their dilutions are listed in 
Table 3. 
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Table 2. List of primary and secondary antibodies and their dilutions for immunofluorescence 
(IF) and/or western blotting (WB). 
Antibody Animal Product code 
Company 
Dilutions 
Primary antibodies 
Alpha-smooth muscle 
actin (α-SMA) 
Mouse monoclonal A2547 
Sigma-Aldrich Corp. 
1:100 for IF 
1:2000 for WB 
β-catenin Rabbit polyclonal H-102 
Santa Cruz 
1:100 for IF 
1:2000 for WB 
Phospho-Smad2/3 Rabbit monoclonal D27F4 
Cell Signaling 
Technology 
1:1000 for WB 
Total-Smad2/3 Rabbit monoclonal 8685 
Cell Signaling 
Technology 
1:100 for IF 
1:1000 for WB 
Tropomyosin CGβ6 
(Tpm1.6-1.9) 
Mouse monoclonal Gift from Peter 
Gunning, University 
of New South Wales, 
Australia 
1:100 for WB 
 
Phospho-EGFRY1068 Rabbit polyclonal 2234 
Cell Signaling 
Technology 
1:1000 for WB 
Phospho-ERK1/2 
(phospho-p44/p42) 
Rabbit polyclonal 9101 
Cell Signaling 
Technology 
1:1000 for WB 
total-ERK1/2 
(p44/p42) 
Rabbit polyclonal 9102 
Cell Signaling 
Technology 
1:1000 for WB 
GAPDH Mouse monoclonal G8795 
Sigma-Aldrich Corp. 
1:1000 for WB 
Secondary antibodies 
Goat anti-mouse 
Alexa-Fluor 488 IgG 
Mouse A11001 
Invitrogen 
1:1000 for IF 
Goat anti-rabbit 
Alexa-Fluor 488 IgG 
Rabbit ab150077 
Abcam 
1:1000 for IF 
Goat anti-mouse 
Alexa-Fluor 594 IgG 
Mouse ab150116 
Abcam 
1:1000 for IF 
Goat anti-rabbit 
Alexa-Fluor 594 IgG 
Rabbit A11037 
Invitrogen 
1:1000 for IF 
Anti-mouse HRP-
conjugated IgG 
Mouse 7076S 
Cell Signaling 
Technology 
1:5000 for WB 
Anti-rabbit HRP-
conjugated IgG 
Rabbit 7074S 
Cell Signaling 
Technology 
1:5000 for WB 
2.2 Immunofluorescence for human explants 
Human anterior capsulorhexis specimens were fixed in 10% NBF overnight and stored in 70% 
ethanol prior to immunofluorescence labelling. Explants were rinsed in PBS/BSA (3 x 5 
minutes) then permeabilised in PBS/BSA containing 0.05% (v/v) Tween-20 (Sigma-Aldrich 
Corp.) (3 x 5 minutes) followed by further rinsing in PBS/BSA (2 x 5 minutes). Explants were 
then incubated in a blocking solution of 3% NGS diluted in PBS/BSA for 30 minutes at room 
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temperature. Primary antibodies were diluted in PBS/BSA with 3% NGS and incubated 
overnight at 4oC in a humidified chamber. The following day, explants were equilibrated to 
room temperature and any unbound primary antibody was removed by rinsing in PBS/BSA (3 
x 5 minutes). The corresponding secondary antibody was diluted 1:1000 in PBS/BSA and 
applied to the explants for 2 hours at room temperature in a dark humidified chamber. Explants 
were rinsed (3 x 5 minutes) in PBS/BSA before counterstaining with 3 µg/ml bisbenzimide 
(Hoechst 33342; Sigma-Aldrich Corp.) for 3 minutes. Explants were then rinsed in PBS/BSA 
(3 x 5 minutes) and mounted with 10% PBS (v/v) in glycerol, before viewing with an epi-
fluorescent microscope (Leica-DMLB, Germany) and Zeiss LSM-5Pa confocal microscope 
(Carl Zeiss AG, Jena, Germany) and photographed using Zen Blue edition (Carl Zeiss AG). 
All primary and secondary antibodies used and their dilutions are listed in Table 3. 
2.3 Western blotting 
Explants were rinsed in cold PBS and protein was extracted in cold lysis buffer containing 25 
mM Tris-HCl (pH 7.5), 250 mM sodium orthovandate, 2.5 mM EDTA, 0.375 M NaCl, 10 mM 
sodium deoxycholate, a protease inhibitor cocktail (Complete; Roche Applied Science) and 
phosphatase inhibitor (PhosStop; Roche Applied Science). Homogenised samples were rotated 
for 2 hours at 4oC to facilitate cell lysis. Lysates were then centrifuged at 15,500g for 15 
minutes at 4oC. Supernatant protein content was quantified using the Micro BCA protein assay 
reagent kit (Thermo Fisher Scientific). 
Protein lysates were combined with Laemmli sample buffer (BioRad Laboratories, Hercules, 
CA, USA) in a 1:1 ratio. Up to 10 µg of lens explant protein extract was loaded onto a 10% 
SDS-PAGE gel for electrophoresis for 1.5 hours at 200 V before being transferred onto an 
Immobilon polyvinylidene fluoride membrane (Merck Millipore) for up to 3 hours at 100 V. 
The membrane was then incubated for 1 hour in a blocking solution of 2.5% BSA in 0.1% 
Tween-20 in Tris-buffered saline (TBST) for phosphorylated proteins and 5% (w/v) non-fat 
skim milk powder in TBST for non-phosphorylated proteins. Membranes were incubated 
overnight on a rocker with the primary antibody at 4°C. All primary and secondary antibodies 
used and their dilutions are listed in Table 3. 
The next day, membranes were rinsed in TBST (3 x 5 minutes) and subsequently incubated for 
2 hours with the corresponding horseradish peroxidase (HRP)-conjugated secondary 
Chapter Two: General Methods 
42 
antibodies. Membranes were then rinsed in TBST (3 x 10 minutes) and incubated in Immobilon 
Western Chemiluminescent HRP Substrate (Merck Millipore) for 2 minutes. The ChemiDoc 
MP imaging system (BioRad Laboratories) was used to capture chemiluminescence signals 
and ImageLab software (BioRad Laboratories) was used to perform densitometric analysis. 
3 Gene analysis 
3.1 Reverse transcriptase-quantitative polymerase chain reaction 
(RT-qPCR) 
Explants were rinsed in cold PBS following a 24-hour treatment period and total RNA 
extraction was performed using the Isolate II RNA Micro Kit (Bioline, Alexandria, NSW, 
Australia) according to the manufacturer’s instructions. RNA concentration and purity was 
assessed using the Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific). RNA 
integrity was determined using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA, USA). Only samples with 260/280 ratios > 2 and RNA integrity numbers > 5 were 
used for subsequent RT-qPCR analysis. 
The SensiFAST cDNA synthesis kit (Bioline) was used to reverse-transcribe total RNA (200 
ng) as per the manufacturer’s instructions. cDNA samples were then diluted 1:12 in nuclease-
free water. Oligonucleotide primers (Table 4) were designed using Primer-BLAST to span the 
exon-exon junction. 
All RT-qPCR reactions were performed using the SensiFAST SYBR No-ROX kit (Bioline). 
Using a Freedom EV075 robotic station with Freedom EVOware Standard 3.2 software (Tecan, 
Port Melbourne, VIC, Australia), 10 µl reactions were set up in a LightCycler 480, 384-well 
plate (Roche Diagnostics Ltd., Forrenstrasse, Switzerland) consisting of 5 µl SYBR, 4 µl 
cDNA and 300 nM forward and reverse primers.  
RT-qPCR analysis was performed using the Roche LightCycler 480 (Roche Diagnostics Ltd.) 
under the following thermal cycling conditions: 95°C for 2 minutes followed by 45 cycles 
consisting of denaturation (95°C, 5 seconds), annealing (60°C, 10 seconds) and extension (72 
°C, 15 seconds). Melting curve profiles (95 °C for 5 minute, 60 °C for 1 minute and then slowly 
heating at 0.11°C/s up to 98°C with continuous measurement of fluorescence per 5°C) were 
conducted at the end of each run to confirm amplification of specific transcripts. 
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Serial dilutions (1:2) were performed to generate standard curves to cover an appropriate 
concentration range. Relative gene expression was reported as a ratio of the gene of interest 
over GAPDH expression using the second derivative maximum method of the LightCycler 
software (Roche Diagnostics Ltd.). All reactions, including minus RT controls and no-template 
controls, were run in duplicate. 
4 Statistical analysis 
Each experiment was performed at least three times. GraphPad Prism version 6.0 (GraphPad 
Software Inc., La Jolla, CA, USA) was used for all graphs. Western blot densitometry data was 
analysed relative to GAPDH, and then relative to the control group (no growth factor and/or 
inhibitors added). Western blot data was analysed by one- or two-way ANOVA with post hoc 
Tukey’s multiple comparisons test as specified. RT-qPCR data was analysed using a one-way 
ANOVA with post hoc Tukey’s multiple comparisons test on GenEx version 6.0 (MultiD 
Analyzes AB, Goteborg, Sweden) and GraphPad Prism. All data is presented as mean ± SEM 
and P < 0.05 was deemed statistically significant. 
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Table 4. Oligonucleotide primers. 
Gene name NCBI accession 
number 
Forward and reverse primers 
Glyceraldehyde 3-
phosphate 
dehydrogenase 
(GAPDH) 
NM_017008.4 Fwd 5'-AGACAGCCGCATCTTCTTGT-3' 
Rev 5'-CTTGCCGTGGGTAGAGTCAT-3' 
Collagen type I alpha 1 
chain (Col1A1) 
NM_053304.1 Fwd 5'-TGACTGGAAGAGCGGAGAGT-3' 
Rev 5'-GATAGCGACATCGGCAGGAT-3' 
Fibronectin (Fn) NM_019143.2 Fwd 5'-CCATCACTGGTCTGGAGCC-3' 
Rev 5'-ACCAGTTGGGGAAGCTCATC-3' 
Alpha-smooth muscle 
actin (α-SMA) 
NM_031004.2 Fwd 5'-CTATGCTCTGCCTCATGCCA-3' 
Rev 5'-CTCACGCTCAGCAGTAGTCA-3' 
Connective tissue 
growth factor (CTGF) 
NM_022266.2 Fwd 5'-GCGTGTGCACTGCCAAAGAT-3' 
Rev 5'-TGGCTCGCATCATAGTTGGG-3' 
Neural-cadherin (N-
cadherin) 
NM_031333.1 Fwd 5'-CTGCCATGACCTTCTACGGA-3' 
Rev 5'-GGGTCTGTCAGGATGGCAAA-3' 
Epithelial-cadherin (E-
cadherin) 
NM_031334.1 Fwd 5'-CTGGACCGAGAGAGTTACCC-3' 
Rev 5'-GGCACCGACCTCATTCTCAA-3' 
Inhibitor of 
differentiation-2 (Id2) 
NM_013060.3 Fwd 5’-CGACTGCTACTCCAAGCTCA-3’ 
Rev 5’-ATTCAGACGCCTGCAAGGAC-3’ 
Inhibitor of 
differentiation-3 (Id3) 
NM_013058.2 Fwd 5’-AGCCTCTTGGACGACATGAA-3’ 
Rev 5’-CTCAGCTGTCTGGATCGGGAG-3’ 
SMAD specific E3 
ubiquitin protein ligase 1 
(Smurf1) 
NM_001109598.1 Fwd 5’-AAGGCTTCAAGGCTCTGCAA-3’ 
Rev 5’-ATTAAAGCAGGTGTGGGCCTT-3’ 
Zinc finger E-box 
binding homeobox 1 
(Zeb1) 
NM_001308265.1 Fwd 5’-AGCCAAATGGAAACCAGGATGA-3’ 
Rev 5’-AGGTCACATGCGTACATCCC-3’ 
Zinc finger E-box 
binding homeobox 2 
(Zeb2) 
NM_001033701.1 Fwd 5’-CAGGGACAGATCAGCACCAA-3’ 
Rev 5’-AAGCGTTTCTTGCAGTTGGG-3’ 
Snail homolog 1 (Snai1) NM_053805.1 Fwd 5’-CGTGTGTGGAGTTCACCTTCC-3’ 
Rev 5’-TTTGCCACTGTCCTCATCGG-3’ 
SMAD family member 7 
(Smad7) 
NM_030858.1 Fwd 5’-CCAACTGCAGACTGTCCAGA-3’ 
Rev 5’-TTCTCCTCCCAGTATGCCAC-3’ 
Epidermal growth factor 
receptor (EGFR) 
NM_031507.1 Fwd 5’-AGAGCCAGAGCCAACGACT-3’ 
Rev 5’-CCACCTCCTGGATGGTCTTTA-3’ 
Heparin binding-
epidermal growth factor 
(HB-EGF) 
NM_012945.1 Fwd 5’-CTCTTTCTGGCCGCAGTGTT-3’ 
Rev 5’-GATCGGTCCCTTCCAAGTCC-3’ 
ADAM metallopeptidase 
domain 9 (Adam9) 
NM_001014772.1 Fwd 5’-GGCTCCCTACTCTCTGACCA-3’ 
Rev 5’-GCAGCAATCCTCTGAGTCCA-3’ 
ADAM metallopeptidase 
domain 10 (Adam10) 
NM_019254.1 Fwd 5’-GCTGGGAGGTCAGTATGGAAAT-3’ 
Rev 5’-TCGTGTGAGACTGCTCGTTT-3’ 
ADAM metallopeptidase 
domain 17 (Adam17) 
NM_020306.2 Fwd 5’-GCAAACAGTCATGGAGGGGT-3’ 
Rev 5’-CCAGGTCAGCCTCCTTTGTAA-3’ 
ADAM metallopeptidase 
domain 19 (Adam19) 
NM_001160228.1 Fwd 5’-GGGCAAGCGAAAGGTGACTA-3’ 
Rev 5’-CAGTGGTGCAGGATGGGATT-3’ 
 
 45 
Chapter Three  
 
Results (Part I) 
BMP-7 suppresses TGFβ-induced EMT in lens epithelial cells 
Intracellularly, a tightly regulated balance of growth factor signalling pathways exists to 
maintain cellular homeostasis and prevent disease. This concept is illustrated in the following 
paper that reveals the importance of balancing two members of the TGFβ superfamily of 
growth factors: TGFβ2 and BMP-7. Although these two factors belong to the same 
superfamily, their roles are vastly different. TGFβ2 is known to potently induce EMT leading 
to pathological diseases such as fibrosis while BMP-7 has been reported to counteract the 
fibrogenic activity of TGFβ2 (Zeisberg et al., 2003b). This paper shows that BMP-7 can block 
TGFβ2-induced EMT in LECs through increased BMP-responsive Smad proteins (Smad1/5) 
and resulting in a suppression of the TGFβ-responsive Smad proteins (Smad2/3). Basal levels 
of BMP-7 target genes, the inhibitors of differentiation (Id)-2 and Id3 are reduced during 
TGFβ2-induced EMT, and the addition of BMP-7 can prevent TGFβ2-induced downregulation 
of Id2/3. A disturbance of the balance of these growth factors favouring TGFβ2 leads to EMT, 
and exogenous administration of BMP-7 can maintain the balance, thus serving as a potential 
drug target for cataract treatment. 
This paper was published in Investigative Ophthalmology and Visual Science in January 2017. 
The work has arisen entirely during my PhD candidature under the guidance of my primary 
supervisor Professor Frank Lovicu who contributed to this manuscript by facilitating me with 
experimental design and manuscript writing. The other co-author, Magdalena Wojciechowski, 
is a PhD candidate in the same laboratory who contributed to this manuscript by assisting me 
with the RT-qPCR data collection and analysis. 
Reference: Shu DY, Wojciechowski M, Lovicu FJ. Bone morphogenetic protein (BMP)-7 
suppresses TGFβ2-induced epithelial-mesenchymal transition (EMT) in the lens: implications 
for cataract prevention. Investigative Ophthalmology and Visual Science 2017; 58(2): 781-
796. 
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Bone morphogenetic protein-7 suppresses TGFβ2-induced 
epithelial-mesenchymal transition in the lens: implications for 
cataract prevention 
 
Daisy Y. Shu, 1,2 Magdalena Wojciechowski1 and Frank J. Lovicu1,2 
1Discipline of Anatomy and Histology, Bosch Institute, The University of Sydney, NSW, 
Australia 
2Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, The University 
of Sydney, NSW, Australia 
Keywords: bone morphogenetic protein (BMP), transforming growth factor-beta (TGFβ), 
epithelial-mesenchymal transition (EMT), cataract 
1 Abstract 
PURPOSE: Epithelial-mesenchymal transition (EMT) of lens epithelial cells (LECs) is a key 
pathologic mechanism underlying cataract. Two members of the transforming growth factor-
beta (TGFβ) superfamily, TGFβ and bone morphogenetic protein-7 (BMP-7) have functionally 
distinct roles in EMT. While TGFβ is a potent inducer of EMT, BMP-7 counteracts the 
fibrogenic activity of TGFβ. We examine the modulating effect of BMP-7 on TGFβ-induced 
EMT in LECs. 
METHODS: Rat lens epithelial explants were treated exogenously with TGFβ2 alone or in 
combination with BMP-7 for up to 5 days. Expression levels of E-cadherin, β-catenin, α-
smooth muscle actin (α-SMA) and phosphorylated downstream Smads were determined using 
immunofluorescence and Western blotting. Reverse transcriptase quantitative PCR (RT-qPCR) 
was used to study gene expression levels of EMT markers and downstream BMP target genes, 
including the Inhibitors of differentiation (Id). 
RESULTS: TGFβ2 induced LECs to transdifferentiate into myofibroblastic cells. Addition of 
BMP-7 suppressed TGFβ2-induced α-SMA protein levels and mesenchymal gene expression, 
with retention of E-cadherin and β-catenin expression to the cell membrane. Addition of BMP-
7 prevented lens capsular wrinkling and cellular loss associated with TGFβ2-induced EMT 
over the 5-day treatment period. The inhibitory effect of BMP-7 was accompanied by an early 
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induction of pSmad1/5 and suppression of TGFβ2-induced pSmad2/3. Treatment with TGFβ2 
alone suppressed gene expression of Id2/3 and addition of BMP-7 restored Id2/3 expression. 
CONCLUSIONS: Exogenous administration of BMP-7 abrogated TGFβ2-induced EMT in rat 
lens epithelial explants. Understanding the complex interplay between the TGFβ- and BMP-7-
associated Smad signalling pathways and their downstream target genes holds therapeutic 
promise in cataract prevention. 
2 Introduction 
Cataract, an opacification of the ocular lens, is the leading cause of blindness worldwide (Foster 
and Resnikoff, 2005). Although cataract surgery restores vision initially, a common post-
operative complication is posterior capsular opacification (PCO). Advances in surgical 
techniques and intraocular lens design have reduced the prevalence of PCO, yet it remains a 
significant and uneradicated problem (Awasthi et al., 2009). Currently, cataract surgery and 
Nd:YAG laser capsulotomy are the only effective treatments for cataract and PCO respectively; 
however, they carry vision-related surgical complications and place major personal and 
financial burden on the aging population (Awasthi et al., 2009). Hence, there is interest in the 
development of non-invasive pharmacologic alternatives to maintain lens transparency. 
There is compelling evidence implicating epithelial-mesenchymal transition (EMT) in the 
pathogenesis of anterior subcapsular cataract (ASC) and PCO. During EMT, polarised lens 
epithelial cells (LECs) relinquish their cobblestone morphology and transdifferentiate into 
spindle-shaped myofibroblastic cells that elongate and migrate across the lens capsule (de 
Iongh et al., 2005). Transforming growth factor-beta (TGFβ) has been studied extensively as a 
key inducer of this lens EMT both in vitro (de Iongh et al., 2005; Wormstone et al., 2002) and 
in vivo (Hales et al., 1999; Lovicu et al., 2002; Robertson et al., 2007). While TGFβ induces 
aberrant lens cell behaviour, other growth factors found in the ocular media such as bone 
morphogenetic protein-7 (BMP-7) regulate normal cellular processes in the lens. Specifically, 
BMP-7 and its receptors have been identified as key regulators of lens induction (Huang et al., 
2015; Luo et al., 1995; Wawersik et al., 1999), gap-junction mediated communication (Boswell 
et al., 2008) and lens fibre differentiation (Belecky-Adams et al., 2002; Boswell et al., 2008; 
Hung et al., 2002) – all critical elements for proper lens development, maintenance and 
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function. Moreover, human genetic mutations in BMP-7 have resulted in severe eye defects 
such as anophthalmia, in addition to kidney and skeletal defects (Wyatt et al., 2010). 
There is a growing body of literature supporting the role of BMP-7 in antagonising TGFβ-
driven EMT (Miyazono et al., 2005). Several studies unequivocally demonstrate that 
exogenous administration of BMP-7 enhanced the recovery rate of TGFβ-induced renal 
fibrosis (Morrissey et al., 2002; Zeisberg et al., 2003b, 2003a). Adenoviral gene transfer of 
BMP-7 suppressed TGFβ-driven corneal scarring in a mouse alkali burn-induced injury model 
(Saika et al., 2005). In a human model of primary open angle glaucoma, BMP-7 antagonised 
TGFβ-induced expression of extracellular matrix proteins in trabecular meshwork cells 
(Fuchshofer et al., 2007). In the lens, however, there is a paucity of literature investigating the 
potential inhibitory role of BMP-7. Adenoviral-mediated overexpression of BMP target genes, 
Inhibitors of differentiation (Id)-2 and Id3, suppressed TGFβ-induced EMT in a murine lens 
epithelial cell line (Kowanetz et al., 2004). However, adenoviral-mediated expression of BMP-
7 in situ delayed but did not completely inhibit EMT in a mouse lens injury-induced model 
(Saika et al., 2006). 
We describe experiments in vitro investigating the role of BMP-7 in modulating TGFβ-induced 
EMT in the lens. This is the first time exogenous administration of BMP-7 has been used to 
counteract TGFβ-induced EMT in the lens epithelial explant system. To establish further 
evidence of the opposing effects of BMP-7 and TGFβ, we examined differences in activation 
of their respective downstream Smad signalling proteins. We found that inhibition of EMT by 
BMP-7 resulted in an increased phosphorylation of BMP-7-responsive Smads (Smad1/5) and 
a concurrent reduction in phosphorylation of TGFβ-responsive Smads (Smad2/3). Moreover, 
we showed that TGFβ suppresses expression of BMP-7 target genes, Id2/3, and the addition of 
BMP-7 restores these Id2/3 levels. Taken together, we highlighted the contrasting roles of 
different TGFβ superfamily members in the lens, in which tight regulation of BMP-7-
responsive Smad-signalling and downstream target genes maintain the normal lens epithelial 
phenotype, and aberrant TGFβ-responsive Smad-signalling leads to the EMT underlying 
fibrotic cataract formation. 
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3 Methods 
3.1 Animals 
Ocular tissues were collected from postnatal-day-21 albino Wistar rats (Rattus norvegicus) that 
were euthanized by carbon dioxide asphyxiation and cervical dislocation. All animal 
procedures conformed to the Association for Research in Vision and Ophthalmology (ARVO) 
Statement for the Use of Animals in Ophthalmic and Vision Research (United States) and the 
National Health and Medical Research Council (NHMRC) Australian Code of Practice for the 
Care and Use of Animals for Scientific Purposes (Australia). All studies were approved by the 
Animal Ethics Committee of the University of Sydney (Australia). 
3.2 Preparation of lens epithelial explants 
Lens epithelial explants were prepared as described previously (West-Mays et al., 2010). All 
tissue culture was performed in Medium 199 with Earle’s salts (Life Technologies, Waltham, 
MA, USA), supplemented with 0.1% bovine serum albumin (BSA; Sigma-Aldrich Corp., St. 
Louis, MO, USA), 0.1 μg/ml L-glutamine (Life Technologies), 100 IU/ml penicillin/100 μg/ml 
streptomycin (Life Technologies) and 2.5 μg/ml Amphostat B (Thermo Fisher Scientific, MA, 
USA) at 37°C in a humidified 5% CO2 incubator. 
The effects of BMP-7 on TGFβ-induced EMT were initially investigated by adding increasing 
doses (1, 5, 10 or 50 ng/ml) of recombinant human BMP-7 (R&D Systems, Minneapolis, MN, 
USA) to explants concurrently in the presence or absence of 200 pg/ml of recombinant human 
TGFβ2 (R&D Systems). Subsequent experiments were performed using 5 ng/ml of BMP-7 as 
this was the lowest inhibitory dosage of BMP-7. LECs were cultured for up to 5 days. For 
short-term exposure studies, TGFβ2 was added alone or in combination with BMP-7 for 2 
hours after which the culture media was removed and replaced with fresh unsupplemented 
media. Cells in explants were viewed with phase-contrast microscopy (CK2, Olympus, Japan) 
and photographed (Leica DFC-280; Leica Camera, Wetzlar, Germany) before being harvested 
for immunofluorescence and western blot analysis. 
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3.3 Assessment of capsular wrinkling 
Following a 5-day culture period, explants were rinsed in water for 1 hour to remove the 
overlying cells, exposing the underlying lens capsule. The bare lens capsule was viewed using 
phase-contrast microscopy and photographed as described above. 
3.4 Immunofluorescence 
Explants were fixed in 100% methanol for 45 seconds and rinsed four times in phosphate 
buffered saline (PBS). This was followed by rinsing (3 x 5 minutes) in PBS supplemented with 
0.1% (wt/vol) BSA (PBS/BSA). Explants then were incubated in 10% normal goat serum 
(NGS) diluted in PBS/BSA for 1 hour. Primary antibodies were diluted in PBS/BSA with 1.5% 
NGS and incubated overnight at 4°C in a humidified chamber. Anti-mouse antibodies specific 
for α-smooth muscle actin (α-SMA; A2547; monoclonal; Sigma-Aldrich Corp.), E-cadherin 
(4A2; monoclonal; Cell Signalling Technology, Danvers, MA, USA) and anti-rabbit antibodies 
specific for β-catenin (H-102; polyclonal; Santa Cruz, TX, USA) and total-Smad2/3 (8685; 
monoclonal; Cell Signalling Technology) were all diluted at 1:100. 
Following application of the primary antibody, explants were equilibrated to room temperature 
and any unbound primary antibody was removed by rinsing in PBS/BSA (3 x 5 minutes). The 
appropriate secondary antibody was diluted 1:1000 in PBS/BSA and applied to the explants 
for 2 hours at room temperature in a dark humidified chamber. E-cadherin and α-SMA were 
detected using goat anti-mouse Alexa-Fluor 488 (Cell Signalling Technology). β-catenin was 
detected using goat anti-rabbit Alexa-Fluor 594 (Abcam, Cambridge, MA, USA). Explants 
were rinsed (3 x 5 minutes) in PBS/BSA before counterstaining with 3 µg/ml bisbenzimide 
(Hoechst 33342; Sigma-Aldrich Corp.) for 2 minutes. Explants then were rinsed in PBS/BSA 
(3 x 5 minutes). Explants were mounted with 10% PBS (vol/vol) in glycerol and viewed with 
a Zeiss LSM-5Pa confocal microscope (Carl Zeiss AG, Jena, Germany). 
3.5 SDS-Page and Western blotting 
Explants were rinsed in cold PBS and cell proteins were extracted in cold lysis buffer 
containing 2.5 mM EDTA, 25 mM Tris-HCl (pH 7.5), 0.375 NaCl, 250 mM sodium 
orthovandate, 10 mM sodium deoxycholate, a protease inhibitor cocktail tablet (Complete; 
Roche Applied Science) and a phosphatase inhibitor tablet (PhosStop; Roche Applied Science). 
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Homogenised samples were rotated for 2 hours at 4°C to facilitate lysis. Lysates were 
precleared by centrifugation at 15,500g for 15 minutes at 4°C. Protein content of the 
supernatant was quantified using the Micro BCA protein assay reagent kit (Thermo Fisher 
Scientific). 
Protein lysates were mixed in a 1:1 ratio with Laemmli sample buffer (BioRad Laboratories, 
Hercules, CA, USA). Up to 10 μg of lens explant protein extract was loaded onto 10% SDS-
PAGE gels for electrophoresis for 1.5 hours at 200 V before being transferred onto an 
Immobilon polyvinylidene fluoride membrane (Merck Millipore, Billerica, MA, USA) for 2 
hours at 100 V. The membrane then was incubated for 1 hour with a blocking solution of 5% 
(wt/vol) nonfat skim milk powder in 0.1% Tween-20 in Tris-buffered saline (TBST) for 
nonphosphorylated proteins and 2.5% BSA in TBST for phosphorylated proteins. Membranes 
were incubated overnight at 4°C with the primary antibody. Anti-mouse antibodies specific 
against α-SMA (A2547; monoclonal, Sigma-Aldrich Corp.), E-cadherin (4A2; monoclonal; 
Cell Signalling Technology), GAPDH (G8795; Sigma-Aldrich Corp.) and anti-rabbit 
antibodies specific against β-catenin (H-102; Santa Cruz Biotechnology), phospho-Smad2/3 
(D27F4; monoclonal; Cell Signalling Technology), total-Smad2/3 (8685; monoclonal; Cell 
Signalling Technology) and phospho-Smad1/5 (41D10; monoclonal; Cell Signalling 
Technology) were all diluted at 1:1000 with the exception of α-SMA and β-catenin that were 
diluted at 1:2000. 
Membranes were rinsed with TBST (3 x 5 minutes) and incubated for 2 hours with the 
appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies, either goat anti-
mouse HRP-conjugated IgG or goat anti-rabbit HRP-conjugated IgG (both diluted 1:5000 in 
TBST; Cell Signalling Technology). Membranes then were rinsed (3 x 10 minutes) in TBST 
and incubated for 2 minutes in Immobilon Western Chemiluminescent HRP Substrate (Merck 
Millipore). Chemiluminescence signals were captured using the ChemiDoc MP imaging 
system (BioRad Laboratories) and densitometric analysis was performed using ImageLab 
software (BioRad Laboratories). 
3.6 Total RNA extraction and cDNA synthesis 
Following a 24-hour treatment period, explants were rinsed in cold PBS and total RNA was 
extracted using the Isolate II RNA Micro Kit (Bioline, Alexandria, NSW, Australia) according 
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to the manufacturer’s instructions. Concentration and purity of RNA was measured using the 
Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific). Integrity of RNA was 
assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). 
Only samples with 260/280 ratios greater than 2 and RNA integrity numbers greater than 8 
were used for reverse transcriptase quantitative PCR (RT-qPCR) analysis. 
3.7 Reverse transcriptase-quantitative polymerase chain reaction 
(RT-qPCR) 
Total RNA (200 ng) was reverse-transcribed using the SensiFAST cDNA synthesis kit 
(Bioline) as per the manufacturer’s instructions. Complementary DNA (cDNA) samples then 
were diluted 1:12 with nuclease-free water. Oligonucleotide primers (Table 4) were designed 
using Primer-BLAST to span the exon-exon junction. 
All RT-qPCR reactions were performed using the SensiFAST SYBR No-ROX kit (Bioline). 
Reactions (10 µl) were set up in a LightCycler 480, 384-well plate (Roche Diagnostics Ltd., 
Forrenstrasse, Switzerland) using a Freedom EV075 robotic station with Freedom EVOware 
Standard 3.2 software (Tecan, Port Melbourne, VIC, Australia) consisting of 4 µl cDNA, 5 µl 
SYBR and 300 nM forward and reverse primers. RT-qPCR analysis was done using the Roche 
LightCycler 480 (Roche Diagnostics Ltd.) under the following thermal cycling conditions: 
95oC for 2 minutes followed by 45 cycles consisting of denaturation (95oC, 5 seconds), 
annealing (60oC, 10 seconds) and extension (72oC, 15 seconds). At the end of each run, melting 
curve profiles (95oC for 5 min, 60oC for 1 minute and then slowly heating at 0.11oC/s up to 
98oC with continuous measurement of fluorescence per 5oC) to confirm amplification of 
specific transcripts. Standard curves were generated by serially diluting (1:2), covering an 
appropriate concentration range. Relative gene expression was determined as a ratio of the gene 
of interest and GAPDH using the second derivative maximum method of the LightCycler 
software (Roche Diagnostics Ltd.). All reactions, including no-template controls and minus RT 
controls, were run in duplicate. 
3.8 Statistical analysis 
Each experiment was performed at least three times and graphing was performed using 
GraphPad Prism version 6.0 (GraphPad Software Inc., La Jolla, CA, USA). Western blot data 
was analysed using GraphPad Prism version 6.0 (GraphPad Software Inc.) by 1- or 2-way 
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ANOVA with post hoc Tukey’s multiple comparisons test. RT-qPCR data was analysed using 
the LightCycler software (Roche Diagnostics Ltd.) and GenEx version 6.0 (MultiD Analyses 
AB, Goteborg, Sweden) using an unpaired 2-tailed t-test. All data are presented as mean ± 
SEM and P < 0.05 was considered statistically significant. 
4 Results 
4.1 BMP-7 blocks TGFβ2-induced EMT of LECs in a dose-dependent 
manner 
Using phase-contrast microscopy, LECs in untreated explants remained as a cuboidal 
monolayer with a characteristic cobblestone-packed arrangement, indicative of a normal 
epithelial phenotype (Fig. 1A). At 48 hours, explants treated with TGFβ2 exhibited an elongate, 
spindle-shaped morphology, indicative of an EMT response (Fig. 1B). While the lowest dose 
of BMP-7 (1 ng/ml) in the presence of TGFβ2 resulted in similar elongation in many cells (Fig. 
1C), higher doses of BMP-7 (from 5 ng/ml) displayed a retention of the normal epithelial 
phenotype, demonstrating suppression of TGFβ2-induced transdifferentiation (Fig. 1D-F). 
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Figure 1. BMP-7 application inhibits TGFβ-induced EMT in a dose-dependent manner. 
Following 48 hours of culture, untreated control explants (A) retained a normal cuboidal layer of 
epithelial cells, whereas cells in explants treated with TGFβ2 alone (B) displayed an elongate, spindle-
shaped morphology (yellow arrows). Co-treatment with TGFβ2 and 1 ng/ml BMP-7 (C, +TB1) also 
resulted in elongate cells (yellow arrows) whereas higher doses of BMP-7 (5, 10 and 50 ng/ml; +TB5, 
+TB10, +TB50) retained the normal lens epithelial phenotype (D-F). Images are representative of 3 
independent experiments. Scale bar: 100 µm. 
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To further explore the suppressive effect of BMP-7 on TGFβ2-induced EMT, we examined the 
expression of epithelial and mesenchymal markers in these treatment groups at 48 hours using 
Western blotting (Fig. 2A). Addition of TGFβ2 to LECs significantly upregulated α-SMA 
expression compared to cells in control explants (P = 0.0001, Fig. 2B). Co-treatment of LECs 
with TGFβ2 and 1 ng/ml of BMP-7 significantly upregulated α-SMA levels compared to that 
seen in control explants (P = 0.0034, Fig. 2B), and exhibited a slight, but not significant 
reduction in α-SMA levels compared to TGFβ2 alone-treated LECs (P = 0.3314, Fig. 2B). Co-
treatment of higher doses of BMP-7 with TGFβ2 resulted in no difference in α-SMA levels 
compared to cells in control explants (P = 0.9899 for 5 ng/ml; P = 0.9991 for 10 ng/ml; P = 
0.9967 for 50 ng/ml, Fig. 2B). As a result of this, the lowest suppressive dose of BMP-7 (5 
ng/ml) was chosen for all subsequent blocking experiments. There was no significant effect in 
the expression of epithelial markers, E-cadherin, and β-catenin between all treatment groups 
(P = 0.9293 for E-cadherin; P = 0.3341 for β-catenin; Fig. 2B). 
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Figure 2. BMP-7 application inhibits TGFβ-induced upregulation of α-SMA in a dose-dependent 
manner. 
Expression levels of epithelial and mesenchymal markers at 48 hours by Western blotting (A) and 
corresponding, relative densitometry analysis (B). In untreated control explants, lens epithelial cells 
showed minimal expression of the mesenchymal marker, α-SMA. TGFβ2 alone and in combination with 
1 ng/ml of BMP-7 significantly upregulated α-SMA expression compared to control explants. Complete 
inhibition of TGFβ2-induced α-SMA expression was evident with co-treatment of BMP-7 at higher doses 
(5 ng/ml and up), displaying no significant difference to control levels. No significant difference was 
observed in the levels of epithelial markers, E-cadherin and β-catenin between all treatment groups. 
Representative Western blots from 3 independent experiments, with data presented relative to GAPDH, 
as the mean ± SEM. One-way ANOVA, Tukey’s post hoc test **P < 0.01, ***P < 0.001. 
 
4.2 BMP-7 application blocks TGFβ-mediated incorporation of α-
SMA into stress fibres 
We examined the localisation of α-SMA in LECs using immunofluorescence confocal 
microscopy. Cells in control explants displayed low basal levels of α-SMA immunoreactivity 
(Fig. 3A), while cells in explants treated with TGFβ2 exhibited strong immunoreactivity for α-
SMA-labelled stress fibres, characteristic of an EMT response (Fig. 3B). Co-treatment with 
BMP-7 (5 ng/ml) inhibited TGFβ2-mediated labelling of α-SMA to stress fibres and resembled 
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cells in control explants (Fig. 3C). Similarly, treatment with BMP-7 (5 ng/ml) alone showed 
no difference in α-SMA-labelling compared to cells in control explants (Fig. 3D). 
 
Figure 3. BMP-7 application blocks TGFβ-mediated α-SMA. 
Immunofluorescence confocal microscopy of control explants at 48 hours showed low levels of basal 
cytoplasmic α-SMA immunoreactivity (A), while explants treated with TGFβ2 exhibited strong 
immunoreactivity for α-SMA, co-labelling to stress fibres (B). Co-treatment with BMP-7 (5 ng/ml) and 
TGFβ2 (C) and treatment with BMP-7 alone (D) showed no difference in α-SMA labelling compared to 
control explants. Images are representative of 3 independent experiments. Scale bar: 50 µm. 
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4.3 BMP-7 application facilitates retention of epithelial membrane 
markers 
Since the protein levels of E-cadherin and β-catenin remained similar in all treatment groups, 
we next investigated for changes in their spatial localisation. In untreated cells, E-cadherin 
(Fig. 4A) and β-catenin (Fig. 4B) were both localised to the cell membranes highlighting the 
cobblestone-packed arrangement. Although E-cadherin remained localised to the cell 
membrane in TGFβ2-treated explants, the expression pattern lacked the normal cobblestone-
packed arrangement, appearing unevenly distributed in an elongate pattern (Fig. 4C). This was 
in contrast to the lack of membranous localisation of β-catenin in the same cells of these 
TGFβ2-treated explants (Fig. 4D). Specifically, β-catenin displayed a pronounced punctate 
labelling in the cell nuclei and cytoplasm following treatment with TGFβ2. Treatment with 
BMP-7 inhibited TGFβ2-induced dysregulation of these epithelial markers with retention of 
E-cadherin (Fig. 4E) and β-catenin (Fig. 4F) labelling to the membrane, again highlighting the 
cobblestone-packed arrangement of the LECs. 
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Figure 4. BMP-7 application facilitates retention of epithelial membrane markers. 
Immunofluorescence confocal microscopy at 48 hours showed that E-cadherin (A) and β-catenin (B) 
were both localized to the cell membrane in control explants. In TGFβ-treated explants, the expression 
pattern of E-cadherin (C) and β-catenin (D) appeared dysregulated and unevenly distributed. Treatment 
with BMP-7 inhibited TGFβ-induced dysregulation of epithelial markers and restored E-cadherin (E) 
and β-catenin (F) labelling to the membrane. Images are representative of 3 independent experiments. 
Scale bar: 50 µm. 
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4.4 BMP-7 application reduces TGFβ-induced mesenchymal gene 
expression 
Following treatment of LECs with TGFβ2 for 24 hours, RT-qPCR showed a significant 
upregulation of mesenchymal gene expression compared to control explants: α-SMA (P < 
0.0001), Col1A1 (P < 0.0001), fibronectin (P < 0.0001), CTGF (P < 0.0001), and N-cadherin 
(P = 0.0003) (Fig. 5). The addition of BMP-7 also significantly upregulated mesenchymal gene 
expression compared to control explants: α-SMA (p = 0.016), Col1A1 (P = 0.014), fibronectin 
(P = 0.0063), CTGF (P = 0.015) and N-cadherin (P = 0.0012); however, this was to a 
significantly lesser extent when compared to TGFβ2 alone: α-SMA (P = 0.0094), Col1A1 (P = 
0.014), fibronectin (P = 0.0018), and CTGF (P = 0.0011) (Fig. 5). Interestingly, the addition 
of BMP-7 did not significantly reduce N-cadherin expression (P = 0.86) compared to TGFβ2 
alone. It should be noted that TGFβ2 only weakly upregulated CTGF and N-cadherin showing 
changes less than 2-fold. Gene expression of the epithelial marker, E-cadherin, did not change 
significantly amongst all treatment groups, corroborating the Western blot data. 
 
Figure 5. BMP-7 application blocks TGFβ-induced mesenchymal gene expression. 
Using RT-qPCR, treatment with TGFβ2 alone for 24 hours resulted in a significant upregulation of 
mesenchymal gene expression (α-SMA, Col1A1, fibronectin, CTGF, N-cadherin) compared to control. 
The addition of BMP-7 significantly reduced mesenchymal gene expression compared to TGFβ2 alone; 
however, a significant difference to control cells was still evident. BMP-7 did not significantly reduce N-
cadherin expression compared to TGFβ2 alone. Gene expression of E-cadherin, also did not change 
significantly amongst all treatment groups. Data from 4 independent experiments is presented relative 
to GAPDH as fold change ± SEM. Unpaired t-test *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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4.5 BMP-7 application blocks TGFβ-induced EMT and apoptosis 
To investigate whether the inhibitory effect of BMP-7 extended beyond 2 days, we followed 
the progression of TGFβ2-induced EMT over a 5-day culture period. Progressive cell loss was 
evident from day 3 of culture indicated by cellular blebbing (dashed-line arrows) and exposed 
areas of bare lens capsule (asterisks) (Fig. 6A). The exposed lens capsule also accentuated the 
presence of lens capsular wrinkling (solid-line arrows) (Fig. 6A). By day 5 of culture with 
TGFβ2, there was extensive cell loss and lens capsular wrinkling (Fig. 6B). Explants co-treated 
with BMP-7 (5 ng/ml) and TGFβ2 retained a confluent epithelial monolayer throughout the 5-
day culture period (Fig. 6C-D), with no evidence of capsular wrinkling (Fig. 6F) when we 
removed the overlying cells, compared to the extensive lens capsular wrinkling in TGFβ2-
treated alone explants (Fig. 6E). Untreated explants (Fig. 6G) and explants treated with BMP-
7 alone (Fig. 6H) retained a monolayer of epithelial cells with no indication of cell loss (Fig. 
6G-H).  
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Figure 6. BMP-7 application blocks TGFβ-induced EMT and apoptosis. 
Phase-contrast microscopy at day 3 of treatment with TGFβ2 (A) shows cellular blebbing (dashed-line 
arrows), exposed areas of bare lens capsule (asterisks) and resultant lens capsular wrinkling (solid-line 
arrows) and by day 5 of culture with TGFβ2 (C), there is marked cell loss and more apparent lens 
capsular wrinkling (solid-line arrows). Treatment with BMP-7 and TGFβ2 at day 3 (B) and day 5 (D). 
After washing off the cells, the underlying lens capsule can be seen at day 5 following treatment with 
TGFβ2 (E) or BMP-7 and TGFβ2 (F). Untreated explants (G) and treatment with BMP-7 only (H) at day 
5. Images are representative of 3 independent experiments. Scale bar: 100 µm. 
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Immunofluorescence labelling of occasional cells remaining in explants treated with TGFβ2 at 
5 days showed α-SMA-labelled stress-fibres (Fig. 7A) and punctate cytosolic β-catenin (Fig. 
7B). In contrast, cells in explants co-treated with BMP-7 and TGFβ2 retained an epithelial 
phenotype, with little to no α-SMA label (Fig. 7C), and membranous β-catenin expression, 
highlighting their packed arrangement (Fig. 7D). 
 
Figure 7. BMP-7 application blocks TGFβ-induced α-SMA expression at 5 days of culture. 
Immunofluorescence confocal microscopy of the occasional remaining cells in TGFβ2-treated explants 
at day 5 of culture showed stress-fibres labelled for α-SMA (A) and punctate cytosolic β-catenin labelling 
(B). Cells in explants co-treated with BMP-7 and TGFβ2 showed minimal α-SMA expression (C) and 
membranous β-catenin labelling (D). Images are representative of 3 independent experiments. Scale 
bar: 50 µm. 
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4.6 BMP-7 application modulates TGFβ2-induced Smad signalling 
To examine the signalling pathways involved in mediating the inhibitory effect of BMP-7 on 
TGFβ2-induced EMT, we monitored for changes in the respective phosphorylated Smads 
during the first 6 hours following treatment (Fig. 8A). Treatment of LECs with BMP-7 alone 
induced a sustained upregulation of pSmad1/5 that was significantly higher than treatment with 
TGFβ2 alone at 2 hours (P = 0.0280), 4 hours (P = 0.0114) and 6 hours (P = 0.0161) (Fig. 8B). 
Co-treatment of cells with BMP-7 and TGFβ2 exhibited an early peak of pSmad1/5 signalling 
at 20 minutes, that was significantly higher than with TGFβ2 alone at this same time point (P 
= 0.0112; Fig. 8B). LECs treated with BMP-7 alone did not have altered basal pSmad2/3 levels. 
Treatment of LECs with TGFβ2 showed a marked increase of pSmad2/3, peaking at 2 hours 
compared to BMP-7 alone (P = 0.0313; Fig. 8C). Co-treatment with BMP-7 significantly 
reduced this 2 hour peak of TGFβ2-induced pSmad2/3 in LECs (P = 0.0048; Fig. 8C).  
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Figure 8. BMP-7 application modulates TGFβ-induced Smad signalling. 
Treatment with BMP-7 alone induced a sustained increase in pSmad1/5 that was significantly higher 
than treatment with TGFβ2 alone at 2, 4 and 6 hours (B). Co-treatment with BMP-7 and TGFβ2 
exhibited an early peak of pSmad1/5 signalling at 20 minutes (B). Treatment with TGFβ2 showed a 
marked increase of pSmad2/3, peaking at 2 hours (C). Co-treatment with BMP-7 significantly reduced 
TGFβ2-driven activation of pSmad2/3 at 2 hours (C). Representative Western blots from 3 independent 
experiments (A) with data presented as mean ± SEM. Two-way ANOVA, Tukey’s post hoc test *P < 
0.05, **P < 0.01 and ***P < 0.001.  
 
 
These findings were further corroborated with immunofluorescence analysis of total Smad2/3 
(tSmad2/3) localisation. Control explants displayed cytoplasmic labelling of tSmad2/3 at both 
20 minutes and 2 hours (Fig. 9A-B). Exposure of LECs to TGFβ2 for 20 minutes and 2 hours 
demonstrated localisation of tSmad2/3 labelling to cell nuclei (Fig. 9C-D). The addition of 
BMP-7 at 20 minutes or 2 hours reduced TGFβ2-induced nuclear translocation of tSmad2/3, 
with retention of cytoplasmic tSmad2/3, similar to control explants (Fig. 9E); however, at 2 
hours, some nuclear translocation of tSmad2/3 was still apparent (Fig. 9F). 
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Figure 9. BMP-7 application modulates nuclear localisation of tSmad2/3. 
Immunofluorescence confocal microscopy showed cytoplasmic labelling of tSmad2/3 at both 20 
minutes (A) and 2 hours (B) in control explants. Exposure of LECs to TGFβ2 for 20 minutes (C) and 2 
hours (D) demonstrated nuclear localisation of tSmad2/3. The addition of BMP-7 at 20 minutes retained 
cytoplasmic tSmad2/3 (E); however, tSmad2/3 some nuclear translocation of tSmad2/3 is evident at 2 
hours (F). Images are representative of 3 independent experiments. Scale bar: 50 µm. 
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4.7 Short-term exposure to BMP-7 blocks TGFβ-induced EMT and 
apoptosis 
Given that BMP-7 induced a peak of pSmad1/5 signalling at 20 minutes and suppression of 
TGFβ2-induced pSmad2/3 at 2 hours, we next asked whether the inhibitory effect of BMP-7 
was dependent on this early time point. LECs exposed to TGFβ2 alone for 2 hours continued 
to undergo EMT over the 5-day culture period with characteristic cell elongation and cell loss, 
but interestingly, minimal lens capsular wrinkling (Fig. 10A-B). The addition of BMP-7 for 20 
minutes blocked TGFβ-induced EMT with retention of a monolayer of epithelial cells over the 
entire culture period (Fig. 10C-D). 
 
Figure 10. Short-term exposure to BMP-7 blocks TGFβ-induced EMT and apoptosis. 
Phase-contrast microscopy showed that LECs exposed to TGFβ2 alone for 2 hours underwent EMT 
over the 5-day culture period with characteristic cell elongation and cell loss (Fig. 10A-B). Co-treatment 
of TGFβ2 and BMP-7 for 2 hours retained a monolayer of epithelial cells over the 5-day culture period 
(Fig. 10C-D). Images are representative of 3 independent experiments. Scale bar: 100 µm. 
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Immunofluorescence labelling of control explants showed minimal α-SMA label (Fig. 11A) 
and membranous β-catenin expression (Fig. 11B). Explants treated with TGFβ2 at 5 days 
showed α-SMA-reactive stress-fibres (Fig. 11C) and punctate cytosolic β-catenin (Fig. 11D). 
Interestingly, LECs co-treated with BMP-7 and TGFβ2 for 20 minutes displayed an 
upregulation in cytoplasmic α-SMA expression (Fig. 11E) despite retaining membranous β-
catenin labelling highlighting the cobblestone cell arrangement (Fig. 11F). 
 
Figure 11. Short-term exposure to BMP-7 modulates TGFβ-induced markers of EMT. 
Immunofluorescence confocal microscopy of control explants showed minimal α-SMA label (A) and 
membranous β-catenin expression (B). At day 5, explants exposed to TGFβ2 alone for 2 hours showed 
α-SMA-reactive stress-fibers (C) and punctate cytosolic β-catenin (D). Co-treatment of TGFβ2 and 
BMP-7 for 20 minutes displayed an upregulation in cytoplasmic α-SMA expression (E) despite retaining 
membranous β-catenin expression (F). Images are representative of 3 independent experiments. Scale 
bar: 50 µm. 
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4.8 BMP-7 inhibits TGFβ2-induced suppression of Id2 and Id3 gene 
expression 
As the Id proteins are reported to be downstream effectors of BMP signalling, we investigated 
the gene expression of Id2 and Id3 using RT-qPCR. Treatment with TGFβ2 alone significantly 
downregulated the expression of Id2 (P = 0.00014) and Id3 (P = 0.0001) compared to levels in 
control explants. The addition of BMP-7 significantly inhibited TGFβ2-induced suppression 
of Id2 (P = 0.0023) and Id3 (p = 0.014), showing no significant difference from control cells 
for both Id2 (P = 0.50) and Id3 (P = 0.62). 
 
Figure 12. BMP-7 inhibits TGFβ-induced suppression of Id2 and Id3 gene expression. 
Using RT-qPCR, treatment with TGFβ2 alone significantly downregulated expression of Id2 and Id3 
compared to control explants. The addition of BMP-7 significantly inhibited TGFβ2-induced suppression 
of Id2 and Id3 showing no significant difference to control explants for both Id2 and Id3. Data from 4 
independent experiments are presented relative to GAPDH as fold change ± SEM. Unpaired t-test *P 
< 0.05, **P < 0.01, ***P < 0.001. 
 
5 Discussion 
The present study shows, for the first time to our knowledge, the direct ability of BMP-7 in 
blocking TGFβ2-driven EMT in the rat lens explant system. We demonstrate that exogenous 
administration of BMP-7 inhibited TGFβ2-induced myofibroblastic transdifferentiation by 
blocking cell elongation and incorporation of α-SMA into stress fibres. Addition of BMP-7 
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suppressed TGFβ2-induced upregulation of mesenchymal gene expression of ECM proteins 
including collagen 1A1, fibronectin and connective tissue growth factor. Although N-cadherin 
was not suppressed by the addition of BMP-7, the fold change in expression of this gene was 
below 2 for all treatment groups. Furthermore, BMP-7 promoted membranous localisation of 
epithelial markers, E-cadherin and β-catenin, maintaining the cobblestone-packed arrangement 
of cells, compared to the dysregulated and punctate cytosolic expression of these markers in 
LECs treated with TGFβ2 alone. Hence, BMP-7 promotes the epithelial phenotype, 
emphasising its role in maintaining lens cell integrity and polarity. 
We show that the inhibitory effect of BMP-7 extends over the entire culture period examined, 
with a monolayer of cuboidal LECs retained by day 5. The progressive cell elongation, cell 
blebbing, extensive cell loss and capsular wrinkling observed in TGFβ2-induced EMT over 5 
days has been well characterised in the rat lens epithelial explant system and mimics 
morphological features of human ASC and PCO (de Iongh et al., 2005). The cell loss induced 
by TGFβ2 has been reported to occur through apoptosis, corroborating the apoptotic features 
typically observed in human ASC and PCO such as chromatin margination and cytoplasmic 
condensation (Maruno et al., 2002). Apoptotic cell death has also been reported in an in vivo 
rabbit lens extraction model and identified at the incised edge of the anterior capsule amongst 
myofibroblast-like cells (Kato et al., 1997). In the present study, BMP-7 promoted cell survival 
by preventing TGFβ2-induced apoptosis. Moreover, BMP-7 prevented EMT-associated lens 
capsular winkling, a key feature of human PCO, highlighting its role in blocking 
myofibroblastic cell transdifferentiation whose contractility is believed to disrupt the surface 
integrity and optical properties of the lens capsule (Marcantonio et al., 2000). 
To elucidate putative elements of the signalling cascade used by BMP-7 to antagonise TGFβ2-
induced EMT, we investigated the expression of phosphorylated Smads. Both BMP-7 and 
TGFβ bind to distinct type II serine-threonine kinase receptors which then form a complex with 
specific type I receptors (Miyazono et al., 2010). The activated receptor complex relays the 
signal to the cytoplasm by phosphorylating Smad2/3 in TGFβ signalling and Smad1/5/8 in 
BMP signalling (Miyazono et al., 2010). Phosphorylated Smads then hetero-oligomerise with 
Smad4, shared by both TGFβ and BMP signalling, that translocates to the nucleus to regulate 
transcription of respective target genes (Miyazono et al., 2010).  
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In this study, treatment with BMP-7 alone increased phosphorylated Smad1/5 with protein 
levels sustained over the 6-hour culture period, indicating that the Smad signalling pathway 
can be activated in rat LECs by exogenous BMP-7. Furthermore, in explants co-treated with 
BMP-7 and TGFβ2, we showed that BMP-7 induces a significant increase in pSmad1/5 
signalling, and concurrently reduces TGFβ2-induced Smad2/3 phosphorylation. These 
findings were corroborated by immunofluorescence data demonstrating that the addition of 
BMP-7 suppressed TGFβ2-induced nuclear translocation of tSmad2/3 at least early in the 
culture period. This is consistent with previous studies demonstrating that the mechanism 
underlying the antagonistic effect of BMP-7 is through direct Smad-dependent inhibition of 
the TGFβ pathway, both in renal (Zeisberg et al., 2003b) and pulmonary fibrosis (Izumi et al., 
2005). Interestingly, in the present study, activation of pSmad1/5 is only evident at 20 minutes 
and falls to basal levels thereafter, suggesting that TGFβ2 may also abrogate BMP-7 signalling 
to some extent, albeit at a later time-point.  
In the present study, short-term treatment of LECs with TGFβ2 for 2 hours was sufficient to 
induce an EMT response over the 5-day treatment period. Our data supported human studies 
where LECs exposed to TGFβ2 for a brief 2-day period resulted in significant and persistent 
long-term fibrotic events over a long 28-day culture period (Wormstone et al., 2006). Co-
treatment with TGFβ2 and BMP-7 for 2 hours blocked the EMT process with retention of an 
epithelial monolayer of LECs displaying membranous β-catenin localisation. Interestingly, α-
SMA expression still was upregulated despite the addition of BMP-7; however, it was not 
incorporated into stress fibres, hence possibly unable to exert contractile activity. This suggests 
that the early surge in pSmad1/5 signalling may be sufficient to initiate downstream BMP-
associated gene transcription, thus preventing subsequent activation of TGFβ2-mediated Smad 
signalling and resultant EMT. This finding has important ramifications in the prevention of 
PCO as it is the transient elevation of TGFβ during cataract surgery that gives rise to post-
operative PCO many years later (Wallentin et al., 1998). It is promising to see that even a short 
exposure to BMP-7 is able to abrogate the potent effects of TGFβ2 over an extended culture 
period and may be a novel treatment for the prevention of PCO. 
Communication between TGFβ and BMP-7 pathways also occurs further downstream of Smad 
proteins at the level of specific target genes. Using a renal epithelial cell line, Zeisberg et al. 
(2003) showed that TGFβ-induced phosphorylation of Smad2/3 and EMT led to reduced E-
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cadherin expression (Zeisberg et al., 2003b). Exogenous addition of BMP-7 increased 
pSmad1/5/8 and this directly blocked pSmad2/3, restoring E-cadherin promoter activity to 
control levels (Zeisberg et al., 2003b) Interestingly, in the present study, expression levels of 
epithelial markers, E-cadherin and β-catenin did not reduce with TGFβ2 treatment. It has been 
reported that instead of being downregulated, E-cadherin and β-catenin can relocate from the 
membrane to the cytoplasm during EMT in human corneal epithelial cells (Kato et al., 2007). 
This is consistent with our study that shows a dysregulated cellular distribution of these 
epithelial markers during TGFβ2-mediated EMT. Since E-cadherin and β-catenin are not 
localised to the membrane in their normal cobblestone-packed arrangement, they can no longer 
fulfil their functional role as cell-cell adhesion molecules in maintaining epithelial cell integrity 
and intercellular junctions, hence promoting the EMT response. 
In addition to the E-cadherin promoter gene, Id proteins have also been identified as 
downstream target genes mediating the antagonistic effect of BMP-7 on TGFβ-induced EMT 
(Izumi et al., 2005; Kowanetz et al., 2004; Saika et al., 2006). Id proteins play a crucial role in 
development and cancer biology, permitting proliferation and preventing premature terminal 
differentiation (Yokota, 2001). Downregulation of Id proteins has been detected during TGFβ-
induced EMT in a prostate cancer model (Ling et al., 2002). BMP-7 also has been shown to 
antagonise TGFβ-induced pulmonary fibrosis by inducing Id2 and Id3 (Izumi et al., 2005), 
while adenoviral gene transfer of Id2 and Id3 delayed injury-induced EMT of LECs in a mouse 
model (Saika et al., 2006). Mouse mutants deficient in Id2 and Id3 enabled BMP-7 to induce 
EMT, further highlighting the importance of BMP-induced Id proteins in antagonising TGFβ-
induced EMT (Kowanetz et al., 2004). Interestingly, in our present study, BMP-7 does not 
upregulate Id2/3 gene expression but rather, is able to inhibit TGFβ-induced Id2/3 gene 
suppression, maintaining Id2/3 gene expression at basal levels. Future research will focus on 
the importance of BMP-induced Id proteins in the lens, and examine the role of dysregulated 
Id expression in promoting EMT to potentially exacerbate cataract formation. 
Using an in vivo capsular injury-induced mouse model, Saika et al. (2006) reported that BMP-
7 upregulated pSmad1/5/8 signalling and inhibited pSmad2 signalling (Saika et al., 2006). 
Although adenoviral gene transfer of BMP-7 suppressed the expression of α-SMA, the EMT 
process was merely delayed and LECs eventually continued to undergo myofibroblastic 
transdifferentiation (Saika et al., 2006). In contrast, our study showed that the inhibitory effect 
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of BMP-7 was maintained over the entire culture period. This may be attributed to differences 
in the model of EMT induction, as well as the administration of BMP-7. In our study, we 
induced EMT by exogenous addition of TGFβ2 whereas, the lens capsular injury-induced 
model of EMT relies on indirect activation of endogenous TGFβ in situ through physical 
damage to the lens that may activate more complex signalling pathways. It is also possible that 
the method of enhancing BMP-7 signalling may play a role; where exogenous administration 
of BMP-7 may be more effective at counteracting the effects of TGFβ compared to adenoviral-
mediated overexpression of BMP-7. 
The in vivo situation, no doubt, differs markedly from our lens explant system given LECs are 
in constant contact with a myriad of growth factors derived from the aqueous humour. These 
growth factors may interact with TGFβ2 and/or BMP-7 in an antagonistic or synergistic 
manner, thus adding to the complexity of effectively inhibiting EMT. For example, fibroblast 
growth factor has been found to exacerbate the cataractogenic effect of TGFβ2 in cultured rat 
lenses (Cerra et al., 2003). The major advantage of our rat lens epithelial explant system is that 
it enables the controlled application and study of growth factors in isolation and/or in 
combination, compared to the in vivo system. Our future research will involve characterising 
the combined actions of other growth factors in the aqueous humour with TGFβ2 and/or BMP-
7 in regulating the EMT process (Iyengar et al., 2009). 
BMP signalling is regulated by several secreted extracellular agonists and antagonists of BMPs 
(Yanagita, 2005). While molecules such as chordin, noggin, gremlin and DAN/Cerberus inhibit 
the binding of BMP to its receptor, other molecules such as Kielin/chordin-like protein are 
enhancers of BMP signalling, increasing BMP binding to its receptor (Yanagita, 2005). 
Gremlin, an extracellular and intracellular BMP antagonist, has been shown to increase ECM 
synthesis in trabecular meshwork cells (Sethi et al., 2011; Wordinger et al., 2007). In human 
lens epithelial cells, silencing gremlin effectively inhibited TGFβ2-induced EMT and ECM 
synthesis (Ma et al., 2014). It is possible that inhibition of gremlin may abolish its inhibitory 
effect of endogenous BMP on TGFβ2, thereby blocking EMT. By investigating the role of 
these extracellular regulators of BMP signalling in the lens, we can potentially augment the 
antagonistic effect of BMP-7 on TGFβ-induced EMT. Future studies should also aim to explore 
the role of other BMP isoforms found in the lens, including BMP-2 and BMP-4 (Boswell et 
al., 2008), in inhibiting EMT, to investigate whether the inhibitory capacity of BMP is unique 
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to BMP-7. The expression levels of BMP antagonists/agonists, BMP receptors and other BMP 
isoforms may influence the efficacy of BMP-7 in inhibiting TGFβ-induced EMT. Hence, 
further investigation is required to understand the tight regulation of BMP signalling before 
there is potential for clinical application. 
BMP-7 is an endogenous growth factor that has a crucial role during lens embryogenesis and 
development. By exploiting this pre-existing BMP pathway in the lens through exogenous 
administration of recombinant human BMP-7 to lens epithelial explants, we have shown that 
TGFβ-driven EMT leading to cataract can be inhibited. Recombinant human BMP-7 has 
already been approved by the US Food and Drug Administration for bone regeneration, and 
clinical trials of a BMP-7 analog has been launched to evaluate its efficacy on diabetic 
nephropathy (Li et al., 2015). BMP-7 hence shows promise as a novel pharmaceutical agent in 
the prevention of ASC and PCO. Future studies will focus on extending these findings to in 
vivo models, characterising the complex regulation of BMP signalling and identifying specific 
BMP-7 target genes mediating its protective effects. 
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Chapter Four  
 
Results Part (II) 
Inhibition of EGFR-signalling suppresses TGFβ-induced EMT in lens 
epithelial cells 
While the first study in Chapter 3 highlighted the importance of the canonical Smad-signalling 
pathway in TGFβ-induced EMT in the lens, this following study delves into the role of the non-
canonical signalling pathways induced by TGFβ and how they work in concert with the Smad 
signalling pathway to ultimately propagate the EMT response. This study reveals the intriguing 
finding that TGFβ is independently able to activate the EGF receptor (EGFR) signalling 
pathway. Inhibition of EGFR signalling using PD153035 blocks TGFβ-induced EMT in LECs 
indicating that EGFR-signalling is required for TGFβ-induced EMT. By systemically 
inhibiting the EGFR-, ERK1/2- and Smad-signalling pathways with PD153035, U0126 and 
SIS3 respectively, and exploring the impact on these signalling pathways, a complex and 
interconnected signalling network between the canonical and non-canonical pathways was 
established. It appears that a positive bidirectional feedback loop exists between EGFR- and 
ERK1/2-signalling and both these pathways feed into the canonical Smad-signalling pathway 
but not vice versa. An array of EMT markers and TGFβ target genes are explored through RT-
qPCR and shed light on potential mechanisms by which TGFβ transactivates or rather, 
“hijacks”, EGFR-signalling. 
This paper was published in Experimental Eye Research in 2018. The work has arisen entirely 
during my PhD candidature under the guidance of my primary supervisor Professor Frank 
Lovicu who contributed to this manuscript by facilitating me with experimental design and 
manuscript writing. The other co-author, Magdalena Wojciechowski, is a PhD candidate in the 
same laboratory who contributed to this manuscript by assisting me with the RT-qPCR data 
collection and analysis. 
Reference: Shu DY, Wojciechowski M, Lovicu FJ. ERK1/2-mediated EGFR-signalling is 
required for TGFβ-induced lens epithelial-mesenchymal transition. Experimental Eye 
Research 2018; 178: 108-121. 
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1Discipline of Anatomy and Histology, Bosch Institute, The University of Sydney, NSW, 
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2Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, The University 
of Sydney, NSW, Australia 
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1 Abstract 
Epithelial-mesenchymal transition (EMT) of lens epithelial cells (LECs) plays a critical role in 
the pathogenesis of fibrotic cataract. Transforming growth factor-beta (TGFβ) is a potent 
inducer of this fibrotic process in lens. Recent studies in cancer progression have shown that 
in addition to activating the canonical Smad signalling pathway, TGFβ can also transactivate 
the epidermal growth factor receptor (EGFR) to enhance invasive cell migration. The present 
study aims to elucidate the involvement of EGFR-signalling in TGFβ-induced EMT in LECs. 
Treatment with TGFβ2 induced transdifferentiation of LECs into myofibroblastic cells, typical 
of an EMT. TGFβ2 induced the phosphorylation of the EGFR and upregulation of Egfr and 
Hb-egf gene expression. Pharmacologic inhibition of EGFR-signalling using PD153035 
inhibited TGFβ-induced EMT, including the upregulation of mesenchymal markers and 
downregulation of epithelial markers. Crosstalk between TGFβ2-induced EGFR and ERK1/2 
was evident, with both pathways impacting on Smad2/3-signalling. Our finding that TGFβ2 
transactivates downstream EGFR-signalling reveals a previously unknown mechanism in the 
pathogenesis of cataract. Understanding the complex interplay between divergent canonical 
and non-canonical signalling pathways, as well as downstream target genes involved in TGFβ-
induced EMT, will enable the development of more effective targeted therapies in the 
pharmacological treatment of cataract. 
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2 Introduction 
Cataract, the opacification of the ocular lens, is the leading cause of global blindness (Foster 
and Resnikoff, 2005). Currently, the only available treatment for cataract is surgery and 
although it effectively restores vision, posterior capsular opacification (PCO) is a common 
post-operative complication necessitating further surgical treatment (Awasthi et al., 2009). The 
vision-related surgical complications associated with cataract surgery and laser capsulotomy 
for PCO place significant personal and financial strain on the aging population, prompting 
interest in the development of non-invasive drug-based alternatives. 
The pathogenesis of PCO post-surgery involves a combination of processes including aberrant 
cellular proliferation, migration and transdifferentiation of the residual lens epithelial cells 
(LECs) across the posterior capsular bag (Nibourg et al., 2015). Epidermal growth factor (EGF) 
is an important regulator of cell proliferation in rat (Iyengar et al., 2009) and human (Jiang et 
al., 2006; Kiyoyuki Majima, 1995) lens epithelial cells and has been implicated in the 
pathogenesis of PCO (Maidment et al., 2004). Treatment of human LECs with EGF promoted 
coverage of the posterior capsular bag and selective inhibition of the EGF receptor (EGFR) 
using AG1478 significantly retarded the growth rates of cells (Maidment et al., 2004). SiRNA-
mediated knockdown of EGFR expression significantly reduced the proliferative capacity of 
human LECs in vitro and progression of PCO in an in vivo rat model (Huang et al., 2011). 
Similarly, blockade of EGFR-signalling using anti-cancer drugs, Erlotinib (Wertheimer et al., 
2014, 2013) or Gefitinib (Wertheimer et al., 2015), reduced proliferation, migration, matrix 
contraction and cell spreading in human lens epithelial cells. 
Transforming growth factor-beta (TGF) has also been implicated in the pathogenesis of 
fibrotic forms of cataract such as anterior subcapsular cataract (ASC) and PCO, and plays a 
key role in inducing LECs to undergo an epithelial-mesenchymal transition (EMT) 
(Wormstone and Eldred, 2015). During EMT, LECs lose their regular cuboidal shape and 
polarity as they transdifferentiate into elongate spindle-shaped myofibroblasts and migrate 
across the lens capsule (de Iongh et al., 2005). In addition to cataract, myofibroblast 
transdifferentiation has been implicated in various models of organ fibrosis including 
progressive kidney disease, pulmonary fibrosis, liver cirrhosis, skin fibrosis, cardiovascular 
disease (Wynn, 2007) and other ocular diseases such as macular degeneration, corneal scarring 
and glaucoma (Shu and Lovicu, 2017). Myofibroblasts secrete excessive amounts of aberrant 
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extracellular matrix (ECM) and generate contractile forces that are transmitted to the 
surrounding ECM to enhance wound contraction and closure (Jun and Lau, 2018). Persistence 
of myofibroblasts leads to pathological contracture, distortion of normal tissue architecture and 
loss of organ function (Tschumperlin et al., 2018). Given that the highly ordered architecture 
of the lens gives rise to its transparency, fibrosis of the lens leads to formation of a scar in the 
lens that manifests as an opaque plaque and, if severe enough, can lead to blindness (de Iongh 
et al., 2005). 
Although several studies have highlighted the anti-proliferative effect of EGFR inhibitors in 
PCO formation, little is known about its ability to abrogate the transdifferentiation of LECs 
into myofibroblasts, another key feature of PCO. Herein, we describe experiments 
investigating the role of EGFR-signalling in modulating TGFβ-induced EMT in a rat lens 
epithelial explant system. We show that blocking EGFR-activity using PD153035 is sufficient 
to block the transdifferentiation of LECs, with an associated reduction in mesenchymal 
markers and retention of epithelial markers. To establish a mechanistic understanding of the 
role of EGFR-signalling in TGFβ-induced EMT, we examined the activation of downstream 
Smad and non-Smad signalling pathways. We show that TGFβ alone is capable of upregulating 
the phosphorylation of EGFR and that this process is dependent on MAPK/ERK1/2-signalling. 
Furthermore, we show that both EGFR- and ERK1/2-signalling feed into the Smad2/3-
signalling pathway. We also demonstrate that inactivating EGFR-signalling inhibits TGFβ2-
induced EMT target genes, highlighting a complex and integrated network of TGFβ-driven 
signalling pathways underlying lens EMT leading to cataract. 
3 Materials and methods 
3.1 Animals 
Ocular lenses were obtained from 21-day-old albino Wistar rats (Rattus norvegicus) following 
euthanasia by carbon dioxide asphyxiation and cervical dislocation. Animal procedures were 
adherent to the Association for Research in Vision and Ophthalmology (ARVO) Statement for 
the Use of Animals in Ophthalmic and Vision Research (USA) and the National Health and 
Medical Research Council (NHMRC) Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes (Australia). All investigations were approved by the Animal 
Ethics Committee of The University of Sydney (Australia). 
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3.2 Preparation of rat lens epithelial explants 
Rat lens epithelial explants were prepared as described previously (West-Mays et al., 2010). 
All tissue culture experiments were performed at 37°C in a humidified 5% CO2 incubator. All 
explants were cultured in serum-free media comprising Medium 199 with Earle’s salts (Life 
Technologies, Waltham, MA, USA), supplemented with 0.1 μg/ml L-glutamine (Life 
Technologies), 0.1% bovine serum albumin (BSA; Sigma-Aldrich Corp., St. Louis, MO, 
USA), 2.5 μg/ml Amphostat B (Thermo Fisher Scientific, MA, USA) and 100 IU/ml 
penicillin/100 μg/ml streptomycin (Life Technologies). 
The roles of canonical and non-canonical pathways in TGFβ-induced EMT was investigated 
by pre-treating explants with 100nM PD153035 (EGFR inhibitor, AG1517, Merck Millipore) 
to block EGFR-signalling, 50µM U0126 (MEK1/2 inhibitor; 9903; Cell Signalling 
Technology) to block ERK1/2 activation (Wojciechowski et al., 2017), or 5µM SIS3 (Smad3 
inhibitor; sc-253565; Santa Cruz Biotechnology) for 2 hours prior to the addition of 200pg/ml 
of recombinant human TGFβ2 (R&D Systems) or 5ng/ml of recombinant human EGF 
(BioLegend, San Diego, California). All inhibitors were diluted in dimethyl sulfoxide (DMSO) 
and an equivalent volume of this solvent was added to all control groups. Explants were 
cultured for up to 5 days. Cells were viewed with phase-contrast microscopy (CK2, Olympus, 
Japan) and photographed (Leica DFC-280; Leica Camera, Wetzlar, Germany) before being 
collected for immunofluorescence, Western blotting or RT-qPCR analysis. For analysis of 
signalling proteins, we had different controls; (i) untreated explants collected at T = 0min, or 
(ii) explants pre-treated for 2h with either DSMO (vehicle) or the respective inhibitors 
(PD153035, U0126 or SIS3). As there was no significant difference in the levels of signalling 
proteins between the different control explants at 0 minutes, 15 minutes, 2 hours or 18 hours 
(see Supplementary Figure S1), we used the untreated group harvested at T = 0 minutes as the 
collective control for the Western blots. All subsequent analyses were performed relative to 
this control group for each blot. 
3.3 Immunofluorescence 
Explants were fixed in 100% methanol for 45s and rinsed 4 times in phosphate buffered 
saline (PBS). This was followed by rinsing (3 x 5 min) in PBS supplemented with 0.1% (w/v) 
BSA (PBS/BSA). Explants were then incubated in 10% normal goat serum (NGS) diluted in 
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PBS/BSA for 1 hour. Primary antibodies were diluted in PBS/BSA with 1.5% NGS and 
incubated overnight at 4°C in a humidified chamber. Anti-mouse antibodies specific for α-
smooth muscle actin (α-SMA; A2547; monoclonal, Sigma-Aldrich Corp.) and anti-rabbit 
antibodies specific for β-catenin (H-102, polyclonal, Santa Cruz, TX, USA), total-Smad2/3 
(8685; monoclonal, Cell Signalling Technology) were all diluted at 1:100. 
 
Following application of the primary antibody, explants were equilibrated to room 
temperature and any unbound primary antibody was removed by rinsing in PBS/BSA (3 x 5 
min). The appropriate secondary antibody was diluted 1:1000 in PBS/BSA and applied to the 
explants for 2h at room temperature in a dark humidified chamber. α-SMA was detected 
using goat anti-mouse Alexa-Fluor 488 IgG (Cell Signalling Technology). β-catenin and 
tSmad2/3 were detected using goat anti-rabbit Alexa-Fluor 594 (Abcam, Cambridge, MA, 
USA). Explants were rinsed (3 x 5 minutes) in PBS/BSA before counterstaining with 3 µg/ml 
bisbenzimide (Hoechst 33342; Sigma-Aldrich Corp.) for 3 min. Explants were then rinsed in 
PBS/BSA (3 x 5 min) and mounted with 10% PBS (v/v) in glycerol, before viewing with a 
Zeiss LSM-5Pa confocal microscope (Carl Zeiss AG, Jena, Germany). 
3.4 SDS-Page and Western blotting 
Explants were rinsed in cold PBS and protein extraction was performed in cold lysis buffer 
containing 25mM Tris-HCl (pH 7.5), 2.5mM EDTA, 0.375M NaCl, 10mM sodium 
deoxycholate, 250mM sodium orthovandate, a phosphatase inhibitor (PhosStop; Roche 
Applied Science) and a protease inhibitor cocktail (Complete; Roche Applied Science). To 
facilitate lysis, homogenised samples were rotated for 2h at 4°C. Lysates were then subject to 
centrifugation at 15,500g for 15min at 4°C. Protein content of the supernatant was quantified 
using the Micro BCA protein assay reagent kit (Thermo Fisher Scientific). 
Protein lysates were combined in a 1:1 ratio with Laemmli sample buffer (BioRad 
Laboratories, Hercules, CA, USA). Up to 10μg of lens explant protein extract was loaded onto 
a 10% SDS-PAGE gel for electrophoresis for 1.5h at 200V before being transferred onto an 
Immobilon polyvinylidene fluoride membrane (Merck Millipore) for 3h at 100V. The 
membrane was then incubated for 1 hour with a blocking solution of 2.5% BSA in 0.1% 
Tween-20 in Tris-buffered saline (TBST) for phosphorylated proteins and 5% (w/v) non-fat 
skim milk powder in TBST for non-phosphorylated proteins. Membranes were incubated 
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overnight with the primary antibody at 4°C. Anti-mouse antibodies specific to α-SMA (A2547; 
monoclonal, Sigma-Aldrich Corp.), tropomyosin CGβ6 (Tpm1.6-1.9, gift from Prof. Peter 
Gunning, University of New South Wales), GAPDH (G8795; Sigma-Aldrich Corp.) and anti-
rabbit antibodies specific to β-catenin (H-102, Santa Cruz), phospho-Smad2/3 (D27F4; 
monoclonal, Cell Signalling Technology), total-Smad2/3 (8685; monoclonal, Cell Signalling 
Technology), phospho-EGFRY1068 (2234; polyclonal, Cell Signalling Technology), phospho-
ERK1/2 (phospho-p44/p42; 9101; polyclonal, Cell Signalling Technology) and total-ERK1/2 
(p44/p42; 9102; polyclonal, Cell Signalling Technology) were all diluted at 1:1000 with the 
exception of α-SMA and β-catenin that were diluted at 1:2000, and tropomyosin diluted at 
1:100. 
Following 3 x 5 min rinses in TBST, membranes were incubated for 2h with the corresponding 
horseradish peroxidase (HRP)-conjugated secondary antibodies, either goat anti-mouse HRP-
conjugated IgG or goat anti-rabbit HRP-conjugated IgG (both diluted 1:5000 in TBST; Cell 
Signalling Technology). Membranes were then rinsed in TBST (3 x 10min) and incubated in 
Immobilon Western Chemiluminescent HRP Substrate (Merck Millipore) for 2min. The 
ChemiDoc MP imaging system (BioRad Laboratories) was used to capture chemiluminescence 
signals and ImageLab software (BioRad Laboratories) was used to perform densitometric 
analysis. 
3.5 Total RNA extraction and cDNA synthesis 
Explants were rinsed in cold PBS after a 24h treatment period and total RNA was extracted 
using the Isolate II RNA Micro Kit (Bioline, Alexandria, NSW, Australia) according to the 
manufacturer’s instructions. The Nanodrop ND-1000 spectrophotometer (Thermo Fisher 
Scientific) was used to assess RNA concentration and purity. The Agilent 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA, USA) was used to determine RNA integrity. Only 
samples with 260/280 ratios > 2 and RNA integrity numbers > 5 were used for subsequent RT-
qPCR analysis. 
3.6 Reverse transcriptase-quantitative polymerase chain reaction 
(RT-qPCR) 
The SensiFAST cDNA synthesis kit (Bioline) was used to reverse-transcribe total RNA (200 
ng) as per the manufacturer’s instructions. cDNA samples were then diluted 1:12 with 
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nuclease-free water. Using Primer-BLAST, oligonucleotide primers (Table 4) were designed 
to span the exon-exon junction. 
All RT-qPCR reactions were conducted using the SensiFAST SYBR No-ROX kit (Bioline). 
Using a Freedom EV075 robotic station with Freedom EVOware Standard 3.2 software (Tecan, 
Port Melbourne, VIC, Australia), 10 µl reactions were set up in a LightCycler 480, 384-well 
plate (Roche Diagnostics Ltd., Forrenstrasse, Switzerland) consisting of 4 µl cDNA, 5 µl 
SYBR and 300 nM forward and reverse primers. RT-qPCR analysis was performed using the 
Roche LightCycler 480 (Roche Diagnostics Ltd.) under the following thermal cycling 
conditions: 95°C for 2min followed by 45 cycles consisting of denaturation (95°C, 5s), 
annealing (60°C,10s) and extension (72°C, 15s). Melting curve profiles (95°C for 5min, 60 °C 
for 1min and then slowly heating at 0.11°C/s up to 98°C with continuous measurement of 
fluorescence per 5°C) were performed at the end of each run to confirm amplification of 
specific transcripts. Serial dilutions (1:2) were performed to generate standard curves to cover 
an appropriate concentration range. Relative gene expression was reported as a ratio of the 
gene of interest over GAPDH expression using the second derivative maximum method of the 
LightCycler software (Roche Diagnostics Ltd.). All reactions, including minus RT controls and 
no-template controls, were run in duplicate. 
3.7 Statistics 
Each experiment was performed at least three times. GraphPad Prism version 6.0 (GraphPad 
Software Inc., La Jolla, CA, USA) was used for all graphs. Western blot data was analysed by 
one- or two-way ANOVA with post hoc Tukey’s multiple comparisons test. RT-qPCR data 
was analysed using a one-way ANOVA with post hoc Tukey’s multiple comparisons test on 
GenEx version 6.0 (MultiD Analyzes AB, Goteborg, Sweden) and GraphPad Prism. All 
Western blot densitometry data was analysed relative to GAPDH, and then relative to the 
control group (no growth factor and/or inhibitors added). All data is presented as mean ± SEM 
and P < 0.05 was deemed statistically significant. 
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4 Results 
4.1 Inhibition of EGFR-signalling blocks TGFβ-induced EMT in lens 
epithelial cells 
To investigate the role of EGFR-signalling in TGFβ-induced EMT, we used the EGFR 
inhibitor, PD153035, to observe for changes in cell morphology over a 5-day culture period. 
Treatment with TGFβ2 induced the cuboidal LECs (Day 0; Figure 1A) to elongate by day 1 
and adopt a spindle-shaped morphology (Figure 1B). Progressive cell loss was apparent from 
day 2 (Figure 1C), indicated by cellular blebbing (yellow arrows) and areas of exposed lens 
capsule (asterisks). On day 3, lens capsular wrinkling was evident in areas of bare lens capsule 
(red arrows; Figure 1D) and this continued through to day 4 (Figure 1E). By day 5, extensive 
cell loss and lens capsular wrinkling was observed (Figure 1F). In comparison, cells in control 
explants retained a cuboidal monolayer with a cobblestone-packed arrangement indicative of 
their normal epithelial phenotype (Figure 1G). Similarly, explants co-treated with PD153035 
and TGFβ2 also retained a monolayer of epithelial cells throughout the 5-day culture period, 
with no indication of cell loss (Figure 1H). 
 
Figure 1. PD153035 blocks TGFβ-induced EMT in lens epithelial cells. 
Phase-contrast microscopy of explants showed that TGFβ2 induced the LECs (day 0; A) to elongate 
into spindle-shaped cells by day 1 (B). Cellular blebbing (yellow arrows) and areas of exposed lens 
capsule (asterisks) are evident by day 2 (C). Lens capsular wrinkling (red arrows) is evident on day 3 
(D) and continued through to day 4 (E). Extensive cell loss is seen at day 5 (F). Control explants at day 
5 retained a cobblestone monolayer (G). Explants co-treated with PD153035 and TGFβ2 also retained 
a monolayer of epithelial cells at day 5 (H). Images are representative of 3 independent experiments. 
Scale bar: 50 µm. 
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4.2 Inhibition of EGFR-signalling blocks TGFβ-induced β-catenin 
translocation and the appearance of α-SMA-labelled stress 
fibres 
We examined the immunofluorescent localisation of β-catenin in LECs at day 5. In control 
explants, β-catenin (Figure 2A) was localised to the cell membrane, highlighting the organised 
tight cobblestone-packed cell arrangement. Following TGFβ2 treatment, immunofluorescent 
labelling of an occasional cell remaining at day 5 in explants showed pronounced punctate 
labelling of β-catenin in the cell nuclei and cytoplasm (Figure 2B). Treatment with PD153035 
inhibited this TGFβ2-induced β-catenin translocation (Figure 2C), remaining localised to the 
cell membrane, although the label was slightly less prominent compared to control explants. 
Treatment of cells with PD153035 alone showed no difference in β-catenin-labelling compared 
to cells in control explants (Figure 2D). 
Control explants exhibited little to no α-SMA immunoreactivity (Figure 2E), while TGFβ2-
treated explants displayed strong immunoreactivity for α-SMA-labelling to newly formed 
stress fibres, a characteristic EMT response (Figure 2F). Co-treatment with PD153035 blocked 
TGFβ2-driven accumulation and incorporation of α-SMA to stress fibres and appeared similar 
to control explants, indicating retention of the epithelial phenotype (Figure 2G). Similarly, 
treatment with PD153035 alone exhibited no difference in α-SMA-labelling compared to cells 
in control explants (Figure 2H). 
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Figure 2. TGFβ2-mediated β-catenin translocation and upregulation of α-SMA is dependent on 
EGFR-signalling. 
Immunofluorescence confocal microscopy at day 5 for β-catenin in control explants (A), TGFβ-treated 
explants (B), explants co-treated with PD153035 and TGFβ2 (C) and treatment with PD153035 alone 
(D). Immunofluorescence confocal microscopy at day 5 for α-SMA in control explants (E), TGFβ2-
treated explants (F), co-treatment with PD153035 and TGFβ2 (G) and treatment with PD153035 alone 
(H). Images are representative of 3 independent experiments. Scale bar: 50 µm. 
 
4.3 Inhibition of EGFR-signalling blocks TGFβ-induced 
mesenchymal protein expression 
To further characterise the suppressive effect of PD153035 on TGFβ2-induced EMT, we 
examined the protein expression of epithelial and mesenchymal cell markers after 48h of 
culture using Western blotting (Figure 3). No significant differences were observed in β-
catenin expression levels between treatment groups (P = 0.4658; Figure 3A). 
Treatment of LECs with TGFβ2 induced a significant upregulation of α-SMA expression 
compared to control explants (P = 0.0201, Figure 3B). Co-treatment of LECs with PD153035 
and TGFβ2, significantly reduced α-SMA levels compared to TGFβ2 alone (P = 0.0444), with 
no significant difference compared to control levels (P = 0.9964). Similarly, treatment with 
PD153035 alone showed no significant difference to control explants (P = 0.9992). 
As tropomyosin has been shown to be required for the stable incorporation of α-SMA into 
stress fibres in myofibroblasts (Prunotto et al., 2015), we compared its expression levels in this 
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EMT response. Similar to α-SMA, treatment of LECs with TGFβ2 induced a significant 
upregulation of tropomyosin compared to control explants (P = 0.009; Figure 3C). Co-
treatment with PD153035 and TGFβ2 significantly elevated tropomyosin levels compared to 
TGFβ2 alone (P = 0.0349), with no significant difference noted when compared to levels in 
control explants (P = 0.9615). PD153035 treatment alone showed no significant difference in 
tropomyosin levels from control explants (P = 0.9995). 
 
Figure 3. Inhibition of EGFR-signalling blocks TGFβ2-induced mesenchymal protein expression. 
Protein expression levels of EMT markers induced by TGFβ2 at 48h, by Western blotting with 
corresponding relative densitometry analysis. No significant difference was observed in β-catenin levels 
between all treatment groups (A). TGFβ2 induced upregulation of α-SMA (B) and tropomyosin (C). 
PD153035 inhibited TGFβ2-induced α-SMA and tropomyosin levels, showing no significant difference 
to control levels. Treatment groups: C (control), T (TGFβ2 alone), TPD (TGFβ2 with PD153035) and 
PD (PD153035 alone). Representative Western blots from 3 independent experiments, with data 
presented relative to GAPDH, as the mean ± SEM. One-way ANOVA, Tukey’s post hoc test *P < 0.05, 
**P < 0.01. 
 
4.4 TGFβ2 differentially activates EGFR-, MAPK/ERK1/2- and 
Smad2/3-signalling 
To further characterise the role of EGFR-signalling in TGFβ2-induced EMT in the lens, we 
monitored for changes in phosphorylation of the EGF receptor (EGFR), MAPK/ERK1/2 and 
Smad2/3 at 15min, 2h and 18h following treatment with TGFβ2 alone, or in conjunction with 
respective inhibitors of these pathways, PD153035, U0126 or SIS3 (Figure 4). 
Chapter Four: Results (Part II) 
87 
4.4.1 EGFR phosphorylation 
TGFβ2 alone induced the upregulation of phosphorylated EGFR (pEGFR) at 18h (P = 0.0014; 
Figure 4A) and the addition of PD153035 or U0126 significantly reduced TGFβ2-induced 
pEGFR (P < 0.0001). While treatment with TGFβ2 alone also appeared to increase pEGFR 
levels at 15min and 2h, this did not reach statistical significance (P > 0.9999 at 15 minutes; P 
= 0.0665 at 2 hours). There were no significant differences in TGFβ2-induced pEGFR with 
SIS3 at all times points (at 15min, P > 0.9999; at 2h, P = 0.3614; at 18h, P = 0.4735). 
4.4.2 ERK1/2 phosphorylation 
TGFβ2 alone induced the upregulation of phosphorylated ERK1/2 (pERK1/2) at 2h (P < 
0.0001; Figure 4B) and the addition of PD153035 or U0126 significantly reduced TGFβ2-
induced pERK1/2 (P < 0.0001). Treatment with TGFβ2 alone appeared to also increase 
pERK1/2 levels at 15 minutes and 18 hours; however, this did not reach statistical significance 
(P = 0.0636 for 15min; P = 0.9695 at 18h). There were no significant changes in TGFβ2-
induced pERK1/2 with SIS3 at all time points (at 15min, P > 0.9999; at 2h, P = 0.84; at 18h, P 
> 0.9999). Total ERK1/2 levels remained constant throughout the culture period (P > 0.9999). 
4.4.3 Smad2/3 phosphorylation 
TGFβ2 alone induced the upregulation of phosphorylated Smad2/3 (pSmad2/3) at all three time 
points, 15min, 2h and 18h (P < 0.0001; Figure 4C). The addition of PD153035 significantly 
reduced TGFβ2-induced pSmad2/3 at 18h (P = 0.0022) but not at earlier time points (15min, 
P = 0.8893; 2h, P = 0.0548). Treatment with U0126 significantly reduced TGFβ2-induced 
pSmad2/3 at 2h (P < 0.0001) but not at 1 min (P = 0.3353) and 18h (P = 0.6522). SIS3 
significantly reduced TGFβ2-induced pSmad2/3 at 15min (P = 0.011) and 2h (P < 0.0001) but 
not at 18h (P = 0.9232). Total Smad2/3 levels remained constant throughout the culture period 
(P > 0.9999). 
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Figure 4. TGFβ2 activates EGFR-, MAPK/ERK1/2- and Smad2/3-signalling. 
Protein expression levels of EGFR, ERK1/2 and Smad2/3 in lens explants at 15 minutes, 2 hours and 
18 hours following TGFβ2-treatment alone, or in conjunction with respective inhibitors of these 
pathways, PD153035, U0126 or SIS3, using Western blotting with corresponding relative densitometry 
analysis. TGFβ2 alone induced the upregulation of phosphorylated EGFR (pEGFR) (A) and the addition 
of PD153035 or U0126 significantly reduced TGFβ2-induced pEGFR levels. TGFβ2 alone induced the 
upregulation of phosphorylated ERK1/2 (pERK1/2) (B) and the addition of PD153035 or U0126 
significantly reduced TGFβ2-induced pERK1/2 levels. The two bands of pERK1/2 depict pERK1 as 
44kDa and pERK2 as 42kDa. Total ERK1/2 levels remained constant throughout the culture period. 
TGFβ2 alone induced the upregulation of phosphorylated Smad2/3 (pSmad2/3) (C). The addition of 
SIS3, U0126 and PD153035 significantly reduced TGFβ2-induced pSmad2/3 at different time points. 
Total Smad2/3 levels remained constant throughout the culture period. Treatment groups: C (control), 
T (TGFβ2 alone), T15 (TGFβ2 alone at 15min), PDT15 (PD153035 with TGFβ2 at 15min), U0T15 
(U0126 with TGFβ2 at 15min), SIS3T15 (SIS3 with TGFβ2 at 15min) and in the remaining labels, the 
‘2’ denotes 2h and ‘18’ denotes 18h. Representative Western blots from 3 independent experiments 
with data presented as mean ± SEM. Two-way ANOVA, Tukey’s post hoc test *P < 0.05, **P < 0.01 
and ****P < 0.0001. 
4.5 Phosphorylation of EGFR by TGFβ2 is a delayed response 
To clarify whether TGFβ2 directly activated EGFR signalling, we next compared the 
expression levels of pEGFR at 1min and 18h after treatment with either TGFβ2 or EGF, a 
known direct activator of the EGF receptor (Figure 5A). TGFβ2 significantly upregulated 
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pEGFR at 18h (P = 0.0007) but not at 1min (P = 0.998) compared to control (Figure 5B). EGF 
significantly upregulated pEGFR at 1 minute (P = 0.0098) and although levels of pEGFR were 
higher than control levels at 18 hours, this did not reach statistical significance (P = 0.9198) 
(Figure 5B). To assess whether the reduced pEGFR observed after 18 hours of treatment with 
EGF was due to reduced bioactivity of EGF over the culture period, media from these explants 
treated with EGF for 18h was collected and applied to fresh untreated explants for 1min. These 
explants showed a significant robust phosphorylation of EGFR (P < 0.0001) indicating that the 
EGF used was still bioactive throughout the culture period examined. 
 
Figure 5. Phosphorylation of EGFR is an indirect, downstream effect of TGFβ2. 
Western blot showing protein expression levels of pEGFR in lens explants at 1min and 18h following 
treatment with either TGFβ2 or EGF alone (A-B). The culture media from explants treated with EGF for 
18 h (18 h EGF) was applied to untreated explants for 1min and pEGFR levels were assessed. ‘T’ 
denotes TGFβ2 and ‘E’ denotes EGF. Representative Western blots from 3 independent experiments 
with data presented as mean ± SEM. One-way ANOVA, Tukey’s post hoc test **P < 0.01, ***P < 0.001 
and ****P < 0.0001. 
 
 
4.6 EGFR-inhibition modulates TGFβ2-induced Smad2/3 
translocation at 18h, but not 2h 
The Western blot data was further supported with immunofluorescence analysis of total 
Smad2/3 (tSmad2/3) localisation. Total Smad2/3-labelling of cell nuclei would indicate the 
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presence of phosphorylated (active) Smad2/3 translocation to the nucleus, hence active TGFβ-
signalling. Cells in control explants displayed tSmad2/3 labelling to their cytoplasm at both 2h 
and 18h (Figure 6A-B). Exposure of LECs to TGFβ2 for 2h and 18h resulted in nuclear 
localisation of tSmad2/3 (Figure 6C-D). The addition of PD153035 with TGFβ2 for 2h did not 
impact on tSmad2/3 nuclear localisation (Figure 6E); however, at 18h, there was a weaker 
nuclear, and more of a cytoplasmic tSmad2/3 label, similar to control explants (Figure 6F). 
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Figure 6. PD153035 modulates TGFβ-induced nuclear translocation of tSmad2/3. 
Immunofluorescence confocal microscopy showed cytoplasmic labelling of total Smad2/3 (tSmad2/3) 
at both 2h (A) and 18h (B) in control explants. Exposure of LECs to TGFβ2 for 2h (C) and 18h (D) 
demonstrated nuclear localisation of tSmad2/3. The addition of PD153035 for 2h also resulted in 
tSmad2/3 nuclear localisation (E); however, at 18h, there was more retention of cytoplasmic 
tSmad2/3 (F). Images are representative of 3 independent experiments. Scale bar: 50 µm. 
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4.7 Inhibition of EGFR-signalling, ERK1/2-signalling or Smad3-
signalling differentially modulates mesenchymal and epithelial 
gene expression 
Given the complex interplay observed between EGFR-, ERK1/2- and Smad2/3-signalling 
pathways, we next investigated their individual roles in modulating mesenchymal and 
epithelial gene expression by treating LECs for 24h with TGFβ2 alone or in combination with 
the respective inhibitors of these pathways, PD153035, U0126 or SIS3 (see supplementary data 
in Section 8 for comprehensive statistical analysis). 
Expression and deposition of aberrant ECM molecules such as collagens I and fibronectin is 
an important initiator and driver of progressive fibrosis (Herrera et al., 2018). Here, we 
investigated the involvement of two well-established ECM markers, collagen type 1 alpha 1 
(Col1a1) and fibronectin (Fn). Treatment of LECs with TGFβ2 for 24 hours induced a 
significant upregulation of Col1a1 (Figure 7A) and Fn (Figure 7B) compared to control 
explants (P < 0.0001). Addition of any of the three inhibitors significantly inhibited TGFβ2-
induced upregulation of Col1a1 and Fn in lens cells (P < 0.0001). 
Treatment of LECs with TGFβ2 for 24h induced a significant upregulation of the myofibroblast 
marker, α-SMA, compared to control explants (P < 0.0001; Figure 7C). U0126 and SIS3 
inhibited TGFβ2-induced upregulation of α-SMA (P = 0.0270 for U0126; P = 0.0244 for SIS3). 
Although PD153035 blocked α-SMA expression at the protein level (Figure 3B), it was unable 
to suppress TGFβ2-induced upregulation of α-SMA gene expression (P > 0.9999). 
Treatment of LECs with TGFβ2 for 24h induced a significant upregulation of the mesenchymal 
marker, Ctgf, compared to control explants (P < 0.0001; Figure 7D). U0126 inhibited TGFβ2-
induced upregulation of Ctgf (P < 0.0001); however, PD153035 and SIS3 did not (P > 0.9999). 
There was no significant increase in the gene expression of the mesenchymal marker Ncad 
with TGFβ2-treatment, compared to control explants (P > 0.9999; Figure 7E). Treatment with 
TGFβ2 significantly downregulated gene expression of the epithelial marker Ecad compared 
to control explants (P < 0.0018; Figure 7F). PD153035 and U0126 both inhibited TGFβ2-
induced downregulation of Ecad (P = 0.0160 for PD153035; P = 0.0017 for U0126); however, 
SIS3 did not (P > 0.9999). 
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No significant differences were found for all the mesenchymal genes examined between 
explants treated with the inhibitors alone and control explants (Figure 7). 
 
Figure 7. PD153035 blocks TGFβ-induced gene expression of EMT markers. 
RT-qPCR revealed differential roles of EGFR-, ERK1/2- and Smad-signalling in TGFβ-induced 
upregulation of EMT markers including Col1a1 (A), Fn (B), α-SMA (C), Ctgf (D), Ncad (E) and Ecad (F). 
Data from 3 independent experiments is presented relative to GAPDH as fold change ± SEM. One-way 
ANOVA, Tukey’s post hoc test *P < 0.05, **P < 0.01, ****P < 0.0001. Col1a1, collagen type 1 alpha 1; 
Fn, fibronectin; α-SMA, alpha-smooth muscle actin; Ctgf, connective tissue growth factor; Ncad, neural 
cadherin; Ecad, epithelial cadherin. 
4.8 Inhibition of EGFR-, ERK1/2- and Smad-signalling differentially 
modulates the expression of downstream EMT target genes 
Several zinc-finger transcription factors have been shown to play critical roles in TGFβ-
induced EMT including Snail (Snai1) and zinc finger E-box-binding (Zeb) family members, 
Zeb1 and Zeb2 (also known as Smad-interacting protein or SIP1) (Garg, 2013). We 
investigated whether these target genes of TGFβ2 played a role in lens EMT and whether their 
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expression depended upon EGFR-, ERK1/2- and Smad-signalling using RT-qPCR following 
a 24-h treatment period with TGFβ2 alone or in combination with PD153035, U0126 or SIS3 
(see supplementary data in Section 8 for further statistical analysis). 
Treatment with TGFβ2 alone significantly upregulated the expression of Zeb1 compared to 
control explants (P = 0.0059, Figure 8A). U0126 blocked TGFβ2-induced upregulation of Zeb1 
(P = 0.0230); however, PD153035 and SIS3 did not (P = 0.7538 for PD153035; P = 0.8383 for 
SIS3). 
In contrast to Zeb1, TGFβ2 alone significantly downregulated Zeb2 expression compared to 
control explants (P = 0.0013; Figure 8B). PD153035 and U0126 both significantly inhibited 
TGFβ2-induced downregulation of Zeb2 (P = 0.0203 for PD153035; P < 0.0001 for U0126); 
however, SIS3 did not (P = 0.9423). 
TGFβ2 alone showed no significant change in Snai1 expression compared to control explants 
(P = 0.7231, Figure 8C). Co-treatment of TGFβ2 with PD153035, U0126 and SIS3 showed no 
significant difference to TGFβ2 alone treated explants (P = 0.9610 for PD153035; P = 0.9994 
for U0126; P = 0.9931 for SIS3). 
Since Smad7 is a known antagonist of TGFβ-signalling (Nakao et al., 1997), we next explored 
the role of Smad7 in our lens EMT system. Treatment with TGFβ2 alone significantly 
upregulated the expression of Smad7 compared to control explants (P = 0.0004, Figure 8D). 
Co-treatment of TGFβ2 with any of the inhibitors showed no significant difference to TGFβ2 
alone-treated explants (P = 0.9898 for PD153035; P = 0.5078 for U0126; P = 0.964 for SIS3). 
Since BMP-signalling has been shown to downregulate EGFR-signalling in the development 
of astrocytes (Scholze et al., 2014) and BMP-7 itself has been found to counteract TGFβ2-
induced EMT in the lens (Shu et al., 2017), we investigated whether EGFR-, ERK1/2- or Smad-
signalling was involved in mediating the inhibitory effect of BMP-7 by examining its 
downstream target genes, Id2, Id3 and Smurf1. Treatment with TGFβ2 alone significantly 
downregulated the expression of Id2 (P < 0.0001; Figure 8E) and Id3 (P = 0.0004, Figure 8F) 
compared to levels in control explants. Addition of any of the three inhibitors did not 
significantly reduce the suppressive effect of TGFβ2 on Id2 (P = 0.9996 for PD153035; P = 
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0.6980 for U0126; P > 0.9999 for SIS3) or Id3 (P = 0.2786 for PD153035; P = 0.9343 for 
U0126; P = 0.9864 for SIS3) compared to TGFβ2 alone treated cells. 
Treatment with TGFβ2 alone significantly upregulated the expression of Smurf1 in LECs 
compared to control explants (P = 0.0109, Figure 8G). U0126 significantly inhibited TGFβ2-
induced upregulation of Smurf1 (P = 0.0059); however, PD153035 and SIS3 did not (P = 
0.0522 for PD153035; P = 0.7382 for SIS3).  
There were no significant differences for all target genes examined between explants treated 
with the inhibitors alone and control explants, with the exception of Smurf1 where co-treatment 
with the inhibitor alone induced a reduction in Smurf1 levels compared to control explants 
(Figure 8; P = 0.0446 for PD153035; P = 0.0008 for U0126; P = 0.0327 for SIS3). 
 
Figure 8. EGFR-inhibition blocks TGFβ2-induced EMT target gene expression. 
RT-qPCR revealed differential roles of EGFR-, ERK1/2- and Smad-signalling in TGFβ-induced 
upregulation of downstream EMT target genes including Zeb1 (A), Zeb2 (B), Snai1 (C), Smad7 (D), Id2 
(E), Id3 (F) and Smurf1 (G). Data from 3 independent experiments are presented relative to GAPDH as 
fold change ± SEM. One-way ANOVA, Tukey’s post hoc test *P < 0.05, **P < 0.01, ***P < 0.001 and 
****P < 0.0001. Zeb, zinc finger E-box-binding; Snai1, snail; Smad7, small mothers against 
decapentaplegic 7, Id, inhibitor of differentiation; Smurf1, Smad ubiquitin regulatory factor 1. 
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4.9 Inhibition of EGFR-, ERK1/2 and Smad-signalling differentially 
modulates TGFβ2-induced upregulation of Egfr and Hb-egf 
gene expression 
To investigate the role of the EGF family in TGFβ2-induced EMT, we evaluated the gene 
expression levels of Egfr and Hb-egf using RT-qPCR following a 24-h culture period. (see 
supplementary data in Section 8 for further statistical analysis). 
Treatment with TGFβ2 alone significantly upregulated expression of Egfr (P = 0.0046, Figure 
9A) compared to control. U0126 and SIS3 significantly inhibited TGFβ2-induced upregulation 
of Egfr (P = 0.0055 for U0126; P = 0.0421 for SIS3); however, PD153035 did not (P = 0.7174). 
Treatment with TGFβ2 alone significantly upregulated expression of Hb-egf (P < 0.0001, 
Figure 9B) compared to control explants. PD153035 and U0126 significantly inhibited TGFβ2-
induced upregulation of Hb-egf (P < 0.0001 for PD153035; P < 0.0001 for U0126); however, 
SIS3 did not (P = 0.8130 for SIS3). 
 
Figure 9. TGFβ2 induces upregulation of Egfr and Hb-egf gene expression. 
RT-qPCR revealed differential roles of EGFR-, ERK1/2- and Smad-signalling in TGFβ-induced 
upregulation of Egfr (A) and Hb-egf gene expression (B). Data from 3 independent experiments are 
presented relative to GAPDH as fold change ± SEM. One-way ANOVA, Tukey’s post hoc test *P < 0.05, 
**P < 0.01 and ****P < 0.0001. 
 
4.10 Inhibition of EGFR-, ERK1/2 and Smad-signalling differentially 
modulates TGFβ2-induced Adam gene expression 
Since members of a disintegrin and metalloproteinase (Adam) family play a key role in 
modulating the shedding of EGFR ligands to enable the release of soluble functional EGFR 
ligands (Kataoka, 2009), we investigated whether TGFβ2 modulated Adam gene expression in 
the lens (see supplementary data in Section 8 for further statistical analysis). 
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Treatment with TGFβ2 alone significantly upregulated the expression of Adam9 in LECs 
compared to control explants (P = 0.0282, Figure 10A). Addition of SIS3 inhibited TGFβ2-
induced upregulation of Adam9 (P = 0.0307); however, PD153035 and U0126 did not (P = 
0.9659 for PD153035; P > 0.9999 for U0126). 
TGFβ2 alone showed no significant change in Adam10 expression compared to control (P = 
0.5204, Figure 10B). Co-treatment of TGFβ2 with PD153035, U0126 or SIS3 showed no 
significant difference in Adam10 levels compared to TGFβ2 alone treated explants (P = 0.1216 
for PD153035; P = 0.1846 for U0126; P > 0.9999 for SIS3). 
In contrast to Adam9, treatment with TGFβ2 alone significantly downregulated the expression 
of Adam17 compared to control (P < 0.0001, Figure 10C). PD153035 and U0126 significantly 
inhibited TGFβ2-induced downregulation of Adam17 (P = 0.0040 for PD153035; P = 0.0128 
for U0126); however, SIS3 did not (P = 0.9690). Interestingly, treatment with SIS3 alone 
significantly reduced Adam17 levels compared to control explants (P = 0.0002). 
Treatment with TGFβ2 alone significantly upregulated the expression of Adam19 compared to 
control (P < 0.0001, Figure 10D). Addition of any of the three inhibitors blocked TGFβ2-
induced upregulation of Adam19 (P < 0.0001 for PD153035; P < 0.0001 for U0126; P = 0.0021 
for SIS3). Interestingly, levels of Adam19 was significantly lower with co-treatment of TGFβ2 
with U0126, than with co-treatment of TGFβ2 with SIS3 (P = 0.0471), indicating that U0126 
may be more effective at inhibiting TGFβ2-induced upregulation of Adam19 than SIS3. 
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Figure 10. EGFR-inhibition differentially modulates TGFβ2-induced changes in Adam gene 
expression. 
RT-qPCR revealed differential roles of EGFR-, ERK1/2- and Smad-signalling in TGFβ-induced 
upregulation of Adam9 (A), Adam10 (B), Adam17 (C) and Adam19 (D). Data from 3 independent 
experiments are presented relative to GAPDH as fold change ± SEM. One-way ANOVA, Tukey’s post 
hoc test *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. 
5 Discussion 
The present study shows, for the first time, that treatment of lens epithelial cells with TGFβ2 
leads to the phosphorylation of the EGFR. We demonstrate that this TGFβ2-induced 
transactivation of EGFR plays a pivotal role in facilitating the EMT process, as 
pharmacological inhibition of EGFR-signalling with PD153035 blocked characteristic features 
of TGFβ2-induced myofibroblastic transdifferentiation. Specifically, PD153035 inhibited 
TGFβ2-induced cellular elongation, cellular blebbing and cell loss, retaining a monolayer of 
cuboidal LECs over the entire culture period examined. The cell loss induced by TGFβ2 is 
known to occur through apoptosis (Maruno et al., 2002), supporting the apoptotic features 
typically seen in human PCO such as cytoplasmic condensation and chromatin margination. 
Moreover, PD153035 abrogated lens capsular wrinkling, a key feature of human PCO 
(Marcantonio et al., 2000), highlighting its ability in maintaining optical surface integrity of 
the lens capsule. 
Although PD153035 suppressed morphological features of TGFβ2-induced myofibroblastic 
transdifferentiation, our findings show differential changes in its ability to suppress 
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mesenchymal biomarkers. The accumulation of aberrant ECM components has been reported 
as a key feature of TGFβ2-induced fibrotic cataract, including ASC and PCO (Lovicu et al., 
2002; Mansfield et al., 2004). In the present study, PD153035 suppressed TGFβ2-induced 
upregulation of Col1a1 and Fn, highlighting a potential role for EGFR-signalling in mediating 
ECM gene expression. Myofibroblasts involved in wound healing typically express α-SMA, 
an actin isoform observed in vascular smooth muscle cells (Di Carlo and Peduto, 2018), and 
incorporation of α-SMA into stress fibres enhances the contractile activity of the myofibroblast 
(Prunotto et al., 2015). Interestingly, in our study, PD153035 suppressed α-SMA expression at 
the protein level but not at the transcription level, suggesting a role for EGFR-signalling in the 
translational control of α-SMA. PD153035 also suppressed TGFβ2-induced upregulation of 
tropomyosin protein expression. Tropomyosin1.6/1.7 isoforms precede the upregulation of α-
SMA in human subcutaneous fibroblasts and facilitate the stable incorporation of α-SMA into 
stress fibres (Prunotto et al., 2015). In this study, PD153035 blocked the presence of TGFβ2-
induced α-SMA stress fibres, highlighting a potential role for EGFR in modulating 
tropomyosin-driven stress fibre formation. Given this discrepancy in protein and gene 
regulation of α-SMA by EGFR-signalling, future experiments will be directed at investigating 
EGFR-mediated regulation of gene expression. For example, since PD153035 was unable to 
suppress TGFβ2-induced upregulation of connective tissue growth factor (Ctgf) gene 
expression, examining protein levels of CTGF would be of interest. 
EGF alone has been shown to induce EMT in breast cancer (Kim et al., 2016), pancreatic cancer 
(Sheng et al., 2017) and oral cancer cells (Xu et al., 2017); however, in the ocular lens, it is 
unable to induce EMT in lens epithelial cells and instead, is better known as a mitogen (Iyengar 
et al., 2009; Lovicu and McAvoy, 2005). Indeed, to our knowledge, the only growth factor 
known to induce EMT in lens epithelial cells is TGFβ. It is therefore intriguing to discover that 
TGFβ is somehow utilising EGFR-signalling to propagate its EMT effect in the lens. Our 
present study highlights potential molecular mechanisms whereby inhibition of EGFR-
signalling by PD153035 is able to suppress TGFβ-induced EMT. We show that inhibition of 
EGFR-signalling promoted retention of the lens epithelial phenotype, highlighting its role in 
maintaining lens epithelial cell integrity and polarity. Although protein expression levels of the 
epithelial marker β-catenin remained similar across all treatment groups, we found differences 
in its spatial localisation. Treatment with TGFβ2-alone induced cytoplasmic and nuclear 
translocation of β-catenin, whereas co-treatment with PD153035 enabled retention of β-catenin 
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to the cell membrane, highlighting the cobblestone-packed arrangement of the cells. Moreover, 
we also showed that TGFβ2 significantly downregulated gene expression of the epithelial 
marker, E-cadherin. Repression of E-cadherin and nuclear translocation of β-catenin have been 
detected in EMT models of renal (Zheng et al., 2009) and pulmonary (Song et al., 2014) 
fibrosis, as well as in human specimens of pterygium (Kato et al., 2007) and proliferative 
vitreoretinopathy (Gamulescu et al., 2006). The high-affinity E-cadherin/β-catenin membrane 
protein complex plays a crucial role in modulating EMT whereby loss of E-cadherin promotes 
the release of β-catenin from the cell membrane, thereby stabilising β-catenin in the cytosol to 
be available for nuclear import (Tian et al., 2011). β-catenin is a crucial element in the canonical 
Wnt signalling pathway in EMT, and nuclear translocation of β-catenin is indicative of aberrant 
activation of Wnt/β-catenin signalling (Peifer and Polakis, 2000), that has been implicated in 
cataract formation (Chong et al., 2009). More recent studies by Taiyab et al., (2016) showed 
that disruption of the E-cadherin/β-catenin complex is a key event during TGFβ-induced EMT 
in rat lens epithelial explants, enabling cytosolic β-catenin to interact and form a complex with 
the cyclic AMP response element-binding protein (CREB)-binding protein, CBP (Taiyab et al., 
2016). In the present study, addition of PD153035 blocked TGFβ-induced downregulation of 
E-cadherin, highlighting a potential role for EGFR-signalling in disrupting the E-cadherin/β-
catenin protein complex. It would be interesting to explore whether TGFβ-induced EGFR-
signalling can cross-talk with Wnt/β-catenin and/or β-catenin/CBP signalling to dysregulate 
the E-cadherin/β-catenin complex and facilitate propagation of the EMT process. 
Several transcriptional repressors of E-cadherin have been identified including zinc-finger 
transcription factors Snail (Snai1), Slug (Snai2), the basic helix-loop-helix factors (Twist1 and 
Twist2) and Zeb family members, Zeb1 and Zeb2 (Garg, 2013). These factors regulate the 
EMT program by recognising and binding to Enhancer Box (E-Box) DNA sequences located 
in the promoter region of the E-cadherin encoding gene (Garg, 2013). Together with the actions 
of various coactivators and corepressors, these transcription factors repress E-cadherin 
expression leading to destruction of cell-cell adhesion linkages at epithelial adherens junctions, 
enabling initiation of the EMT program (Garg, 2013). Interestingly, our findings highlighted 
contrasting roles for Zeb1 and Zeb2 gene expression in TGFβ2-induced EMT. Treatment with 
TGFβ2 alone resulted in an upregulation of Zeb1 and downregulation of Zeb2. Co-treatment 
with PD153035 blocked TGFβ2-induced downregulation of Zeb2, restoring Zeb2 levels to 
baseline. Opposing functions of Zeb in regulating the TGFβ-signalling pathway have been 
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previously reported whereby Zeb1 was found to synergise with TGFβ in activating 
transcription of the same reporter genes, while Zeb2 repressed TGFβ-mediated transcription 
(Postigo, 2003). The antagonistic roles of Zeb on TGFβ-induced Smad-signalling were further 
revealed to involve the differential recruitment of coactivators and corepressors (Postigo et al., 
2003). It would be of interest to explore whether EGFR-signalling may act as a molecular 
switch in modulating the expression of transcriptional coactivators and corepressors in TGFβ-
induced EMT in the lens. Although we showed a significant reduction in Snai1 gene expression 
in the PD153035 and TGFβ2 co-treatment group compared to TGFβ2 alone, the fold changes 
across all treatment groups were minimal, indicating that Snai1 may not play a major role in 
mediating TGFβ-induced EMT in our rat lens epithelial explant system. 
Inhibition of EGFR-signalling with Erlotinib has been shown to reduce TGFβ2 mRNA and 
protein levels in human lens epithelial cells, indicating a synergistic relationship between 
EGFR-signalling and TGFβ2 (Wertheimer et al., 2014). In the present study, we examined this 
relationship from a different perspective and show that TGFβ2 itself can transactivate 
phosphorylation of EGFR-signalling and increase gene expression of Egfr and Hb-egf. The 
transactivation of EGFR by TGFβ has been reported in models of renal fibrosis (Chen et al., 
2012; Samarakoon et al., 2013; Uchiyama-Tanaka et al., 2002), hepatic cancer (Murillo et al., 
2005), gastric cancer (Ebi et al., 2010; Voon et al., 2013), pulmonary cancer (Liu et al., 2007) 
and squamous cell carcinoma (Lee et al., 2010). These studies show that the transactivation 
process occurs rapidly within 1 hour of TGFβ treatment which is considerably more rapid than 
the 18 hours observed in our rat lens epithelial explants. These studies used TGFβ1 at a range 
of 1-5 ng/ml which is much higher than our dosage of 200 pg/ml of TGFβ2. The difference in 
the isoform and concentration may impact on the time period of this transactivation process. 
While we have specifically investigated the transactivation of EGFR at the Y1068 tyrosine 
kinase, other studies have observed changes in other tyrosine kinases such as Y1092 (Voon et 
al., 2013) and this would be of interest to explore in future studies. Voon et al., (2013) showed 
that total EGFR levels increased following treatment with TGFβ1 in a gastric cancer mouse 
model while pEGFR at Y1068 and Y1092 remained unchanged. It is possible that there may 
be changes in total EGFR levels following the addition of TGFβ in our system and this would 
require further investigation. While total EGFR levels may change, our data shows that it is the 
phosphorylation of EGFR that is required for the EMT process as blocking this 
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phosphorylation process using the tyrosine kinase inhibitor PD153035 blocks the EMT 
response over the five-day culture period. 
This transactivation process has been shown to involve members of a disintegrin and 
metalloproteinase (Adam) family that induce ‘ectodomain shedding’ or cleavage of EGF 
ligands such as HB-EGF to release functionally active soluble factors into the extracellular 
space to bind and activate the EGFR (Kataoka, 2009). We show differential changes in the 
upregulation of various Adam genes. Specifically, treatment with TGFβ2 induced an 
upregulation in Adam19 gene expression, and co-treatment with U0126, PD153035 or SIS3 
suppressed Adam19 to basal levels. In contrast, co-treatment with U0126 or PD153035 
inhibited TGFβ2-induced downregulation of Adam17 gene expression. TGFβ1 has been shown 
to induce the rapid activation of Adam17 and subsequently activate EGFR-signalling in rat 
hepatocytes (Murillo et al., 2005). Moreover, activation of Adam17 was found to induce pro-
HB-EGF shedding, resulting in nuclear translocation of the C-terminal fragment of HB-EGF 
and EGFR-transactivation in human gastric cancer development (Ebi et al., 2010). 
Interestingly, our findings showed that TGFβ2 upregulated Adam19 rather than Adam17, 
indicating that Adam19 may play a more important role in liberating EGF ligands to induce 
subsequent activation of EGFR signalling during EMT in our rat lens epithelial explant system. 
It is surprising to note that Adam17 gene expression is reduced following TGFβ2 addition and 
similarly reduced with SIS3, an inhibitor of TGFβ2 signalling. It is unclear what role, if any, 
Adam17 plays in the lens EMT process and requires further investigation. We show that in 
addition to the role of EGFR-signalling, ERK1/2- and Smad-signalling may also contribute to 
mediating TGFβ-induced Adam19 expression in myofibroblast transdifferentiation of lens 
epithelial cells. Although the addition of PD153035 showed a significant increase in Adam9 
and Adam10 expression, compared to TGFβ2 alone, there was minimal overall change between 
treatment groups. Adam9 and Adam10 gene expression have previously been shown to be 
upregulated following post-surgical injury in human lenses (Hodgkinson et al., 2010), 
suggesting that the disparity in our findings could be attributable to differences between the 
human and rat explant models. Our subsequent experiments will involve further characterising 
the mechanistic role of Adams in mediating TGFβ-induced lens EMT by identifying shedding 
cleavage sites, understanding determinants of shedding susceptibility and how Adams 
ultimately modulate downstream canonical and non-canonical signalling cascades. 
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Here, we show that that TGFβ2 induces the upregulation of phosphorylated EGFR at 18 hours. 
While there was variability in the label for pEGFR on western blotting (owing to challenges 
involved in probing for a large protein of 175kDa and a phosphorylated protein that is as not 
strongly expressed compared to other phosphorylated antibodies such as pERK1/2), a 
statistically significant trend was observed at 18 hours. In our experiments, we used the 
chemiluminescence form of detection; however, fluorescence detection may be a better 
alternative (Ghosh et al., 2014; Janes 2015) and will be considered for future experiments 
involving pEGFR. 
The transactivation of EGFR signalling has been shown to induce ERK1/2 signalling in models 
of kidney fibrosis (Reich et al., 2005; Roudabush et al., 2000). Previous work in our laboratory 
has revealed a critical role for ERK1/2-signalling in the initiation of TGFβ2-induced EMT in 
rat lens epithelial explants (Wojciechowski et al., 2017). Interestingly, our findings 
demonstrate that not only did PD153035 block ERK1/2-signalling, but inhibition of ERK1/2-
signalling using U0126 also blocked phosphorylation of EGFR. The overlapping roles of 
EGFR- and ERK1/2-signalling are further highlighted in the Venn diagram (see Figure 11), 
indicating a potential bi-directional positive-feedback loop between EGFR- and ERK1/2-
signalling pathways. Notably, in our study, the genes regulated by EGFR-signalling all appear 
to involve ERK1/2 signalling but not vice-versa. Similarly, with the exception of Adam9, genes 
regulated by Smad-signalling all appear to involve ERK1/2 activity but not vice-versa, 
indicating a central role for ERK1/2-signalling in mediating TGFβ-induced EMT in lens 
epithelial cells. It would be of interest to probe for other genes of interest that may be sensitive 
to PD153035 treatment, and potentially specific to ERK1/2-independent EGFR-signalling in 
TGFβ-induced lens EMT. It has been reported in cancer cells that EGFR upregulates the 
expression of TWIST (Lo et al., 2007), cyclin D1 (Lin et al., 2001), Aurora-A (Hung et al., 
2008) and Cox-2 (Lo et al., 2010), and it would be worthwhile to explore these target genes in 
this context. 
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Figure 11. Venn diagram depicting the role of ERK1/2-, EGFR- and Smad-signalling in 
upregulating TGFβ2-induced EMT markers. 
TGFβ-signalling plays a role in all of the EMT target genes within the green oval and all these genes 
are upregulated with TGFβ2 except for the genes marked with a downward arrow that are 
downregulated with TGFβ2. The genes outside the oval in the blue rectangle are those that do not 
change in expression following treatment with TGFβ. The three overlapping circles within the green 
oval depict the overlapping roles of ERK1/2-, EGFR- and Smad-signalling in upregulating EMT target 
genes. 
 
 
We show that both EGFR and ERK1/2 have the capacity to crosstalk with TGFβ2-induced 
Smad2/3; however, Smad2/3-signalling was not found to impact on both EGFR- and ERK1/2-
signalling, at least up to the 18-h time point examined. Indeed, inhibition of EGFR with 
PD153035 not only blocked TGFβ2-induced phosphorylation of Smad2/3 proteins but also 
reduced their nuclear translocation at the 18-h time point. It is important to note that inhibition 
of EGFR-signalling did not block nuclear translocation of tSmad2/3 at 2h, but it did at 18h, 
highlighting a temporal role in the regulation and integration of canonical and non-canonical 
TGFβ-dependent signalling pathways. It is possible that TGFβ-driven ERK1/2 is upregulated 
at 2 hours which may then upregulate EGFR-signalling by 18h. Meanwhile, the canonical 
Smad-signalling pathway is independently upregulated by TGFβ as rapidly as 15 min and 
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remains constant throughout the culture period with the non-canonical ERK1/2- and EGFR-
signalling pathways eventually feeding into Smad-signalling at 2h and 18h, respectively. Our 
future studies will involve clarification of these inferences on the temporal regulation of TGFβ-
driven signalling pathways through a more detailed characterisation of the phosphorylation of 
these pathways over a longer culture period. 
Work in our laboratory has shown that SIS3 is able to block TGFβ-induced EMT in rat lens 
epithelial explants over a five-day culture period with cells remaining as an epithelial 
monolayer, highlighting the efficacy and potency of this inhibitor (Wojciechowski et al., 2016). 
SIS3 blocks TGFβ-induced upregulation of Smad2/3 and does not impact on other signalling 
pathways such as ERK1/2 or EGFR, highlighting the specificity of the inhibitor. 
In addition to ERK1/2, other MAPK pathways such as p38 have been reported to play a role in 
lens EMT (Boswell et al., 2017). Boswell et al., (2017) showed that inhibition of the p38 
MAPK pathway suppressed TGFβ-induced EMT and cellular migration in embryonic chick 
lens epithelial cell cultures. Interestingly, the authors showed that blockade of p38 MAPK did 
not prevent TGFβ-driven fibre cell differentiation that is also evident in their model. Rather, 
inhibition of mTOR signalling with rapamycin blocked TGFβ-induced fibre cell differentiation 
but not EMT and cellular migration. Rapamycin; however, has been shown to attenuate TGFβ-
induced EMT in cultured human lens epithelial cells, suggesting that mTOR signalling may 
play a species-dependent role in lens EMT (Q. Meng et al., 2013). It would be of interest to 
explore how these non-canonical signalling pathways such as p38 MAPK and mTOR integrate 
their signals with ERK1/2- and EGFR-signalling, and whether these signals are ultimately 
integrated with the canonical TGFβ/Smad signalling pathway. 
Does TGFβ directly bind to the EGF receptor or does it indirectly activate EGFR signalling? 
Here, we show that while EGF phosphorylated EGFR within 1min, treatment with TGFβ did 
not lead to the immediate phosphorylation of the EGFR until 18h, suggesting that the 
transactivation of EGFR by TGFβ may not be a direct effect on the receptor, but rather a 
downstream indirect signalling event. Future experiments are required to shed light on this 
question including, (i) whether a complete knockdown/absence of the EGF receptor can 
prevent TGFβ-induced EMT, and (ii) whether functional loss of the extracellular ligand-
binding domain of the EGF receptor (using a monoclonal antibody designed to specifically 
block this), whilst preserving the intracellular tyrosine kinase domain can prevent TGFβ-
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induced EMT, and vice versa. Intriguingly, we show that although EGF can phosphorylate 
EGFR signalling rapidly within 1min, pEGFR levels fall at 18h, despite EGF maintaining its 
bioactivity at this time. It is possible that activation of EGF-EGFR signalling may initiate a 
negative feedback loop (e.g. via Sprouty proteins, see Shin et al., 2015), thereby ensuring its 
own precise signal regulation. Once activated, EGFR signalling can be terminated by 
internalisation of receptor-ligand complexes (Yarden, 2001). Activated EGFR can either be 
directed towards a canonical clathrin-dependent pathway for endocytosis (Wiley and Burke, 
2001) or a “fast” clathrin-independent pathway involving an E3 ubiquitin ligase Cbl that targets 
activated receptors for ubiquitination (Sigismund et al., 2005). It would be worthwhile for 
future studies to explore the mechanism of EGFR signal reduction following EGF application 
in our rat lens explant system. Moreover, given dimerisation of the EGFR is an essential step 
in signal transduction, Kluba et al., (2015) discovered the existence of an EGFR monomer-
dimer equilibrium whereby phosphorylation of EGFR shifted the monomer-dimer equilibrium 
back towards the monomeric state (Kluba et al., 2015). It would be of interest to explore 
whether such oscillatory behaviour of the monomer-dimer ratio of EGF-bound EGFR also 
exists in the ocular lens, to ensure orchestrated regulation of EGFR signalling output. 
In addition to exploring Smad2/3, our findings also show that TGFβ2 induced upregulation of 
the inhibitory Smad, Smad7. TGFβ has been shown to rapidly induce Smad7 gene expression 
through a negative feedback loop that then associates with the TGFβ-receptor-complex to limit 
phosphorylation of Smad2/3 through competitive inhibition (Nakao et al., 1997). Since 
PD153035 or U0126 did not reduce TGFβ-induced upregulation of Smad7, EGFR- and/or 
ERK1/2-signalling may not play a role in modulating Smad7 expression. Alternatively, it has 
been proposed that Smad7 antagonises TGFβ-signalling in the nucleus by binding to the Smad-
responsive element, thereby disrupting the functional Smad-DNA complex (Zhang et al., 
2007). As PD153035- and/or U0126-treatment still maintain elevated levels of TGFβ-driven 
Smad7 expression, this elevated Smad7 may continue to contribute to the inhibition of 
Smad2/3-signalling, posing an interesting area for further investigation. 
Work in our laboratory has previously shown a role for BMP7 in antagonising TGFβ-induced 
EMT through upregulation of downstream BMP target genes, Id2/3 (Shu et al., 2017). In the 
present study, we show that PD153035 was unable to block TGFβ-induced downregulation of 
Id2/3. In contrast, BMP7 effectively restored TGFβ-induced downregulation of Id2/3 levels 
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back to baseline (Shu et al., 2017). Moreover, PD153035 was unable to block TGFβ-induced 
upregulation of Smad ubiquitin regulatory factor (Smurf)1, but U0126 was able to, indicating 
a link between the inhibitory activity of ERK1/2 and BMP-signalling. Smurf1 is a known 
negative regulator of BMP-signalling and binds to its receptor-regulated Smads (Smad1/5), 
subsequently promoting their ubiquitination and degradation (Murakami, 2003). Taken 
together, these findings regarding the inhibitory activity of BMP7 and PD153035 in TGFβ-
induced lens EMT may be mediated by independent pathways. 
6 Conclusions 
A complex network of signalling pathways underlies TGFβ-induced EMT in the lens. Here, 
we highlight a key role for EGFR-signalling in EMT and that TGFβ indirectly transactivates 
EGFR-signalling, a previously unknown mechanism in the pathogenesis of ASC or PCO. We 
show that inhibition of EGFR-signalling with PD153035 effectively blocks key morphological 
and molecular features of TGFβ-induced EMT in rat lens epithelial explants. Moreover, 
PD153035 can differentially modulate the expression of downstream EMT target genes 
involved in E-cadherin repression and metalloproteinases involved in EGFR-signalling. The 
interplay between Smad2/3-, EGFR- and ERK1/2-signalling pathways highlights a complex 
and integrated network of intracellular communication underlying the EMT program.  
Overexpression of EGFR has been reported in many human epithelial cancers, and EGFR 
inhibitors such as Erlotinib and Gefitinib have been approved for treatment of these cancers 
(Rocha-Lima et al., 2007). Our findings that TGFβ-induced transactivation of EGFR-signalling 
plays an important role in lens fibrosis may catalyse a deeper understanding of molecular 
mechanisms between cancer and fibrosis. This link was proposed over 30 years ago with the 
concept that tumours are “wounds that do not heal” (Dvorak, 1986). Targeting EGFR-
signalling potentially opens up a new avenue in the prevention of cataract. While our current 
findings enhance our understanding of the signalling pathways involved in TGFβ-induced lens 
EMT, future studies will be aimed at further elucidating the contribution of EGFR-signalling 
in modulating the EMT program leading to cataract. 
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8 Supplementary Material 
8.1 Supplementary figure 
 
Figure S1. Expression of signalling proteins in untreated explants over the culture period. 
Using Western blotting, we compared the expression levels of signalling proteins from untreated 
explants collected at 0 min (C), 15 min (C15), 2 h (C2) and 18 h (C18) with explants pre-treated with 
the different inhibitors (PD, PD153035; U0,U0126 or SIS, SIS3) collected at (Panel A). Although the 
basal levels of pEGFR appeared slightly reduced by adding PD153035, this was not statistically 
significant (P = 0.9150). Similarly, although basal levels of pERK1/2 appeared reduced by adding 
PD153035 and U0126, this did not reach statistical significance (P = 0.2463 for PD153035, P = 0.062 
for U0126). There were also no significant differences for pEGFR (Panel B), pERK1/2 (Panel C), 
pSmad2/3 (Panel D), tERK1/2 (Panel E), or tSmad2/3 (Panel F) (P > 0.05). Representative Western 
blots were analysed from 3 independent experiments, with data presented as mean ± SEM. One-way 
ANOVA, Tukey’s post hoc test was used for analysis. 
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8.2 Analysis of real-time quantitative polymerase chain reaction 
(RT-qPCR) data 
Using RT-qPCR, we investigated whether key EMT markers, TGFβ target genes, EGF family 
members and Adams genes played a role in lens EMT and whether their expression depended 
upon EGFR-, ERK1/2- and Smad-signalling using RT-qPCR following a 24-h treatment period 
with TGFβ2 alone or in combination with PD153035, U0126 or SIS3. 
8.2.1 Collagen 1A1 
Treatment of LECs with TGFβ2 for 24 h induced a significant upregulation of Col1a1 
compared to control explants (P < 0.0001; Figure 7A). Inhibition of EGFR- or ERK1/2-
signalling inhibited TGFβ2-induced upregulation of Col1a1 (P < 0.0001 for PD153035; P < 
0.0001 for U0126) with no difference to control levels (P = 0.7019 for PD153035; P = 0.9875 
for U0126). Although SIS3 significantly inhibited TGFβ2-induced upregulation of Col1a1 (P 
< 0.0001), it was still significantly higher than control levels (P = 0.0231). 
8.2.2 Fibronectin 
Treatment of LECs with TGFβ2 for 24 h induced a significant upregulation of Fn compared to 
control explants (P < 0.0001; Figure 7B). Inhibition of EGFR-, ERK1/2- or Smad3-signalling 
inhibited TGFβ2-induced upregulation of Fn (P < 0.0001 for PD153035; P < 0.0001 for U0126; 
P = 0.0005 for SIS3) with no difference to control levels (P = 0.9813 for PD153035; P = 0.9873 
for U0126; P = 0.4262 for SIS3). 
8.2.3 α-SMA 
Treatment of LECs with TGFβ2 for 24 h induced a significant upregulation of the 
myofibroblast marker, α-SMA, compared to control explants (P < 0.0001; Figure 7C). 
Inhibition of ERK1/2- or Smad3-signalling inhibited TGFβ2-induced upregulation of α-SMA 
(P = 0.0270 for U0126; P = 0.0244 for SIS3), however they still exhibited a significant 
difference to control levels (P = 0.0452 for U0126; P = 0.0498 for SIS3). Although PD153035 
blocked α-SMA expression at the protein level (Figure 3B), it was unable to suppress TGFβ2-
induced upregulation of α-SMA gene expression (P > 0.9999) and was significantly different 
to control levels (P < 0.0001). 
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8.2.4 Ctgf  
Treatment of LECs with TGFβ2 for 24 h induced a significant upregulation of the 
mesenchymal marker, Ctgf, compared to control explants (P < 0.0001; Figure 7D). Inhibition 
of ERK1/2- inhibited TGFβ2-induced upregulation of Ctgf (P < 0.0001), with no significant 
difference to control levels (P > 0.9999). Inhibition of EGFR- or Smad3-signalling did not 
inhibit TGFβ2-induced upregulation of Ctgf (P > 0.9999 for PD153035; P > 0.9999 for SIS3) 
with a significant difference to control explants (P < 0.0001 for PD153035; P < 0.0001 for 
SIS3). 
8.2.5 Ncad and Ecad 
There was no significant increase in the gene expression of the mesenchymal marker Ncad 
with TGFβ2-treatment, compared to control explants (P > 0.9999; Figure 7E). Treatment with 
TGFβ2 significantly downregulated gene expression of the epithelial marker Ecad compared 
to control explants (P < 0.0018; Figure 7F). Inhibition of EGFR- or ERK1/2-signalling 
inhibited TGFβ2-induced downregulation of Ecad (P = 0.0160 for PD153035; P = 0.0017 for 
U0126), with no difference to control levels (P > 0.9999 for PD153035; P > 0.9999 for U0126). 
SIS3 did not inhibit TGFβ2-induced downregulation of Ecad (P > 0.9999) and was 
significantly downregulated compared to control explants (P = 0.0288). 
No significant differences were found for all the mesenchymal genes examined between 
explants treated with the inhibitors alone and control explants (Figure 7). 
8.2.6 Zeb1 
Treatment with TGFβ2 alone significantly upregulated the expression of Zeb1 compared to 
control explants (P = 0.0059, Figure 8A). Inhibition of ERK1/2- blocked TGFβ2-induced 
upregulation of Zeb1 (P = 0.0230) with no significant difference to control levels (P > 0.9999). 
Although co-treatment of PD153035 or SIS3 with TGFβ2 did not show a significant difference 
in Zeb1 levels compared to control explants (P = 0.5506 for PD153035; P = 0.4520 for SIS3), 
it did not significantly inhibit TGFβ2-induced upregulation of Zeb1 (P = 0.7538 for PD153035; 
P = 0.8383 for SIS3). 
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8.2.7 Zeb2 
In contrast to Zeb1, TGFβ2 alone significantly downregulated Zeb2 expression compared to 
cells of control explants (P = 0.0013; Figure 8B). Inhibition of EGFR- and ERK1/2-signalling 
significantly inhibited TGFβ2-induced downregulation of Zeb2 (P = 0.0203 for PD153035; P 
< 0.0001 for U0126) with no significant difference to control levels (P > 0.9999 for PD153035; 
P = 0.4717 for U0126). Although co-treatment with SIS3 and TGFβ2 did not show a significant 
difference in Zeb2 levels compared to control explants (P = 0.1202), it did not significantly 
inhibit TGFβ2-induced downregulation of Zeb2 (P = 0.9423). 
8.2.8 Snail 
TGFβ2 alone showed no significant change in Snai1 expression compared to control explants 
(P = 0.7231, Figure 8C). Co-treatment of TGFβ2 with PD153035, U0126 and SIS3 showed no 
significant difference to TGFβ2 alone treated explants (P = 0.9610 for PD153035; P = 0.9994 
for U0126; P = 0.9931 for SIS3) with no difference to control levels (P = 0.2951 for PD153035; 
P = 0.9906 for U0126; P = 0.4401 for SIS3). 
8.2.9 Smad7  
Treatment with TGFβ2 alone significantly upregulated the expression of Smad7 compared to 
control explants (P = 0.0004, Figure 8D). Co-treatment of TGFβ2 with PD153035 or U0126 
showed no significant difference to TGFβ2 alone treated explants (P = 0.9898 for PD153035; 
P = 0.5078 for U0126) and was significantly elevated compared to control levels (P = 0.0341 
for PD153035; P = 0.0167 for U0126). Co-treatment with TGFβ2 and SIS3 showed no 
significant difference to control explants (P = 0.551); however, this was not significantly 
different from TGFβ2 alone treated explants (P = 0.964). 
8.2.10 Id2/3 
Treatment with TGFβ2 alone significantly downregulated the expression of Id2 (P < 0.0001; 
Figure 8E) and Id3 (P = 0.0004, Figure 8F) compared to levels in control explants. Inhibition 
of EGFR-, ERK1/2- or Smad3-signalling did not significantly reduce the suppressive effect of 
TGFβ2 on Id2 (P = 0.9996 for PD153035; P = 0.6980 for U0126; P > 0.9999 for SIS3) 
compared to TGFβ2 alone treated cells, and was significantly elevated compared to control (P 
= 0.0033 for PD153035; P = 0.0485 for U0126; P = 0.0018 for SIS3). Although co-treatment 
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with PD153035 or U0126 and TGFβ2 did not show a significant difference in Id3 levels 
compared to control explants (P = 0.4867 for PD153035; P = 0.0555 for U0126), it did not 
significantly inhibit TGFβ2-induced downregulation of Id3 (P = 0.2786 for PD153035; P = 
0.9343 for U0126). Co-treatment with SIS3 and TGFβ2 was significantly elevated compared 
to control explants (P = 0.0006), showing no significant difference in Id3 levels compared to 
TGFβ2 alone treated explants (P = 0.9864). 
8.2.11 Smurf1 
Treatment with TGFβ2 alone significantly upregulated the expression of Smurf1 in LECs 
compared to control explants (P = 0.0109, Figure 8G). The addition of U0126 significantly 
inhibited TGFβ2-induced upregulation of Smurf1 (P = 0.0059), showing no significant 
difference to cells in control explants (P = 0.9690). Although co-treatment with PD153035 or 
SIS3 and TGFβ2 did not show a significant difference in Smurf1 levels compared to control 
explants (P > 0.9999 for PD153035; P = 0.6210 for SIS3), it did not significantly inhibit 
TGFβ2-induced upregulation of Smurf1 (P = 0.0522 for PD153035; P = 0.7382 for SIS3).  
There were no significant differences for all target genes examined between explants treated 
with the inhibitors alone and control explants, with the exception of Smurf1 where co-treatment 
with the inhibitor alone induced a reduction in Smurf1 levels compared to control explants 
(Figure 8; P = 0.0446 for PD153035; P = 0.0008 for U0126; P = 0.0327 for SIS3). 
8.2.12 Egfr  
Treatment with TGFβ2 alone significantly upregulated expression of Egfr (P = 0.0046, Figure 
9A) compared to control explants. Inhibition of ERK1/2- and Smad-signalling significantly 
inhibited TGFβ2-induced upregulation of Egfr (P = 0.0055 for U0126; P = 0.0421 for SIS3) 
with no significant difference to control levels (P = 0.9948 for U0126; P > 0.9999 for SIS3). 
Although co-treatment with PD153035 and TGFβ2 did not show a significant difference in 
Egfr levels compared to control explants (P = 0.5360), it did not significantly inhibit TGFβ2-
induced upregulation of Egfr (P = 0.7174). 
8.2.13 Hb-egf  
Treatment with TGFβ2 alone significantly upregulated expression of Hb-egf (P < 0.0001, 
Figure 9B) compared to control explants. Inhibition of EGFR- and ERK1/2-signalling 
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significantly inhibited TGFβ2-induced upregulation of Hb-egf (P < 0.0001 for PD153035; P < 
0.0001 for U0126) with no significant difference to control levels (P > 0.9999 for PD153035; 
P = 0.9156 for U0126). In contrast, inhibition of Smad-signalling did not inhibit TGFβ2-
induced upregulation of Hb-egf (P = 0.8130 for SIS3) and showed a significant difference to 
control explants (P < 0.0001 for SIS3). 
8.2.14 Adam9 
Treatment with TGFβ2 alone significantly upregulated the expression of Adam9 in LECs 
compared to LECs of control explants (P = 0.0282, Figure 10A). Addition of SIS3 inhibited 
TGFβ2-induced upregulation of Adam9 (P = 0.0307) showing no difference to control levels 
(P > 0.9999). Although co-treatment of TGFβ2 with PD153035 or U0126 showed no 
significant difference in Adam9 levels compared to control explants (P = 0.1759 for PD153035; 
P = 0.0527 for U0126), it was also not significantly different to explants treated with TGFβ2 
alone (P = 0.9659 for PD153035; P > 0.9999 for U0126). 
8.2.15 Adam10 
TGFβ2 alone showed no significant change in Adam10 expression compared to control 
explants (P = 0.5204, Figure 10B). Co-treatment of TGFβ2 with PD153035, U0126 or SIS3 
showed no significant difference in Adam10 levels compared to TGFβ2 alone treated explants 
(P = 0.1216 for PD153035; P = 0.1846 for U0126; P > 0.9999 for SIS3), and no significant 
difference to control levels (P = 0.8947 for PD153035; P = 0.9590 for U0126; P = 0.7244 for 
SIS3). 
8.2.16 Adam17  
In contrast to Adam9, treatment with TGFβ2 alone significantly downregulated the expression 
of Adam17 in LECs, compared to LECs of control explants (P < 0.0001, Figure 10C). Inhibition 
of EGFR- and ERK1/2-signalling significantly inhibited TGFβ2-induced downregulation of 
Adam17 (P = 0.0040 for PD153035; P = 0.0128 for U0126), with no significant difference to 
control levels (P > 0.9999 for PD153035; P = 0.4717 for U0126). Co-treatment with SIS3 and 
TGFβ2 also showed no significant difference in Adam17 expression to TGFβ2 alone treated 
explants (P = 0.9690) and was significantly reduced compared to control levels of Adam17 (P 
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= 0.0095). Interestingly, treatment with SIS3 alone significantly reduced Adam17 levels 
compared to control explants (P = 0.0002). 
8.2.17 Adam19 
Treatment with TGFβ2 alone significantly upregulated the expression of Adam19 compared to 
control explants (P < 0.0001, Figure 10D). Inhibition of EGFR-, ERK1/2- or Smad3-signalling 
inhibited TGFβ2-induced upregulation of Adam19 (P < 0.0001 for PD153035; P < 0.0001 for 
U0126; P = 0.0021 for SIS3) with no difference from control levels (P = 0.9742 for PD153035; 
P = 0.3573 for U0126; P = 0.7295 for SIS3).
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Chapter Five 
 
Results (Part III)  
Enhanced EGF receptor-signalling augments TGFβ-induced EMT in LECs 
EGF, a ligand specific for activating EGFR-signalling, exists inherently in the aqueous humour 
and can induce lens epithelial cell (LEC) proliferation (Iyengar et al., 2009). Given that EGFR-
signalling can be activated by TGFβ during lens EMT, this third study aimed to decipher how 
exogenous EGF impacts on TGFβ-induced EMT. While EGF itself is unable to induce EMT 
in LECs, this study revealed that it can augment the EMT-inducing properties of TGFβ. Co-
treatment of LECs with EGF and TGFβ not only resulted in a more pronounced morphological 
elongation and transdifferentiation of LECs into myofibroblast cells, compared to TGFβ alone, 
but induced higher protein expression levels of mesenchymal markers. Furthermore, adding 
EGF to a lower, less effective dose of TGFβ2 (50 pg/ml) induced LECs to undergo EMT 
similar to treatment with a higher dose of TGFβ2 (200 pg/ml), suggesting that EGF may 
sensitise LECs to be more responsive to the less potent dose of TGFβ or in fact that it can 
amplify the TGFβ-induced signalling of the lower dose. Both EGF and TGFβ activate EGFR- 
and ERK1/2-signalling; however, only TGFβ is able to activate the Smad2/3-signalling 
pathway. When the two growth factors are combined, all three pathways are activated with the 
cells receiving dual inputs for EGFR- and ERK1/2-signalling from both growth factors that 
may contribute to the augmented EMT response we observe. Building on the array of gene data 
in the earlier study involving treatment with TGFβ alone, this study explores the same genes 
for treatment with EGF alone and co-treatment with TGFβ and EGF, revealing a shift in the 
regulation of these genes by EGFR-, ERK1/2- and Smad-signalling. Inhibition of EGFR-
signalling using PD153035 abrogated the augmented EMT response induced by co-treatment 
with EGF and TGFβ. By directly blocking EGFR-signalling, the activity of both EGF and 
TGFβ can be simultaneously suppressed, thus serving as a potential drug target for treating 
cataract. 
This manuscript has been submitted for publication and is currently under review. The work 
has arisen entirely during my PhD candidature under the guidance of my primary supervisor 
Professor Frank Lovicu who contributed to this manuscript by facilitating me with 
experimental design and manuscript writing. 
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Enhanced EGF receptor-signalling potentiates TGFβ-induced lens 
epithelial-mesenchymal transition 
Daisy Y. Shu, 1,2 and Frank J. Lovicu1,2 
1Discipline of Anatomy and Histology, Bosch Institute, The University of Sydney, NSW, 
Australia 
2Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, The University 
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Keywords: lens, fibrosis, transforming growth factor-beta (TGFβ), epidermal growth factor 
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cataract, myofibroblast, posterior capsular opacification, ERK1/2, Smad 
1 Abstract 
The ocular lens is exposed to numerous growth factors that influence its behaviour in diverse 
ways. While many of these, such as FGF and EGF promote normal cell behaviour, TGFβ is 
unique in that it can also induce lens cell pathology, namely, the epithelial-mesenchymal 
transition (EMT) of LECs (LECs) leading to fibrotic cataract formation. The present study 
explores how EGF impacts on TGFβ-induced EMT in the lens. LECs in explants prepared from 
21-day-old Wistar rats were treated with either 200 pg/ml TGFβ2, 5 ng/ml EGF, or a 
combination of these, with or without a 2-hour pre-treatment of an EGFR inhibitor 
(PD153035), MEK inhibitor (U0126) or Smad3 inhibitor (SIS3). Co-treatment of LECs with 
TGFβ2 and EGF, compared with TGFβ2 alone, resulted in a more pronounced elongation and 
transdifferentiation of the LECs into myofibroblastic cells, with higher protein levels of 
mesenchymal cell markers (α-SMA and tropomyosin). Combining EGF with a less potent 
lower dose of TGFβ2 (50 pg/ml) induced LECs to undergo EMT equivalent to treatment with 
a higher dose of TGFβ2 (200 pg/ml) within 5 days of culture. EGF alone, nor the lower dose 
of TGFβ2, were able to induce EMT in LECs within 5 days. Co-treatment of LECs with EGF 
and TGFβ2 induced a temporal shift in the phosphorylation levels of Smad2/3, ERK1/2 and 
EGFR and changed the expression patterns of downstream EMT target genes, compared to 
treatment of LECs with either growth factor alone. Inhibition of EGFR-signalling with 
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PD153035 blocked the EMT response induced by co-treatment with EGF and TGFβ2. Taken 
together, our data demonstrate that EGF can potentiate TGFβ2 activity to enhance EMT in 
LECs, further highlighting the importance of EGFR-signalling in cataract formation. By 
directly blocking EGFR signalling, the activity of both EGF and TGFβ2 can be simultaneously 
reduced, thereby serving as a potential target for cataract prevention. 
2 Introduction 
The ocular lens is bathed by many different growth factors, such as fibroblast growth factor 
(FGF), bone morphogenetic protein (BMP), insulin-like growth factor (IGF), epidermal growth 
factor (EGF), and transforming growth factor-beta (TGFβ), that differentially influence cellular 
behaviour (Lovicu and McAvoy, 2005). While some growth factors, such as EGF, facilitate 
normal physiological processes such as cell proliferation (Iyengar et al., 2009), other growth 
factors including TGF play a role in lens pathology leading to cataract (Liu et al., 1994). 
Cataract, the loss of ocular lens transparency, is the leading cause of blindness worldwide 
(Foster and Resnikoff, 2005). 
TGF stimulates LECs (LECs) to undergo an epithelial-mesenchymal transition (EMT) 
leading to fibrotic forms of cataract, such as anterior subscapular cataract and posterior capsular 
opacification (PCO) following cataract surgery (de Iongh et al., 2005). During EMT, LECs 
lose their regular cuboidal shape and polarity, transdifferentiate into elongate spindle-shaped 
myofibroblasts, secrete extracellular matrix (ECM) proteins and migrate across the lens capsule 
(Hales et al., 1995). 
Studies in different tissues have shown that EGF, when combined with TGF, can enhance the 
EMT response; EGF and TGF1 synergistically enhanced tumour invasiveness in lung 
epithelial cells (Saha et al., 1999), pig thyroid epithelial cells (Grände et al., 2002) and 
epithelial ovarian cancer cells (Xu et al., 2010). In a model of renal fibrosis, adding EGF 
enhanced TGF-induced EMT in HK-2 cells by accentuating E-cadherin loss and collagen I 
gel contraction (Docherty et al., 2006). Co-stimulation of rat intestinal epithelial cells with EGF 
and TGF1 induced dramatic morphological cellular changes indicative of EMT in a 
MAPK/ERK1/2-dependent manner (Uttamsingh et al., 2008). In the eye, co-treatment with 
EGF and TGF1 induced 90% of rabbit corneal keratocytes to transform into myofibroblasts, 
an increase from 12% when treated with TGF1 alone (He and Bazan, 2008). In contrast to the 
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above, there are reports whereby EGF blocks TGF activity. Carmona-Cuenca et al., (2006) 
showed that EGF blocked TGF-induced production of ROS and upregulation of Nox4 in fetal 
rat hepatocytes (Carmona-Cuenca et al., 2006). Blocking the EGF pathway enhanced TGF-
induced apoptosis in rat hepatoma cells, with an associated increase in oxidative stress through 
elevated Nox4 and ROS production (Sancho et al., 2009). The pro-survival effect of EGF was 
also observed in renal HK-2 cells where adding EGF blocked TGF-induced apoptosis during 
EMT in a PI3K/Akt-dependent manner (Docherty et al., 2006). 
Given the differential effect of EGF on TGF activity in different cell types, the present study 
aimed to investigate how EGF impacts on TGF-induced EMT in LECs. Recent work from 
our laboratory reported that TGF was able to transactivate the EGF receptor (EGFR) in rat 
lens epithelial cell explants, and showed that inhibition of EGFR-signalling blocked the ability 
of TGF to induce EMT (Shu et al., 2018). Given EGFR-signalling is required for TGF-
induced lens EMT, we set out to determine what effect exogenous EGF has on the EMT 
response induced by TGF2 and in lens. In the present study we compared the influence of 
EGF on TGF activity in the lens, to treatment with either growth factor alone, by 
characterising changes in the regulation of EMT target genes and the canonical and non-
canonical TGF-signalling pathways (EGFR-, MAPK/ERK1/2- and Smad-signalling). 
3 Methods 
3.1 Animals 
21-day-old albino Wistar rats (Rattus norvegicus) were euthanised by carbon dioxide 
asphyxiation and cervical dislocation. Eyes were enucleated and ocular lenses were isolated. 
Animal procedures adhered to the Association for Research in Vision and Ophthalmology 
(ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research (USA) and the 
National Health and Medical Research Council (NHMRC) Australian Code of Practice for the 
Care and Use of Animals for Scientific Purposes (Australia). Experiments were approved by 
the Animal Ethics Committee of the University of Sydney (Australia). 
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3.2 Preparation of rat lens epithelial explants 
Rat lens epithelial explants were prepared as described previously (West-Mays et al., 2010). 
Explants were placed in a humidified, 5% CO2 incubator at 37°C. Tissues were placed in 
Medium 199 with Earle’s salts (Life Technologies, Waltham, MA, USA), supplemented with 
0.1% (w/v) bovine serum albumin (BSA; Sigma-Aldrich Corp., St. Louis, MO, USA), 0.1 
μg/ml L-glutamine (Life Technologies), 2.5 μg/ml Amphostat B (Thermo Fisher Scientific, 
MA, USA) and 100 IU/ml penicillin/100 μg/ml streptomycin (Life Technologies). 
Explants were treated with recombinant human TGFβ2 (R&D Systems) at 200 pg/ml or 50 
pg/ml alone, with or without EGF at 5 ng/ml (BioLegend, San Diego, California). To 
investigate the involvement of downstream TGFβ2-signalling pathways, explants were pre-
treated with inhibitors of specific pathways including; 100nM PD153035 (EGFR inhibitor, 
AG1517, Merck Millipore), 50µM U0126 (MEK1/2 inhibitor; 9903; Cell Signalling 
Technology) to block ERK1/2 activation, or 5µM SIS3 (Smad3 inhibitor; sc-253565; Santa 
Cruz Biotechnology), for 2 hours prior to the addition of the growth factor(s). All inhibitors 
were diluted in dimethyl sulfoxide (DMSO) and an equal volume of this solvent was added to 
the control explants. 
Explants were cultured for up to 5 days. Cell morphology was examined with phase-contrast 
microscopy (CK2, Olympus, Japan) and photographed (Leica DFC-280; Leica Camera, 
Wetzlar, Germany) before being harvested for immunofluorescence, Western blotting or RT-
qPCR. For signalling proteins, all Western blot analyses were performed relative to the 
untreated group harvested as T = 0 minutes as we previously found no significant differences 
in the levels of signalling proteins over the culture period when explants were left untreated 
(Shu et al., 2018). 
3.3 Immunofluorescence 
Explants were fixed in 100% methanol (45 seconds) and rinsed 4 times in phosphate buffered 
saline (PBS). Explants were then rinsed (3 x 5 minutes) in PBS supplemented with 0.1% (w/v) 
BSA (PBS/BSA). This was followed by incubation in 10% normal goat serum (NGS) diluted 
in PBS/BSA for 1 hour. Primary antibodies were diluted in PBS/BSA with 1.5% NGS and 
incubated at 4°C in a humidified chamber overnight. Anti-rabbit IgG antibodies specific for β-
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catenin (H-102, polyclonal, Santa Cruz, TX, USA), total-Smad2/3 (8685; monoclonal, Cell 
Signalling Technology), and anti-mouse antibodies specific for α-smooth muscle actin (α-
SMA; A2547; monoclonal, Sigma-Aldrich Corp.) were all diluted at 1:100. 
The following day, explants were equilibrated to room temperature and any unbound primary 
antibody was removed by rinsing in PBS/BSA (3 x 5 minutes). The appropriate secondary 
antibody (diluted 1:1000 in PBS/BSA) was then applied to the explants for 2 hours in a dark 
humidified chamber at room temperature. β-catenin and total Smad2/3 were detected using 
goat anti-rabbit Alexa-Fluor 488 (Abcam, Cambridge, MA, USA). α-SMA was detected using 
goat anti-mouse Alexa-Fluor 594 IgG (Abcam, Cambridge, MA, USA). Explants were rinsed 
in PBS/BSA (3 x 5 minutes) and then counterstained for 3 minutes with 3 µg/ml bisbenzimide 
(Hoechst dye 33342; Sigma-Aldrich Corp). Explants were then rinsed in PBS/BSA (3 x 5 
minutes). Explants were mounted with 10% (v/v) PBS in glycerol, and viewed with a Zeiss 
LSM-5Pa confocal microscope (Carl Zeiss AG, Jena, Germany). 
3.4 SDS-Page and Western blotting 
Intact explants were rinsed in cold PBS to remove excess culture media. Proteins were 
extracted in cold lysis buffer containing 25mM Tris-HCl (pH 7.5), 2.5mM EDTA, 10mM 
sodium deoxycholate, 0.375M NaCl, 250mM sodium orthovandate, a phosphatase inhibitor 
(PhosStop; Roche Applied Science), and a protease inhibitor cocktail (Complete; Roche 
Applied Science). Homogenised samples were rotated for 2 hours at 4°C. Lysates were 
centrifuged at 15,500g for 15 minutes at 4°C. The supernatant was extracted and its protein 
content was quantified using the Micro BCA protein assay reagent kit (Thermo Fisher 
Scientific). 
Protein lysates were added to Laemmli sample buffer in a 1:1 ratio (BioRad Laboratories, 
Hercules, CA, USA). Up to 10μg of protein was loaded onto a 10% SDS-PAGE gel for 
electrophoresis for 1.5 hours at 200 V, and transferred for 3 hours at 100 V to an Immobilon 
polyvinylidene fluoride membrane (Merck Millipore). The membrane was incubated (1 hour) 
with a blocking solution of 2.5% BSA in 0.1% Tween-20 in Tris-buffered saline (TBST) for 
phosphorylated proteins, and 5% (w/v) non-fat skim milk powder in TBST for non-
phosphorylated proteins. Membranes were incubated overnight at 4°C with the primary 
antibody. Anti-mouse antibodies specific to GAPDH (G8795; Sigma-Aldrich Corp.), α-SMA 
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(A2547; monoclonal, Sigma-Aldrich Corp.), tropomyosin CGβ6 (Tpm1.6-1.9, provided by 
Prof. Peter Gunning, University of New South Wales, Australia), and anti-rabbit antibodies 
specific to β-catenin (H-102, Santa Cruz), phospho-Smad2/3 (D27F4; monoclonal, Cell 
Signalling Technology), total-Smad2/3 (8685; monoclonal, Cell Signalling Technology), 
phospho-EGFRY1068 (2234; polyclonal, Cell Signalling Technology), phospho-ERK1/2 
(phospho-p44/p42; 9101; polyclonal, Cell Signalling Technology) and total-ERK1/2 (p44/p42; 
9102; polyclonal, Cell Signalling Technology) were all diluted at 1:1000, except for α-SMA 
and β-catenin that were both diluted at 1:2000, with the anti-tropomyosin antibody diluted 
1:100. 
Membranes were rinsed in TBST (3 x 5 minutes) and incubated for 2 hours with the 
corresponding horseradish peroxidase (HRP)-conjugated secondary antibodies, either goat 
anti-mouse HRP-conjugated IgG or goat anti-rabbit HRP-conjugated IgG (both diluted 1:5000 
in TBST; Cell Signalling Technology). Membranes were rinsed in TBST (3 x 10 minutes) and 
incubated in Immobilon Western Chemiluminescent HRP Substrate (Merck Millipore) for 2 
minutes. Chemiluminescence signals were captured using the ChemiDoc MP imaging system 
(BioRad Laboratories) and densitometric analysis was performed using ImageLab software 
(BioRad Laboratories). Relative protein expression was stated as a ratio of the protein of 
interest compared to GAPDH levels. 
3.5 Total RNA extraction and cDNA synthesis 
After a 24-hour treatment period, explants were rinsed in cold PBS. Total RNA was extracted 
using the Isolate II RNA Micro Kit (Bioline, Alexandria, NSW, Australia). RNA concentration 
and purity was analysed using the Nanodrop ND-1000 spectrophotometer (Thermo Fisher 
Scientific). RNA integrity was determined using the Agilent 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA, USA). Only samples with 260/280 ratios > 2 and RNA 
integrity numbers > 5 were used for RT-qPCR. 
3.6 Reverse transcriptase-quantitative polymerase chain reaction 
(RT-qPCR) 
The SensiFAST cDNA synthesis kit (Bioline) was used to reverse-transcribe total RNA (200 
ng). cDNA samples were diluted 1:12 with nuclease-free water. Oligonucleotide primers 
(Table 4) were designed to span the exon-exon junction using Primer-BLAST. 
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RT-qPCR reactions were performed using the SensiFAST SYBR No-ROX kit (Bioline) in a 
LightCycler 480, 384-well plate (Roche Diagnostics Ltd., Forrenstrasse, Switzerland). 10 µl 
reactions were set up using a Freedom EV075 robotic station with Freedom EVOware Standard 
3.2 software (Tecan, Port Melbourne, VIC, Australia) consisting of 4 µl cDNA, 5 µl SYBR 
and 300 nM forward and reverse primers. RT-qPCR analysis was conducted under the 
following thermal cycling conditions described previously (Shu et al., 2018). Relative gene 
expression was described as a ratio of the levels of the gene of interest compared to GAPDH 
levels using the second derivative maximum method of the LightCycler software (Roche 
Diagnostics Ltd.). All reactions were run in duplicate, including minus RT controls and no-
template controls. 
3.7 Statistics 
All experiments were performed at least three times. Graphs were created in GraphPad Prism 
version 6.0 (GraphPad Software Inc., La Jolla, CA, USA). Western blot data was assessed by 
one- or two-way ANOVA with post hoc Tukey’s multiple comparisons test. RT-qPCR data 
was evaluated using a one-way ANOVA with post hoc Tukey’s multiple comparisons test on 
GenEx, version 6.0 (MultiD Analyzes AB, Gothenburg, Sweden) and GraphPad Prism. Data 
is presented as mean ± SEM with P < 0.05 deemed statistically significant. Schematic figures 
were created with BioRender. 
4 Results 
4.1 EGF augments TGF2-induced EMT in LECs 
To investigate the impact of EGF on TGFβ-induced EMT, we monitored for changes in cell 
morphology over a five-day culture period using phase-contrast microscopy. At day 2, control 
explants remain as a monolayer of cuboidal epithelial cells arranged in an organised 
cobblestone manner (Figure 1A). Treatment with TGFβ2 induced some LECs to elongate and 
adopt a spindle-shaped morphology, characteristic of an EMT response (Figure 1B). Co-
treatment with TGFβ2 and EGF resulted in more pronounced EMT response, with increased 
numbers of ordered elongate, spindle-shaped cells (Figure 1C), compared to treatment with 
TGFβ2 alone. Treatment with EGF alone retained a monolayer of cuboidal epithelial cells, 
similar to control explants at day 2 (Figure 1D). 
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Figure 1. Co-treatment of LECs with EGF and TGFβ2 induces an elevated EMT response. 
Phase-contrast microscopy of LEC explants at day 2, either untreated control explants (A), or treated 
with TGFβ2 (B), EGF (C) and EGF plus TGFβ2 (D). Images are representative of 3-independent 
experiments. Scale bar: 50 µm. 
 
4.2 EGF potentiates a low dose of TGFβ2 to induce an EMT in LECs 
To further characterise EGF’s ability to augment TGFβ-induced EMT, for comparison, cells 
were treated with a lower dose of TGFβ (50 pg/ml, that typically does not induce EMT within 
the 5 day culture period) and were also exposed to EGF (5 ng/ml). Control explants remained 
as an epithelial monolayer at day 5 (Figure 2A), with β-catenin labeling to the cell membrane, 
highlighting their cobblestone arrangement (Figure 2E) and minimal α-SMA labeling (Figure 
2I). Explants treated with the higher dose of 200 pg/ml TGFβ2 for 5 days underwent an EMT 
with marked cell loss, evident from the few remaining spindle-shaped cells present (Figure 
2B). Immunofluorescent labeling of these occasional cells displayed punctate labeling of β-
catenin in the cell nuclei and cytoplasm (Figure 2F) with markedly high α-SMA labeling that 
was incorporated into stress fibers (Figure 2J). In contrast, treatment with a low dose of TGFβ2 
(50 pg/ml) did not induce this EMT within 5 days, and appeared similar to control explants 
(Figure 2C), with β-catenin remaining localised to the cell membrane (Figure 2G) with little α-
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SMA immunoreactivity in cells (Figure 2K). Adding EGF to the lower dose of TGFβ2 now 
induced cells to undergo a prominent EMT by day 5, with the presence of spindle-shaped 
mesenchymal cells (Figure 2D). These cells showed a loss of β-catenin from the cell membrane 
(Figure 2H) and increased α-SMA-labeling of stress fibers, indicative of an EMT response; a 
comparable response to the higher dose of TGFβ2 administered alone (Figure 2L). 
 
Figure 2. EGF potentiates TGFβ2-induced EMT. 
Representative phase contrast micrographs at day 5 for control explants (A), or explants treated with 
200 pg/ml TGFβ2 (B), 50 pg/ml TGFβ2 (C) and EGF plus 50 pg/ml TGFβ2 (D). Immunofluorescent 
labeling at day 5 of culture for β-catenin (E, F, G, H) and α-SMA (I, J, K, L). Images are 
representative of 3 independent experiments. Scale bar: 50 µm. 
 
 
4.3 EGF potentiates Smad-signalling induced by a low dose TGFβ2 
As EGF was able to potentiate the EMT response of a lower dose of TGFβ2, we investigated 
how this correlated to the activation of downstream signalling pathways, notably, EGFR-, 
ERK1/2- and Smad-signalling (Figure 3). While a low dose of TGFβ2 did not significantly 
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upregulate pSmad2/3 levels up to 18 hours culture (P > 0.05; Figure 3B), it did still significantly 
upregulate pEGFR levels at 18 hours compared to control explants (P = 0.0058, Figure 3A), 
similar to TGFβ2 alone at 200 pg/ml (see Figure 7B). Adding EGF to a low dose of TGFβ2 
shifted the activation profile of pEGFR earlier, with a significant increase of pEGFR at 15 
minutes and 2 hours (P < 0.0001 for 2 hours; P = 0.0065 for 18 hours). Adding EGF with the 
low dose TGFβ2 also significantly increased pSmad2/3 levels at 18 hours (P = 0.0029). No 
significant differences were observed for pERK1/2 (Figure 3C), tERK1/2 and tSmad2/3 levels 
for all treatment groups (P > 0.05) (Figure 3). 
 
Figure 3. EGF modulates TGFβ2-activation of EGFR-, ERK1/2- and Smad-signalling in LECs. 
Western blots of phosphorylated EGFR, ERK1/2 and Smad2/3 in lens epithelial explants treated for 
15 minutes, 2 hours and 18 hours with 50 pg/ml TGFβ2 alone or in combination with EGF, with 
corresponding relative densitometric analysis for pEGFR (A), pSmad2/3 (B) and pERK1/2 (C). Total 
ERK1/2 and total Smad2/3 levels remained constant throughout the culture period. Treatment groups: 
0 (untreated explants at 0 minutes), T (50 pg/ml TGFβ2), TE (50 pg/ml TGFβ2 + 5 ng/ml EGF), with 
‘15’, ‘2’ and ‘18’ denoting 15 minutes, 2 hours and 18 hours, respectively. Representative western 
blots from 3 independent experiments with data presented as mean ± SEM. Two-way ANOVA, 
Tukey’s post hoc test **P < 0.01 and ****P < 0.0001. 
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4.4 Inhibition of EGFR-signalling blocks EMT in LECs 
We next investigated the effect of blocking EGFR activation when cells were co-treated with 
the higher dose of TGFβ2 and EGF for up to 5 days. Treatment of explants with TGFβ2 alone 
(Figure 4A) induced the progressive loss of cells with evident cellular blebbing (yellow arrows) 
and prominent lens capsular wrinkling (red arrows) in areas of exposed bare lens capsule. Co-
treatment with TGFβ2 and EGF induced a similar appearance to treatment with TGFβ2 alone 
at day 5, with progressive cell loss, cell blebbing and capsular wrinkling (Figure 4C). 
PD153035 not only blocked the enhanced EMT, but the complete EMT response induced by 
co-treatment with TGFβ2 and EGF, with cells remaining as an epithelial monolayer by day 5 
(Figure 4D). Addition of only PD153035, the EGFR inhibitor, did not impact the LECs that 
were maintained in their epithelial state at day 5 of culture (Figure 4B). 
 
Figure 4. EMT in LECs cultured with EGF and TGFβ2 is completely blocked by PD153035. 
Phase-contrast microscopy of LEC explants at day 5, either treated with TGFβ2 (A), PD153035 alone 
(B), EGF plus TGFβ2 (C) or PD153035 and EGF plus TGFβ2 (D). Many refractile cells (yellow 
arrows) highlight dying cells, and lens capsular wrinkling (red arrows) is seen in areas of exposed 
bare lens capsules. Images are representative of 3-independent experiments. Scale bar: 50 µm. 
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4.5 Inhibition of EGFR-signalling blocks EMT changes induced by 
TGFβ plus EGF 
To characterise the effect of EGF on the EMT response, we examined the immunofluorescent 
localisation of different molecular markers in LECs at day 2. In control explants, β-catenin 
(Figure 5A) was localised to the cell membrane, highlighting the organised tight cobblestone-
packed arrangement of LECs. TGFβ2 treatment alone resulted in a punctate labeling of β-
catenin in cell nuclei and cytoplasm (Figure 5B). Co-treatment with TGFβ2 and EGF similarly 
resulted in a loss of β-catenin from the cell membrane with more punctate cytoplasmic β-
catenin labeling; however, some of the elongated cells still exhibited some membranous β-
catenin localisation (Figure 5C). Addition of PD153035 to TGFβ2 plus EGF-treated explants, 
maintained β-catenin to the membrane, similar to control explants (Figure 5D). Control 
explants exhibited little to no α-SMA immunoreactivity at day 2 (Figure 2E), while TGFβ2-
treated explants displayed strong immunoreactivity for α-SMA-labeling in newly formed stress 
fibers, a characteristic EMT response (Figure 2F). Co-treatment of LECs with TGFβ2 and EGF 
also induced strong immunoreactivity for α-SMA-positive stress fibers (Figure 2G). Adding 
PD153035 to TGFβ2 plus EGF blocked the formation of α-SMA-positive stress fibers, but 
there was still some amorphous cytoplasmic α-SMA immunoreactivity (Figure 2H). 
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Figure 5. Co-treatment of LECs with EGF and TGFβ2 induces β-catenin translocation and 
elevated α-SMA that is dependent on EGFR-signalling. 
Immunofluorescent labeling at day 2 for β-catenin and α-SMA in control explants (A, E), TGFβ-treated 
explants (B, F), EGF- plus TGFβ2-treated explants (C, G) and PD153035, and EGF- plus TGFβ2-
treatment (D, H). Images are representative of 3-independent experiments. Scale bar: 50 µm. 
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4.6 Inhibition of EGFR-signalling blocks EMT protein marker 
expression 
To further characterise the effect of EGF on TGFβ-induced EMT, we examined the level of 
epithelial and mesenchymal protein markers after 48 hours of culture using western blotting 
(Figure 6). No significant differences were observed in β-catenin levels between all treatment 
groups (P > 0.05; Figure 6A). Treatment with TGFβ2 induced a significant increase in protein 
levels of mesenchymal markers, such as α-SMA and tropomyosin, compared to control 
explants (P = 0.0201 for α-SMA, Figure 3B; P = 0.009 for tropomyosin, Figure 6C). Co-
treatment with TGFβ2 and EGF significantly elevated α-SMA and tropomyosin levels 
compared to control (P < 0.0001 for both), and TGFβ2-alone-treated explants (P = 0.0003 for 
α-SMA; P < 0.0001 for tropomyosin). 
Adding PD153035 significantly reduced TGFβ2-induced increases of both α-SMA and 
tropomyosin (P = 0.0444 for α-SMA; P = 0.0349 for tropomyosin), showing no significant 
difference to levels in control explants (P > 0.05). Similarly, adding PD153035 to cells co-
treated with TGFβ2 plus EGF significantly reduced increases of both α-SMA and tropomyosin, 
compared to TGFβ2 plus EGF-treated explants (P = 0.0003 for α-SMA; P < 0.0001 for 
tropomyosin); however, this still remained significantly higher than levels in control explants 
(P = 0.0267 for α-SMA; P = 0.0142 for tropomyosin). Treatment with PD153035 alone, 
showed no significant differences in protein levels to that of control explants (P > 0.05). 
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Figure 6. Co-treatment with EGF and TGFβ2 increases mesenchymal protein expression that is 
dependent on EGFR-signalling. 
Protein levels of EMT markers at 48 hours using western blotting of lens epithelial explants, with 
corresponding relative densitometric analysis for β-catenin (A), α-SMA (B) and tropomyosin (C), 
relative to GAPDH. Treatment groups: C (control), T (TGFβ2 alone), TPD (TGFβ2 + PD153035), TE 
(TGFβ2 + EGF), TEPD (TGFβ2 + EGF + PD153035), PD (PD153035 alone). Representative western 
blots from 3 independent experiments, with data presented relative to GAPDH, as the mean ± SEM. 
One-way ANOVA, Tukey’s post hoc test *P < 0.05, **P < 0.01, ***P < 0.001. ****P < 0.0001. 
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4.7 TGFβ2 and EGF differentially activate EGFR-, MAPK/ERK1/2- 
and Smad2/3-signalling 
To understand the individual roles of EGFR-, ERK1/2- and Smad2/3-signalling following 
treatment with TGFβ2 and EGF, we monitored for changes in phosphorylation of these 
signalling pathway members at 15 minutes, 2 hours and 18 hours by co-culturing with the 
respective inhibitors of these pathways, PD153035, U0126 or SIS3 (Figures 7-9). 
4.7.1 EGFR phosphorylation 
Treatment of LECs with TGFβ2 alone increased pEGFR levels at 18 hours compared to control 
explant levels (P = 0.0008, Figure 7). Treatment with EGF alone significantly increased 
pEGFR at 15 minutes and 2 hours (P = 0.0042 at 15 minutes; P < 0.0001 at 2 hours, Figure 
7A). Treatment with both TGFβ2 and EGF increased pEGFR at all three time points compared 
to control levels (P = 0.0009 at 15 minutes; P < 0.0001 at 2 hours, P < 0.0001 at 18 hours, 
Figure 7A). 
Blocking EGFR-signalling using PD153035 blocked the increased pEGFR induced by TGFβ2, 
EGF or co-treatment (specifically occurring at 18 hours for TGFβ2, P < 0.0001; 15 minutes for 
EGF, P = 0.0063, 2 hours for EGF, P < 0.0001; 15 minutes for co-treatment, P = 0.0002, 2 
hours and 18 hours for co-treatment, P < 0.0001). Inhibition of ERK1/2-signalling using U0126 
also blocked pEGFR induced by TGFβ2 (specifically at 18 hours, P < 0.0001), EGF or co-
treatment (at 2 hours, P < 0.0001). In contrast, inhibition of Smad-signalling using SIS3 did 
not impact on pEGFR-signalling in any of the treatment groups (P > 0.05) (Figure 7). It is 
interesting to note that inhibition of ERK1/2-signalling using U0126 at 15 minutes induced an 
increase of pEGFR-signalling with EGF-treatment, and EGF plus TGFβ2-treated explants (P 
< 0.0001 for both), but not TGFβ2-alone treated explants (Figure 7). 
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Figure 7. EGF induces a temporal shift in TGFβ2-induced EGFR phosphorylation. 
Western blots of phosphorylated EGFR levels in lens epithelial explants treated for 15 minutes, 2 hours 
and 18 hours with TGFβ2 alone, EGF alone or co-treatment with both growth factors, with or without 
inhibitors of EGFR- (PD153035), ERK1/2- (U0126) or Smad- (SIS3) signalling (A), with corresponding 
relative densitometric analysis (B-E). Treatment groups: 0 (untreated explants at 0 minutes), T (TGFβ2), 
E (EGF), TE (TGFβ2 + EGF), 15 (15 minutes), 2 (2 hours), 18 (18 hours), PD (PD153035), U0 (U0126) 
and SIS (SIS3). Representative western blots from 3 independent experiments with data presented as 
mean ± SEM. Two-way ANOVA, Tukey’s post hoc test **P < 0.01, ***P < 0.001 and ****P < 0.0001. 
 
 
 
4.7.2 ERK1/2 phosphorylation 
Adding TGFβ2, EGF or co-treating with both, all upregulated pERK1/2 at various time points 
(2 hours for TGFβ2, 15 minutes for EGF and from 15 minutes for co-treatment, P < 0.0001, 
Figure 8). Inhibition of ERK1/2-signalling using U0126 blocked ERK1/2-signalling induced 
by TGFβ2, EGF or co-treatment (occurring specifically at 2 hours for TGFβ2, 15 minutes for 
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EGF and from 15 minutes for co-treatment, P < 0.0001) (Figure 8). Inhibition of EGFR-
signalling using PD153035 also reduced ERK1/2-signalling induced by TGFβ2, EGF or co-
treatment with both, occurring at the same time points as for U0126 treatment (P < 0.0001). 
Adding SIS3 showed no significant difference for all treatment groups (P > 0.05). There were 
no significant differences in total ERK1/2 levels for all treatment groups (P > 0.05) (Figure 8). 
 
Figure 8. EGF induces a temporal shift in TGFβ2-induced ERK1/2-phosphorylation. 
Western blots of phosphorylated ERK1/2 (pERK1/2) levels in lens epithelial explants treated for 15 
minutes, 2 hours and 18 hours with TGFβ2 alone, EGF alone or co-treatment with both growth factors, 
and in combination with the inhibitors of EGFR-, ERK1/2- or Smad-signalling, namely PD153035, 
U0126 or SIS3, respectively (A), with corresponding relative densitometric analysis (B-E). Treatment 
groups: 0 (untreated explants at 0 minutes), T (TGFβ2), E (EGF), TE (TGFβ2 + EGF), 15 (15 minutes), 
2 (2 hours), 18 (18 hours), PD (PD153035), U0 (U0126) and SIS (SIS3). Total ERK1/2 levels remained 
constant throughout the culture period. Representative western blots from 3 independent experiments 
with data presented as mean ± SEM. Two-way ANOVA, Tukey’s post hoc test ****P < 0.0001. 
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4.7.3 Smad2/3 phosphorylation 
Treatment with TGFβ2 or co-treatment with EGF both increased pSmad2/3 levels at various 
time points: for TGFβ2 (15 minutes, P = 0.0011; 2 hours, P < 0.0001; 18 hours, P = 0.0007) 
and for co-treatment (2 hours, P = 0.0002; 18 hours, P = 0.0362). Treatment with EGF alone 
or in combination with any of the inhibitors showed no significant difference in pSmad2/3 
levels from control (P > 0.05) (Figure 9). 
Inhibition of EGFR, ERK1/2 or Smad-signalling blocked TGFβ2-induced pSmad2/3 levels at 
various time points (occurring specifically at 18 hours for PD153035, P = 0.022; 2 hours for 
U0126, P = 0.0102 and for SIS3, P < 0.0001). Notably, SIS3 was able to suppress TGFβ2-
induced pSmad2/3 at all three time points investigated but this only reached statistically 
significance at 2 hours. This is in contrast to our previous data set (Figure 4, Page 88) showing 
that SIS3 was able to block TGFβ2-induced pSmad2/3 at both 15 minutes and 2 hours. The 
most likely explanation for this discrepancy is experiment-to-experiment variability. Only SIS3 
was able to block pSmad2/3 induced by the co-treatment, and this occurred at 2 hours (P = 
0.037). No significant differences were observed for total Smad2/3 levels for all treatment 
groups (P > 0.05) (Figure 9). 
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Figure 9. Co-treatment of LECs with TGFβ2 and EGF promotes Smad2/3-signalling. 
Western blots of phosphorylated Smad2/3 (pSmad2/3) levels in lens epithelial explants treated for 15 
minutes, 2 hours and 18 hours with TGFβ2 alone, EGF alone or co-treatment with both growth factors, 
and in combination with PD153035, U0126 or SIS3 (A), with corresponding relative densitometric 
analysis (B-E). Treatment groups: 0 (untreated explants at 0 minutes), T (TGFβ2), E (EGF), TE (TGFβ2 
+ EGF), 15 (15 minutes), 2 (2 hours), 18 (18 hours), PD (PD153035), U0 (U0126) and SIS (SIS3). Total 
Smad2/3 levels remained constant throughout the culture period. Representative western blots from 3 
independent experiments with data presented as mean ± SEM. Two-way ANOVA, Tukey’s post hoc 
test *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. 
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4.8 EGFR-inhibition modulates TGFβ2-induced Smad2/3 
translocation  
To further explore the role of Smad2/3, we assessed the localisation of total Smad2/3 
(tSmad2/3) using immunofluorescence confocal microscopy. For Smad2/3 to translocate to the 
nucleus, it first needs to be phosphorylated, hence, cell nuclei labeling for total Smad2/3 would 
indicate Smad2/3 in its phosphorylated (active) state, and hence highlight active TGFβ-
signalling. Cells in control explants showed tSmad2/3 labeling to their cytoplasm at both 2 
hours and 18 hours (Figure 10A-B). Similarly, treatment with EGF alone, EGF plus PD153035 
and PD153035 alone (Figure 10C-H) maintained tSmad2/3 labeling to their cytoplasm at both 
2 hours and 18 hours. Exposure of cells to TGFβ2 resulted in nuclear localization of tSmad2/3 
at both 2 hours and 18 hours (Figure 10I-J). Adding PD153035 to TGFβ2 for 2 hours did not 
impact on tSmad2/3 nuclear localisation (Figure 10K); however, at 18 hours, there was a 
weaker nuclear, and more cytoplasmic tSmad2/3 label, similar to control explants (Figure 10L). 
Treatment with TGFβ2 plus EGF also induced nuclear localisation of tSmad2/3 at both 2 hours 
and 18 hours (Figure 10M-N), and addition of PD153035 did not impact on tSmad2/3 nuclear 
localisation at 2 hours but showed more of a cytoplasmic tSmad2/3 label at 18 hours (Figure 
10 O-P). 
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Figure 10. PD153035 modulates nuclear translocation of Smad2/3 induced by TGFβ2 and EGF 
co-treatment. 
Immunofluorescence showed cytoplasmic labelling of total Smad2/3 (tSmad2/3) at both 2 hours (A, C, 
E, G) and 18 hours (B, D, F, H) in control explants (A, B), and EGF alone-treated explants (C, D), in 
explants treated with EGF and PD153035 (E, F), and explants treated with PD153035 (G, H). Nuclear 
localisation of tSmad2/3 was seen in explants treated with TGFβ2 for 2 hours (I) and 18 hours (J), with 
changes in tSmad2/3 localisation seen when explants were co-treated with TGFβ2 and PD153035 (K, 
L), co-treated with TGFβ2 and EGF (M, N), and treated with a combination of TGFβ2, EGF and 
PD153035 (O, P). Images are representative of 3 independent experiments. Scale bar: 50 µm. 
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4.9 EGFR-, ERK1/2 and Smad-signalling differentially modulate 
EMT gene expression 
Using RT-qPCR, we recently showed that EGFR-, ERK1/2- and Smad-signalling played 
differential roles in modulating the expression of key EMT genes upregulated by TGFβ2 (Shu 
et al., 2018). Here, we build on these findings by comparing the changes in the regulation of 
these EMT genes upon treatment with either EGF alone or in combination with TGFβ2. The 
findings are summarized as a Venn diagram (Figure 11) to highlight and compare the 
overlapping roles of EGFR-, ERK1/2 and Smad-signalling for each of the EMT genes 
examined. Tables and graphs containing all the primary data and detailed statistical analysis 
for each gene can be found in the supplementary material (Figures S1-S4 and Table S1). 
The central overlapping region in Figure 11A contains three genes (namely, Col1a1, Fn and 
Adam19) that are upregulated by TGFβ2 and also all reduced by the addition of any of the three 
selective inhibitors, PD153035, U0126 or SIS3, indicating that these genes are dependent on 
EGFR-, ERK1/2 and Smad-signalling. Since adding EGF alone did not impact on Col1a1, Fn 
and Adam19 expression (Figure 11B), it was not surprising to find that co-treating cells with 
EGF and TGFβ2 continued to upregulate these genes and be dependent on all three signalling 
pathways (Figure 11C), similar to TGFβ2-alone treated explants.  
There were other examples where the regulation of EMT genes remained the same between 
treatment with TGFβ2 alone and co-treatment with EGF. Both Zeb1 and Smurf1 were 
upregulated by TGFβ2 alone and dependent only on ERK1/2-signalling (Figure 11A). EGF 
alone did not impact on their levels (Figure 11B), and thus, co-treating explants with TGFβ2 
plus EGF also did not impact on their regulation, remaining dependent only upon ERK1/2-
signalling (Figure 11C). The regulation of Id2/3 appeared to be upregulated by both TGFβ2 
and TGFβ2 plus EGF and this was independent of any of the three signalling pathways. 
A key mesenchymal marker found to be upregulated by both TGFβ2, and TGFβ2 plus EGF, 
but not by EGF alone was α-SMA. TGFβ2-induced upregulation of α-SMA was found to be 
dependent on both ERK1/2- and Smad-signalling, with both U0126 and SIS3 reducing TGFβ2-
induced α-SMA expression, respectively. While co-treatment with TGFβ2 plus EGF also 
upregulated α-SMA gene expression compared to control explants, these levels were 
significantly lower compared to TGFβ2 alone. Adding U0126 or SIS3 reduced α-SMA levels 
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in TGFβ2 plus EGF-treated explants; however, it was surprising to note that adding PD153035 
induced a significant increase in α-SMA levels compared to TGFβ2 plus EGF-treated explants 
(see Figure S1). 
There were several instances where adding EGF altered the signalling pathways that regulated 
TGFβ2-induced EMT gene expression, with some gene expression now more reliant on the 
enhanced EGFR-signalling. E-cad and Zeb2 were both downregulated by TGFβ2 addition and 
this was dependent upon both ERK1/2- and EGFR-signalling. Adding EGF to TGFβ2 also 
induced the downregulation of these two genes, but now they were exclusively dependent on 
EGFR-signalling. Smad7 and Adam9 were both upregulated by TGFβ2 and solely dependent 
upon Smad-signalling; however, adding EGF modulated the regulation of these two genes to 
be solely dependent on EGFR-signalling.  
In contrast, adding EGF could also modulate the regulation of EMT markers towards non-
EGFR signalling pathways. For example, downregulation of Adam17 expression by TGFβ2 
was dependent on both ERK1/2- and EGFR-signalling, but adding exogenous EGF shifted the 
regulation of this gene to be exclusively dependent on Smad-signalling. TGFβ2 upregulated 
Egfr expression and this was dependent on both ERK1/2- and Smad-signalling, but the addition 
of EGF shifted the regulation of this gene to be driven exclusively by ERK1/2-signalling. 
Explants treated with TGFβ2-alone upregulated Hb-egf expression through ERK1/2- and 
EGFR-signalling, but when EGF was added, Hb-egf expression also became dependent on 
Smad-signalling. Moreover, TGFβ2 upregulated Ctgf expression was dependent on ERK1/2-
signalling, but after adding EGF, this upregulation became independent of any of the signalling 
pathways investigated. 
Ncad, Snai1 and Adam10 gene expression remained unaffected by treatment with TGFβ2, EGF 
or co-treatment, indicating that variation of these three EMT genes did not play a significant 
role in our EMT model. 
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Figure 11. Venn diagram depicting the contribution of EGFR-, ERK1/2- and Smad-signalling 
following treatment with TGFβ2 and EGF. 
All of the EMT target genes within the blue oval are upregulated following treatment with TGFβ2 alone 
(A, data from Shu et al., 2018), EGF alone (B) or co-treatment with TGFβ2 and EGF (C). The genes 
outside the oval in the white rectangle are those that do not change in expression following growth 
factor treatment. All genes are upregulated following treatment except for the genes marked with a 
downward arrow that are downregulated. The three overlapping circles within the blue oval depict the 
overlapping roles of ERK1/2-, EGFR- and Smad-signalling in this differential gene expression. 
 
 
5 Discussion 
The present study shows, for the first time, that EGF can augment TGFβ2-induced EMT in rat 
lens epithelial cell explants. These results build on our previous study in which TGFβ2 was 
found to transactivate EGFR-signalling, independent of exogenous EGF (Shu et al., 2018). 
Here, we show that co-treatment of TGFβ2 with EGF induces a more pronounced EMT 
response compared to TGFβ2 alone, both morphologically and biochemically. Adding EGF 
induces more cells to elongate into myofibroblasts compared to TGFβ2 alone, and this was 
accompanied by an increase in protein levels of mesenchymal markers, specifically α-SMA 
and tropomyosin, as well as changes in gene expression of key EMT markers and TGFβ2 target 
genes. EGF potentiated a less effective dose of TGFβ2 (50 pg/ml) to stimulate EMT at a similar 
rate to that of the higher dose of TGFβ2 (200 pg/ml). Co-treatment with EGF and TGFβ2 
activated a complex and integrated network of signalling pathways involving EGFR-, ERK1/2- 
and Smad-signalling that differed from treatment with either growth factor alone. 
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Our findings align with previous studies in non-ocular systems that showed a role for EGF in 
enhancing TGFβ activity (Buonato et al., 2015; Docherty et al., 2006; Grände et al., 2002; Saha 
et al., 1999; Uttamsingh et al., 2008). Using lung and pancreatic cancer cell lines, Buonato et 
al., (2015) showed that co-treatment with TGFβ1 and EGF induced a more ‘complete’ EMT, 
whereas treatment with TGFβ1 alone induced a partial EMT, and treatment with EGF alone 
induced a “modest” EMT response (Buonato et al., 2015). The EGF augmentation of TGFβ1-
induced EMT, resulted in a greater reduction in E-cadherin expression and elevation of the 
mesenchymal marker, vimentin, compared to treatment with either growth factor alone 
(Buonato et al., 2015). 
While it is well documented in many cancer models that EGF can induce EMT (Cheng et al., 
2012; Cordonnier et al., 2015; Kim et al., 2016; Wang et al., 2014; Xu et al., 2017), it was only 
recently reported that EGF can induce an EMT in the ocular lens (Dong et al., 2018), in contrast 
to our findings. The authors showed that EGF alone could upregulate the expression of 
mesenchymal markers (fibronectin and α-SMA) and downregulate the epithelial marker, E-
cadherin using an in vitro model of primary human LECs (Dong et al., 2018). In our rat lens 
epithelial cell explants, while EGF cannot induce EMT, it does induce lens epithelial cell 
proliferation (Iyengar et al., 2009), highlighting a difference between the use of primary cell 
explants vs. passaged cells. Given that EGF has the ability to augment the EMT response 
induced by TGFβ, this opens a new perspective in understanding the cross-talk mechanisms 
between TGFβ- and EGF-signalling pathways. 
We previously showed that TGFβ2 alone activated both canonical Smad2/3- and non-canonical 
EGFR- and ERK1/2-signalling pathways in LECs (Shu et al., 2018). In the present study we 
show that EGF activates both EGFR- and ERK1/2-signalling but not the Smad2/3-signalling 
pathway. Combining TGFβ2 and EGF not only results in activation of all three pathways but 
also leads to a temporal shift in the activation profile of EGFR- and ERK1/2-signalling, 
bringing forward the 2 hour activation of ERK1/2-signalling and 18 hour activation of EGFR-
signalling with TGFβ2 alone, to as early as 15 minutes activation. Diverse signalling pathways 
are temporally fine-tuned and filtered leading to complex computations making up the defined 
network of intracellular signalling (Bhalla, 2002). Given that we observed a temporal shift in 
the phosphorylation of signalling pathways upon co-treatment of the cells with TGFβ2 and 
EGF, compared to either growth factor alone, suggests that the temporal tuning properties of 
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signalling networks are altered when processing different growth factor stimuli. Using 
mathematical modelling of four major kinases, including the MAPKs, Bhalla (2002) 
discovered an unexpectedly simple mechanism for temporal tuning that was based on the 
weighted summation of signalling inputs from various pathways with different time-courses 
(Bhalla, 2002). It would be interesting to explore whether Smad- and EGFR-signalling also 
follow similar tuning properties to protein kinases. Future studies are required for a deeper 
understanding of how these signalling inputs are integrated, as well as with other signalling 
pathways that have been implicated in fibrotic cataract, including Rho/ROCK- (Cho and Yoo, 
2007), PI3K/Akt- (Yao et al., 2008), mTOR- (Meng et al., 2013) and β-catenin/Wnt- (Taiyab 
et al., 2016) signalling pathways. It is possible that there may be changes in the interactions 
between canonical and non-canonical signalling cascades beyond the 18-hour time point 
examined in this study and future studies will be directed at investigating temporal variations 
over a longer period. 
Work in our laboratory has identified the ERK1/2-signalling pathway as an important initiator 
of TGFβ2-induced EMT in LECs since inhibition of ERK1/2-signalling using U0126 abrogates 
the EMT response (Wojciechowski et al., 2017, 2018). Similarly, blocking EGFR-signalling 
using PD153035 can also inhibit TGFβ2-induced EMT, highlighting the importance of EGFR-
signalling to the EMT program (Shu et al., 2018). By combining EGF and TGFβ2, cells are 
likely now receiving dual inputs for ERK1/2- and EGFR-signalling from each of the growth 
factors independently (and that perhaps synergize), in addition to the single input of Smad-
signalling from TGFβ2 (see schematic in Figure 12). Previous studies in cancer cells found that 
EGF enhances the TGFβ-driven EMT response through potentiation of ERK1/2 signalling 
(Buonato et al., 2015; Grände et al., 2002; Uttamsingh et al., 2008). We propose that EGF may 
enhance TGFβ-induced EMT in LECs by potentiating both EGFR- and ERK1/2- signalling. 
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Figure 12. Schematic of activated TGFβ- and EGF-signalling pathways leading to lens EMT. 
TGFβ induces EMT through activation of the canonical Smad2/3-signalling pathway, and non-canonical 
ERK1/2- and EGFR-signalling pathways. EGF activates EGFR- and ERK1/2-signalling but not Smad2/3 
pathways, and is unable to induce EMT. When TGFβ and EGF are combined, Smad2/3-, ERK1/2- and 
EGFR-signalling pathways are activated, receiving dual inputs from both growth factors to augment the 
EMT response. The double headed arrow between EGFR and ERK1/2 indicates a positive feedback 
loop between these two signalling pathways. 
 
Although EGF is able to activate EGFR- and ERK1/2-signalling, it alone cannot induce EMT 
in our lens explant system. This raises interesting questions as to which signalling pathways 
are essential in propagating the EMT response. While blockade of EGFR- and/or ERK1/2-
signalling is sufficient to prevent EMT, it appears that merely activating EGFR- and ERK1/2- 
without Smad-signalling (as is the case with treating LECs with only EGF) is insufficient for 
the induction of EMT. Is it necessary for Smad-signalling to be activated in combination with 
these non-canonical pathways in order for EMT to occur? Previous studies have highlighted 
the importance of TGFβ/Smad-signalling in lens EMT (Li et al., 2011; Saika et al., 2004; 
Wormstone et al., 2004). Although blockade of EGFR- and ERK1/2-signalling can also block 
TGFβ-induced production of ECM proteins and α-SMA, and the subsequent EMT response, 
these pathways alone are not enough to induce the EMT response in rat lens epithelial explants. 
There may be a difference in the EGFR- and/or ERK1/2-signalling pathways induced by EGF 
compared to that induced by TGFβ, and further experiments are required to clarify the precise 
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role of these individual pathways, and how the integration of these signalling inputs ultimately 
results in the EMT response. 
A shift in the overlapping roles of EGFR-, ERK1/2- and Smad-signalling pathways in 
regulating key EMT target genes occurs when explants are co-treated with EGF and TGFβ2 
compared to either growth factor alone (see Figure 11). For certain genes, adding EGF favoured 
EGFR-signalling such that the regulation of gene expression became exclusive to EGFR-
signalling. This is in contrast to TGFβ2-alone treated explants where there are no genes 
regulated by endogenous EGFR-signalling, but rather, there are only overlapping regions 
where EGFR-signalling is involved. Although EGF alone is unable to induce Smad-signalling, 
its addition to LECs with TGFβ2 appears to shift the relationship between Smad and non-Smad 
signalling pathways. Previously, we showed that in TGFβ2 alone-treated explants, the non-
canonical EGFR- and ERK1/2-signalling pathways both feed into the canonical Smad-
signalling pathway (Shu et al., 2018). Here, we show that the EGFR-signalling pathway feeds 
into Smad-signalling at 18 hours in TGFβ2 plus EGF-treated explants. Immunofluorescence 
labelling of tSmad2/3 proteins further highlighted this finding by showing reduced nuclear 
translocation of Smad2/3 upon addition of PD153035 in explants co-treated with TGFβ2 plus 
EGF. This effect was seen at 18 hours, but not 2 hours, indicating a temporal role in the 
interplay between canonical and non-canonical TGFβ-dependent signalling pathways. 
Inhibition of EGFR-signalling using PD153035 appeared to reduce pSmad2/3 levels at 18 
hours; however, this was not statistically significant.  
In addition to exploring Smad2/3, we also showed that TGFβ2, and TGFβ2 plus EGF, both 
induced upregulation of the inhibitory Smad gene, Smad7. TGFβ rapidly induces Smad7 
transcription via a negative feedback mechanism to ensure precise control of TGFβ activity 
(Nakao et al., 1997). Smad7 can compete with Smad2/3 for binding to the TGFβ type I receptor 
to prevent its phosphorylation (Massague and Chen, 2000). Smad7 can also bind to the Smad-
responsive element in the nucleus, thereby interfering with the formation of a functional Smad-
DNA complex (Zhang et al., 2007). In our study, adding PD153035 to TGFβ2 plus EGF, 
elevated Smad7 expression levels beyond the increased levels already seen with TGFβ2 plus 
EGF. Whether this elevated Smad7 is contributing to the increased inhibition of Smad-
signalling, thereby enabling PD153035 to abrogate Smad2/3 nuclear translocation and inhibit 
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EMT is not clear. Future studies will be directed towards understanding how varying levels of 
Smad7 may contribute to different aspects of the EMT program. 
We show here that EGF can potentiate the activity of a lower dose of TGFβ2 on lens cells. The 
higher dose of TGFβ2 used is able to induce EMT in rat LECs by day 2 and this proceeds to 
complete cell loss via apoptosis by day 4 to 5 (Maruno et al., 2002). The lower dose of TGFβ2 
at 50 pg/ml is unable to induce this characteristic morphological transition over this same 5-
day culture period; however by adding EGF, a comparable EMT response to that seen with the 
higher dose of TGFβ2 is observed. It appears that EGF may sensitise the cells to become more 
responsive to a low-dose of TGFβ2. The different dosage of TGFβ2 also induces a shift in the 
activation profile of its downstream signalling pathways. While the lower dose of TGFβ2 (50 
pg/ml) is still able to phosphorylate EGFR-signalling at 18 hours, similar to the 200 pg/ml 
TGFβ2 (Shu et al., 2018), adding EGF shifts this to an earlier time point of 15 minutes. This 
low dose of TGFβ2 did not increase pERK1/2 nor Smad-signalling within the 18 hours; 
however, in combination with EGF, we observed an elevation of Smad-signalling at this time. 
This is an interesting finding given EGF itself is unable to activate Smad-signalling, but 
appears to potentiate and dynamically shift the downstream TGFβ2-induced signalling 
network, highlighting the cross-talk between non-canonical EGFR- and canonical Smad-
signalling pathways. 
We previously showed that treatment with TGFβ2 alone transactivated the phosphorylation of 
EGFR-signalling and increased gene expression of Egfr and Hb-egf (Shu et al., 2018). 
Transactivation of EGFR-signalling by TGFβ is reported to involve the Adams family of genes, 
that are known to induce “ectodomain shedding” (the proteolytic cleavage of membrane-bound 
EGF ligands, e.g. HB-EGF) to release functionally active soluble factors to bind and activate 
the EGFR (Kataoka, 2009). While treatment with TGFβ2 upregulates Adam9 and 
downregulates Adam17 expression, treatment with TGFβ2 plus EGF does not. Contrary to this, 
treatment with TGFβ2 alone and TGFβ2 plus EGF both upregulated Adam19 expression, and 
this upregulation could be suppressed to basal levels with the addition of PD153035, U0126 or 
SIS3, indicating the importance of EGFR-, ERK1/2- and Smad-signalling pathways in the 
EMT process. The importance of Adam19 in EMT has been demonstrated in cancer and 
embryological studies (Foroutan et al., 2017; Kurohara et al., 2004). Using a computational 
bioinformatics approach, a transcriptional signature for TGFβ-induced EMT was established 
Chapter Five: Results (Part III) 
147 
with a large set of breast cancer cell lines and clinical brain, bone and skin cancers that showed 
high TGFβ-signalling activity (Foroutan et al., 2017). The authors identified Adam19 to be 
part of the TGFβ-induced EMT signature amongst other well-known EMT genes, such as Fn 
and Col1a1 (Foroutan et al., 2017). Adam19 also plays a key role in EMT of endocardial 
epithelial cells in generating the mesenchyme of the septa and valves during heart 
morphogenesis (Kurohara et al., 2004). Future studies will be directed towards characterising 
the functional and mechanistic role(s) of Adams genes during lens EMT, more specifically 
directed towards the molecular mechanisms underpinning Adam19 gene upregulation, and if 
and how Adam19 facilitates or is required for TGFβ-induced lens EMT. 
During EMT, myofibroblasts typically express α-SMA in stress fibres to enhance 
myofibroblast contractility (Hinz et al., 2012). Tropomyosin1.6/1.7 isoforms precede the 
upregulation of α-SMA and facilitate the stable incorporation of α-SMA into stress fibres 
(Prunotto et al., 2015). In our study, EGF significantly augmented the protein levels of TGFβ2-
induced α-SMA and tropomyosin, when compared to TGFβ2 alone treatment. The molecular 
mechanisms underpinning EGF-induced augmentation of TGFβ2-induced α-SMA and 
tropomyosin need to be elucidated. The recruitment of α-SMA to stress fibres has also been 
shown to involve focal adhesion kinase (FAK) (Goffin et al., 2006). EGF itself is known to 
induce actin polymerisation to facilitate actin assembly through FAK-signalling, with EGFR-
activation of FAK-signalling observed in breast cancer (Long et al., 2010; Tai et al., 2015) and 
human retinal pigment epithelial cells (Park and Kim, 2018) via a Src-dependent mechanism. 
This putative mechanism is yet to be explored in our model. 
Treatment with TGFβ2 alone and in combination with EGF both induced a significant 
upregulation of α-SMA gene expression; however, it was less with the co-treatment. This 
discrepancy in higher protein levels and reduced gene expression of α-SMA suggests 
complexities in the regulatory mechanisms governing its transcription and translation, turnover 
and degradation. Protein abundance often mirrors biological function (Vogel and Marcotte, 
2012), with regulatory proteins being produced and degraded very rapidly, while structural 
proteins (such as α-SMA) are more typically longer-lived. Whether the addition of EGF to 
TGFβ2 slows protein degradation rates of α-SMA awaits to be seen. Moreover, miRNAs and 
other translational regulators such as RNA-binding proteins have been found to fine-tune 
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protein levels (Vogel and Marcotte, 2012) and thus, exploring their contributions to α-SMA 
expression levels in EMT would also be of interest. 
Treatment with TGFβ2 alone or TGFβ2 plus EGF both reduced gene expression of the 
epithelial marker, E-cadherin, with co-treatment showing slightly lower E-cadherin gene 
expression compared to TGFβ2 alone, concomitant with loss of the epithelial phenotype. 
Intriguingly, treatment with TGFβ2 alone and TGFβ2 plus EGF both induced loss of the β-
catenin label from the cell membrane; however, it appeared that co-treatment with TGFβ2 plus 
EGF showed some retention of membranous β-catenin. Although, changes to the E-cadherin/β-
catenin complex has been well characterised in TGFβ2-induced lens EMT, it has not been 
explored in the context of lens EMT induced by co-treatment with TGFβ2 and EGF. In TGFβ2 
alone treated explants, disruption of the E-cadherin/β-catenin complex was found to be a key 
event during EMT, enabling cytosolic β-catenin to interact and form a complex with cyclic 
AMP response element-binding protein (CREB)-binding protein (CBP) (Taiyab et al., 2016). 
β-catenin is also a key component of the canonical Wnt signalling pathway during EMT and 
has been implicated in cataract (Chong et al., 2009). Since there is some retention of β-catenin 
to the cell membrane, it remains unclear whether β-catenin signalling also plays a similar role 
in modulating the EMT response with TGFβ2 plus EGF, compared to TGFβ2 alone. 
Furthermore, since there is some discrepancy between downregulation of E-cadherin and 
retention of membranous β-catenin, it would be of interest to explore the extent to which 
uncoupling of the high-affinity E-cadherin/β-catenin membrane protein complex occurs during 
lens EMT induced by co-treatment with TGFβ2 and EGF. 
Perturbing EGFR-signalling by adding PD153035 blocked the downregulation of E-cadherin 
induced by the TGFβ2 and EGF combination, indicating retention of the epithelial phenotype. 
In contrast, adding U0126 or SIS3 were unable to increase E-cadherin levels to baseline control 
levels suggesting that EGFR-signalling, and not so much ERK1/2- or Smad-signalling, may 
play a more significant role in downregulating E-cadherin following treatment with TGFβ2 
plus EGF. Downregulation of E-cadherin is considered a hallmark of EMT in metastatic cancer 
(Wendt et al., 2011), fibrosis (Zheng et al., 2009) and fibrotic cataract (Choi et al., 2007). Potent 
transcriptional repressors of E-cadherin include the zinc-finger transcription factors Snail 
(Snai1), Slug (Snai2) and Zeb family members, Zeb1 and Zeb2 (Garg, 2013). These factors 
modulate the EMT response by recognizing and binding to multiple enhancer boxes (E-boxes) 
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located in the promoter region of the E-cadherin encoding gene. Binding of these transcription 
factors to E-cadherin E-boxes leads to disassembly of cell-cell adhesion linkages at epithelial 
adherens junctions, triggering the EMT program (Garg, 2013). In metastatic lung cancer, 
knockdown of E-cadherin activated both EGFR- and ERK1/2-signalling pathways and resulted 
in Zeb1-dependent MMP2 induction and subsequent EMT (Bae et al., 2013). It would be 
worthwhile to explore whether a similar EGFR/ERK/ZEB axis also occurs during EMT of 
LECs. Interestingly, we found a contrasting role for Zeb1 and Zeb2 gene expression in lens 
EMT. Treatment with TGFβ2 alone and TGFβ2 plus EGF both resulted in an upregulation of 
Zeb1 and downregulation of Zeb2. EGFR- and ERK1/2-signalling appear to be acting in 
distinct ways to regulate different Zeb genes, whereby, U0126, but not PD153035 blocked the 
upregulation of Zeb1, whereas PD153035, but not U0126 blocked the downregulation of Zeb2. 
It would be of interest to explore the functional differences in Zeb1 and Zeb2 and correlate this 
with their different activation profiles during EMT. Nathu et al., (2009) identified reductions 
in E-cadherin mRNA and early increases in MMP9 mRNA during TGFβ-induced lens EMT 
(Nathu et al., 2009). Given that Zeb genes are known to regulate E-cadherin, do they also 
induce MMPs to facilitate ECM protein degradation and subsequent propagation of the EMT 
response? In an epithelial ovarian cancer model, Xu et al., (2010) showed that EGF itself did 
not produce MMP2 but augmented TGFβ-induced production of MMP2, thereby rendering a 
more invasive phenotype (Xu et al., 2010). Further studies will be directed at comparing the 
role of MMPs and EGFR-signalling in TGFβ- versus TGFβ plus EGF-driven lens EMT. 
We previously revealed a role for BMP-7 in antagonising TGFβ-induced EMT by upregulating 
BMP target genes, Id2/3 (Shu et al., 2017). Here we show that TGFβ and TGFβ plus EGF both 
reduce basal levels of Id2/3. BMP-7 was found to block TGFβ-induced downregulation of 
Id2/3 levels, restoring Id2/3 to baseline levels (Shu et al., 2017). In contrast, PD153035 was 
unable to block the downregulation of Id2/3, nor did it block the upregulation of the Smad 
ubiquitin regulatory factor (Smurf)1 induced by TGFβ and TGFβ plus EGF. Smurf1 is an 
established negative regulator of BMP-signalling that binds to BMP-responsive Smads 
(Smad1/5), subsequently stimulating their ubiquitination and degradation (Murakami, 2003). 
Adding U0126, however; was able to block the upregulation of Smurf1, indicating a potential 
link between ERK1/2 and BMP-signalling. Taken together, this suggests that independent 
pathways may modulate the inhibitory activities of BMP-7 and PD153035 in lens EMT. 
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6 Conclusions 
It is well established that TGFβ-induced EMT is a key mechanism in the pathogenesis of 
fibrotic cataract. In situ; however, TGFβ does not work in isolation and can be influenced by 
the activity of other ocular growth factors. Here, we highlight a role for EGF in potentiating 
TGFβ-induced EMT, extending our current understanding of the role of EGFR-signalling in 
lens EMT. EGF appeared to sensitise LECs to be more responsive to TGFβ, inducing a more 
pronounced EMT, with elevated protein expression of mesenchymal markers. EGF also 
temporally shifted the activation profiles of TGFβ-induced Smad2/3-, EGFR- and ERK1/2-
signalling. We reveal a complex, cooperative network between the canonical Smad and non-
canonical EGFR- and ERK1/2-signalling pathways in upregulating EMT markers and 
downstream TGFβ target genes following treatment with TGFβ and EGF compared to TGFβ 
alone. EGFR inhibitors including Erlotinib and Gefitinib have already been approved for 
treatment of several human epithelial cancers (Rocha-Lima et al., 2007) and indeed, 
Wertheimer et al., (2018) found that intraocular lenses soaked in Erlotinib prevented PCO 
formation in a human capsular bag model with no toxicity to other ocular cells (Wertheimer et 
al., 2018). By targeting EGFR-signalling, we can effectively antagonise both TGFβ and EGF 
signalling, thereby simultaneously abrogating both the ability of TGFβ to induce EMT and the 
ability of EGF to potentially augment this activity. 
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8 Supplementary Material 
8.1 Supplementary figures 
 
Figure S1. Co-treatment of LECs with TGFβ2 and EGF upregulated EMT markers. 
RT-qPCR revealed differential roles for EGFR-, ERK1/2- and Smad-signalling in the regulation of EMT 
markers following treatment with TGFβ2, EGF or both for 24 hours. EMT markers investigated include 
Col1a1 (A), Fn (B), α-SMA (C), Ctgf (D), Ncad (E) and Ecad (F). C (untreated explants), T (TGFβ2 only 
treated), TE (TGFβ2 plus EGF), E (EGF only), PD (PD153035), U0 (U0126), SIS (SIS3), Col1a1, 
collagen type 1 alpha 1; Fn, fibronectin; α-SMA, alpha-smooth muscle actin; Ctgf, connective tissue 
growth factor; N-cadherin, neural cadherin; E-cadherin, epithelial cadherin. Data from 3 independent 
experiments is presented relative to GAPDH as fold change ± SEM. One-way ANOVA, Tukey’s post 
hoc test *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. 
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Figure S2. Co-treatment of LECs with TGFβ2 and EGF upregulates EMT target genes. 
RT-qPCR revealed differential roles for EGFR-, ERK1/2- and Smad-signalling in regulating EMT target 
genes following treatment with TGFβ2, EGF or both for 24 hours. EMT target genes investigated include 
Zeb1 (A), Zeb2 (B), Snai1 (C), Smad7 (D), Id2 (E), Id3 (F) and Smurf1 (G). C (untreated explants), T 
(TGFβ2 only), TE (TGFβ2 plus EGF), E (EGF only), PD (PD153035), U0 (U0126), SIS (SIS3), Zeb, 
zinc finger E-box-binding; Snai1, snail; Smad7, small mothers against decapentaplegic 7, Id, inhibitor 
of differentiation; Smurf1, Smad ubiquitin regulatory factor 1. Data from 3 independent experiments are 
presented relative to GAPDH as fold change ± SEM. One-way ANOVA, Tukey’s post hoc test *P < 0.05, 
**P < 0.01, ***P < 0.001 and ****P < 0.0001.  
 
 
Figure S3. Co-treatment of LECs with TGFβ2 and EGF differentially upregulates Egfr and Hb-egf 
gene expression. 
RT-qPCR revealed differential roles for EGFR-, ERK1/2- and Smad-signalling in regulating genes of 
the EGF family following treatment with TGFβ2, EGF or both for 24 hours. EGF family genes 
investigated include Egfr (A) and Hb-egf gene expression (B). C (untreated explants), T (TGFβ2 only), 
TE (TGFβ2 plus EGF), E (EGF only), PD (PD153035), U0 (U0126), SIS (SIS3), Egfr (epidermal growth 
factor receptor), Hb-egf (heparin binding EGF-like growth factor). Data from 3 independent experiments 
are presented relative to GAPDH as fold change ± SEM. One-way ANOVA, Tukey’s post hoc test *P < 
0.05, **P < 0.01 and ****P < 0.0001. 
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Figure S4. Co-treatment of LECs with TGFβ2 and EGF induces differential changes in Adam 
gene expression. 
RT-qPCR revealed differential roles for EGFR-, ERK1/2- and Smad-signalling in regulating genes of 
the Adam family following treatment with TGFβ2, EGF or a combination of the two for 24 hours. Adam 
family genes investigated include Adam9 (A), Adam10 (B), Adam17 (C) and Adam19 (D). C (untreated 
explants), T (TGFβ2 only), TE (TGFβ2 plus EGF), E (EGF only), PD (PD153035), U0 (U0126), SIS 
(SIS3), Adam (a disintegrin and metalloproteinase). Data from 3 independent experiments are 
presented relative to GAPDH as fold change ± SEM. One-way ANOVA, Tukey’s post hoc test *P < 0.05, 
**P < 0.01, ***P < 0.001 and ****P < 0.0001. 
 
8.2 Supplementary table 
Table S1. Summary of genes significantly differentially expressed in supplementary figures. 
Gene Treatment group Up/downregulation P value Significance 
Col1a1 C vs. T ↑ < 0.0001 **** 
 C vs. TE ↑ < 0.0001 **** 
 TE vs. TEPD ↓ < 0.0001 **** 
 TE vs. TEU0 ↓ < 0.0001 **** 
 TE vs. TESIS ↓ 0.0001 *** 
Fn C vs. T ↑ <0.0001 **** 
 C vs. TE ↑ <0.0001 **** 
 TE vs. TEPD ↓ 0.0275 * 
 TE vs. TEU0 ↓ 0.0006 *** 
 TE vs. TESIS ↓ 0.0138 * 
α-SMA C vs. T ↑ <0.0001 **** 
 C vs. TE ↑ <0.0001 **** 
 T vs. TE ↓ 0.0034 ** 
 TE vs. TEPD ↑ 0.0002 *** 
 TE vs. TEU0 ↓ 0.0059 ** 
 TE vs. TESIS ↓ 0.0011 ** 
Ctgf C vs. T ↑ <0.0001 **** 
 C vs. TE ↑ <0.0001 **** 
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Ecad C vs. T ↓ 0.0052 ** 
 C vs. TE ↓ 0.0002 *** 
 TE vs. TEPD ↑ 0.0001 *** 
Zeb1 C vs. T ↑ 0.0003 *** 
 TE vs. TEU0 ↓ 0.0149 * 
Zeb2 C vs. T ↓ 0.0007 *** 
 C vs. TE ↓ 0.002 ** 
 TE vs. TEPD ↑ 0.0211 * 
 E vs EU0 ↑ 0.0005 *** 
Smad7 C vs. T ↑ <0.0001 **** 
 C vs. TE ↑ <0.0001 **** 
 TE vs. TEPD ↑ 0.0189 * 
Id2 C vs. T ↓ <0.0001 **** 
 C vs. TE ↓ 0.0001 *** 
 E vs. EU0 ↑ 0.0444 * 
Id3 C vs. T ↓ <0.0001 **** 
 C vs. TE ↓ <0.0001 **** 
Smurf1 C vs. T ↑ 0.0464 * 
 TE vs. TEU0 ↓ 0.0373 * 
Egfr C vs. T ↑ 0.008 ** 
 TE vs. TEU0 ↓ 0.0012 ** 
Hb-egf C vs. T ↑ <0.0001 **** 
 C vs. TE ↑ <0.0001 **** 
 TE vs. TEPD ↓ 0.0393 * 
 TE vs. TEU0 ↓ <0.0001 **** 
 TE vs. TESIS ↑ 0.0017 ** 
Adam9 C vs. T ↑ 0.007 ** 
 C vs. TEPD ↑ 0.007 ** 
 T vs. TE ↓ 0.007 ** 
 TE vs. TEPD ↑ 0.007 ** 
Adam10 C vs. E ↓ 0.0018 ** 
Adam17 C vs. T ↓ 0.0014 ** 
 C vs. E ↓ 0.0007 *** 
 T vs. TE ↑ 0.0059 ** 
 TE vs. TESIS ↓ 0.0136 * 
 E vs. EPD ↑ 0.0012 ** 
Adam19 C vs. T ↑ <0.0001 **** 
 C vs. TE ↑ <0.0001 **** 
 TE vs. TEPD ↓ 0.0011 ** 
 TE vs. TEU0 ↓ <0.0001 **** 
 TE vs. TESIS ↓ 0.0059 ** 
 TE vs. E ↓ 0.0002 *** 
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Translation from animal to human tissue 
In the past few decades, substantial progress has been made in our understanding of the 
pathogenesis of fibrotic cataract using various animal and human models (Wormstone and 
Eldred, 2015). Since work in our laboratory has primarily involved rat lens epithelial explants 
and transgenic mice, we aimed to translate our findings to human tissue. The experiments in 
our earlier Results (Part I-III) were exclusively performed on rat lens epithelial explants; 
however, the experiments described herein are with human lens epithelial explants adapted 
from post-operative human lens anterior capsulorhexis tissue. For my PhD candidature, human 
ethics approval for this project was granted by the University of Sydney Human Research 
Ethics Committee (see letter of approval in the Appendix). The patient information statement 
and patient consent form can be found in the Appendix. 
The first section of this chapter is a case report published in Optometry and Vision Science that 
describes the histopathological features of an anterior subscapular plaque obtained during 
routine cataract surgery, highlighting the role of myofibroblast transdifferentiation in the 
pathogenesis of ASC.  
The second section of this chapter is an excerpt from the review article published in Progress 
in Retina and Eye Research that describes our human lens epithelial explant system developed 
from the anterior capsulorhexis tissue obtained during cataract surgery. Similar to our rat lens 
epithelial explant system, this system enables human lens epithelial cells to be retained on their 
native basement membrane. While our work with this human model is still in its early stages, 
our hope is that continued work in optimising this model for further experimental techniques 
will enable us to study and better understand the role of signalling pathways leading to cataract. 
The work has arisen entirely during my PhD candidature under the guidance of my primary 
supervisor Professor Frank Lovicu who contributed to the case report and review article by 
facilitating me with experimental design and manuscript writing. My auxiliary supervisor Dr. 
Keith Ong provided the human lens specimens and facilitated with clinical data interpretation 
for the case report. 
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1 Histopathology of subcapsular cataract in a patient with atopic 
dermatitis  
Daisy Y. Shu,1,2 Keith Ong2,3 and Frank J. Lovicu1,2 
1Discipline of Anatomy and Histology, Bosch Institute, The University of Sydney, NSW, 
Australia 
2Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, The University 
of Sydney, NSW, Australia 
3Northern Clinical School, The University of Sydney, NSW, Australia 
Key words: anterior subcapsular cataract (ASC); atopic dermatitis; myofibroblast; 
transforming growth factor-beta (TGFβ); epithelial-mesenchymal transition (EMT) 
1.1 Abstract 
Purpose: To report the histopathological features of anterior subcapsular cataract associated 
with atopic dermatitis. 
Case Report: A 29-year-old man with atopic dermatitis presented with bilateral anterior 
subcapsular cataract. Following routine cataract surgery, the anterior subcapsular cataractous 
tissue was obtained as an anterior capsulorhexis flap and prepared as a wholemount for 
histological analysis. The wholemount consisted of a well-demarcated central greyish-white 
plaque surrounded by transparent capsule, corroborating the slit-lamp biomicroscopic 
appearance. Higher magnification of the plaque revealed a fibrous and amorphous mass, most 
likely extracellular matrix owing to the presence of irregularly arranged bundled strands of 
fibrils, typical of collagen. Lens epithelial cells at the plaque were densely packed and 
myofibroblast-like and immunoreactive for alpha-smooth muscle actin. In contrast, lens 
epithelial cells more distant from the plaque retained their regular cuboidal arrangement and 
regular spacing, and were not labeled for alpha-smooth muscle actin, similar to lens epithelial 
cells obtained from a non-cataractous case. 
Conclusions: The presence of alpha-smooth muscle actin-reactive elongated cells at the plaque 
suggests that the cuboidal lens epithelial cells making up the anterior subcapsular cataract have 
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transdifferentiated into spindle-shaped myofibroblastic cells that produce and deposit aberrant 
extracellular matrix. This transdifferentiation process, more commonly known as an epithelial-
mesenchymal transition, contributes to a fibrotic response leading to the development of human 
anterior subcapsular cataract. 
1.2 Introduction 
Anterior subcapsular cataract, a characteristically dense, white opacity directly beneath the 
anterior lens capsule, is often associated with atopic dermatitis, uveitis, and mechanical or 
chemical ocular trauma (Marcantonio et al., 2003). The prevalence of anterior subcapsular 
cataract is relatively uncommon in Europe and North America at 2-3% of cataract (Marcantonio 
et al., 2003) compared to 4.8% in Asian countries (Johar et al., 2007; Kim and Joo, 2008). 
There is little in the literature regarding the age-specific incidence of anterior subcapsular 
cataract, however; unlike more common forms of cataract such as nuclear or cortical, it appears 
to be more prevalent in younger populations; 74% of patients with anterior subcapsular cataract 
are younger than 60 years of age with an average age at diagnosis of 51.9 years (Kim and Joo, 
2008). 
There is a compelling body of evidence implicating epithelial-mesenchymal transition in the 
pathogenesis of anterior subcapsular cataract, characterised by transdifferentiated 
myofibroblastic cells surrounded by an accumulation of extracellular matrix, immediately 
below the anterior lens capsule (Johar et al., 2007). Numerous animal models such as cultured 
embryonic chick lens cells, rat lens epithelial explants, whole rat lens culture and transgenic 
mice have been utilised to model the pathogenesis of anterior subcapsular cataract; however, 
there has been a paucity of research using human tissue (Wormstone and Eldred, 2015). Hence, 
histopathological examinations of excised human lens tissue are fundamental in translating 
these animal studies to the human condition. In this case report, we describe the 
histopathological features of a human lens capsulorhexis with anterior subcapsular cataract. 
1.3 Case Report 
A 29-year-old man of Asian-descent presented with bilateral dense anterior subcapsular 
cataract (Figures 1A-B) with best-corrected visual acuity of 20/60 in the right eye and 20/120 
in the left. He was first diagnosed with cataract at 21 years of age following reports of 
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symptoms of glare and decreased vision. His medical history was significant for atopic 
dermatitis, especially on his face and neck, for which he was prescribed topical betamethasone 
dipropionate cream for occasional use. On clinical examination, the patient had no other 
identifiable eye pathology. 
The anterior subcapsular cataractous tissue was obtained as an anterior capsulorhexis flap 
during routine cataract surgery involving phacoemulsification and intraocular lens 
implantation in the left eye. There were no post-operative complications and the best corrected 
visual acuity was 20/20 in the left eye following surgery. A non-cataractous control tissue was 
obtained from a 68-year-old male of Asian-descent who underwent cataract surgery of the right 
eye for a dense nuclear and cortical cataract. 
The anterior capsules with adherent cells, including lens epithelial cells, were fixed 
immediately in neutral buffered formalin (10%) and prepared as a wholemount. Phase-contrast 
microscopy was used to examine morphological features. Detailed cellular spatial 
characteristics were analysed by staining cell nuclei with Hoechst 33342 (3μg/ml; Calbiochem, 
USA). To determine whether these lens epithelial cells had undergone an epithelial-
mesenchymal transition, the myofibroblastic marker, alpha-smooth muscle actin (1:100 
dilution; A2547, Sigma-Aldrich, MO, USA), tagged using an Alexa Fluor 594-conjugated goat 
anti-mouse secondary antibody (1:1000 dilution; Molecular Probes, Invitrogen, CA, USA), 
was visualised using epifluorescence microscopy (Leica DMLB, Wetzlar, Germany). Given 
the capsulorhexis contained normal (circular nuclei) and pathological (elongated nuclei) lens 
epithelia, we had an internal negative control for the alpha-smooth muscle actin-labelling. The 
specificity of the alpha-smooth muscle actin antibody used is validated by many of our past 
studies using Western blotting and immunofluorescent labelling where it has been featured 
(Shin et al., 2012; Zhao et al., 2015). 
The wholemount consisted of a well-demarcated central greyish-white plaque (Figure 1C) 
surrounded by transparent capsule (margins outlined by arrows), corroborating the slit-lamp 
biomicroscopic appearance (Figure 1A). Higher magnification of the plaque revealed a fibrous 
and amorphous mass of extracellular matrix consistent with the presence of irregularly 
arranged bundled strands, that appeared to be typical of collagen fibrils (Figure 1D). Without 
further studies specifically labelling for collagen, we cannot further characterise or confirm the 
exact nature of these fibrils. 
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Figure 1. Microscopy images of the ASC plaque. 
Slit-lamp biomicroscopic photographs of the anterior subcapsular cataract in the left eye with diffuse 
illumination (A) and optic section (B). Phase-contrast microscopy of the anterior subcapsular plaque 
shows a white, amorphous mass evident centrally (*) within the capsulorhexis specimen (edges 
denoted by red arrows) in (C). A magnified view of the surface of this plaque (D) under phase contrast 
shows regular strands (yellow arrows) representing fibrils that are typical of collagen that comprises 
the abundant extracellular matrix of the plaque. 
 
The anterior lens epithelium showed a gradual transition in cell morphology extending from 
the plaque to more peripheral non-plaque regions. Using a Hoechst stain, lens epithelial cells 
at the plaque (Figure 2A) show more elongate cell nuclei that are unevenly distributed, with 
many nuclei apposed and overlapping each other, indicative of cell multilayering (Figure 2B). 
These cells were immunoreactive for alpha-smooth muscle actin (Figure 2C). Lens epithelial 
cells in the transition zone between the plaque and non-plaque regions (Figure 2D) displayed 
a more regular organisation (Figure 2E) and a sparsity of alpha-smooth muscle actin labelling 
compared to the plaque region (Figure 2F). The images in this transition zone are focused on 
the plane of the lens epithelial cells adjacent to the plaque and hence, the upper region of the 
images where the edge of the plaque is evident (*) is out of focus due to the greater thickness 
of the plaque. Lens epithelial cells at the non-plaque regions (Figure 2G) were evenly 
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distributed with more uniformly rounded nuclei, also more compact spacing (Figure 2H), and 
little if any expression of alpha-smooth muscle actin (Figure 2I). The control tissue of the non-
cataractous patient displayed this same cell uniformity (Figure 2J) to the non-plaque region of 
the anterior subcapsular cataractous tissue. Although the cell nuclei are a similar size and shape 
(Figure 2K) compared to the non-plaque region (Figure 2H), the control lens epithelial cells 
are more tightly spaced with higher cell density and exhibit no immunoreactivity for the 
myofibroblastic marker, alpha-smooth muscle actin (Figure 2L). 
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Figure 2. Comparison of regional differences between lens epithelial cells at the plaque and 
adjacent to the plaque. 
The dashed line demarcates the transition of normal lens epithelial cells (below line) into myofibroblastic 
cells (above line) as they approach the plaque (* denotes the edge of the plaque). Cells at the plaque 
(A) with Hoechst staining (B) appear denser, display more closely associated elongate cell nuclei and 
multilayering and are immunoreactive for alpha-smooth muscle actin (C). Directly adjacent to the plaque 
(D*), lens epithelial cells appear more flattened and regularly spaced, maintaining the rounded 
appearance of their nuclei (E), but still express alpha-smooth muscle actin (F). Directly beyond this 
region, a population of well-defined, more regularly spaced cobblestone epithelial cells is evident (G) 
exhibiting uniform round nuclei (H) and notably little to no expression of alpha-smooth muscle actin (I). 
Lens epithelial cells of a non-cataractous patient appear more compact and uniform (J) compared to 
the anterior subcapsular cataractous tissue with regular and circular nuclei with no evidence of 
multilayering (K) and no immunoreactivity for alpha-smooth muscle actin (L). 
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1.4 Discussion 
Atopic dermatitis is a chronic inflammatory skin disease characterised by erythematous 
plaques, intense pruritus and cutaneous hypersensitivity to environmental triggers (Bair et al., 
2011). The prevalence of atopic dermatitis has been steadily increasing, with 10-20% of 
children and 1-3% of adults affected globally (Bair et al., 2011). The incidence of cataract 
development in patients with atopic dermatitis has been reported from 5-38% with the age of 
onset ranging from adolescence into adulthood (Bair et al., 2011). 
The precise pathogenic mechanisms underlying cataract formation in atopic dermatitis remain 
elusive. It has been suggested that patients with atopic dermatitis have an intrinsic defect in 
their epithelial cells, resulting in defective barrier function and greater susceptibility to 
oxidative stress and inflammatory mediators such as interleukin-6, tumour necrosis factor and 
transforming growth factor-beta (Bair et al., 2011). Corticosteroid therapy has also been 
associated with cataract formation; however, this usually results in the posterior subcapsular 
type (Bair et al., 2011). Interestingly, the incidence of cataract in corticosteroid-naïve atopic 
dermatitis patients was no different compared to patients with a history of both topical and 
systemic corticosteroid use, suggesting that the incidence of posterior subcapsular cataract 
formation in patients with atopic dermatitis cannot be explained by the use of corticosteroids 
alone (Niwa and Iizawa, 1994). 
Evidence from animal research supports the role of epithelial-mesenchymal transition in the 
pathogenesis of anterior subcapsular cataract (de Iongh et al., 2005). Epithelial-mesenchymal 
transition is a phenomenon whereby polarised epithelial cells undergo morphologic and 
molecular changes to give rise to elongate, motile, matrix-producing mesenchymal cells 
(Figure 3A) (Kalluri and Weinberg, 2009). In the ocular lens, epithelial-mesenchymal 
transition drives lens epithelial cells to relinquish their cobblestone morphology and 
transdifferentiate into spindle-shaped myofibroblastic cells that elongate and migrate across 
the lens capsule leading to anterior subcapsular cataract (Figure 3B) (de Iongh et al., 2005). 
During this process, lens epithelial cells lose their characteristic epithelial membrane markers, 
such as E-cadherin, and acquire mesenchymal markers such as alpha-smooth muscle actin and 
express aberrant extracellular matrix proteins (de Iongh et al., 2005). Transforming growth 
factor-beta has been identified as a potent inducer of this epithelial-mesenchymal transition (de 
Iongh et al., 2005). 
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Figure 3. Schematic diagram of epithelial-mesenchymal transition and anterior subcapsular 
cataract. 
During epithelial-mesenchymal transition (A), lens epithelial cells lose their polarity and normal cellular 
adhesions and transdifferentiate into spindle-shaped mesenchymal cells that secrete extracellular 
matrix. The normal human lens (B, left) consists of a monolayer of lens epithelial cells overlying a mass 
of fibre cells, all encased within a thick basement membrane, the lens capsule. Epithelial-mesenchymal 
transition also leads to anterior subcapsular cataract (B, right) with aberrant accumulation of 
mesenchymal cells and extracellular matrix (in red). 
 
The present case reveals variations in cell density between plaque and non-plaque regions of 
the anterior subcapsular cataractous tissue which supports the role of the epithelial-
mesenchymal transition process in the pathogenesis of anterior subcapsular cataract. As lens 
epithelial cells undergo epithelial-mesenchymal transition, they appear to migrate towards the 
region of the plaque and in doing so, lose their uniform arrangement and begin to flatten across 
a wider area before ultimately becoming incorporated into the fibrotic mass of multilayered 
cells and extracellular matrix at the plaque. It is not clear whether the expression of alpha-
smooth muscle actin precedes, proceeds or is concomitant with the cell shape changes observed 
(reflected in the change in shape of cell nuclei). Future studies will be aimed at elucidating the 
temporal changes in protein expression, and correlating this to cell morphology by analysing 
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anterior subcapsular cataract specimens presenting at different stages of severity. This is one 
advantage of in vivo transgenic mouse models that exhibit anterior subcapsular cataract, as they 
enable the study of not only the induction, but also the spatial and temporal progression of 
anterior subcapsular cataract in a reproducible manner. With this we can more effectively 
translate to human anterior subcapsular cataract pathology. 
This anterior subcapsular cataract case demonstrates many molecular and morphologic 
similarities to previous animal and human research involving transforming growth factor-beta-
induced epithelial-mesenchymal transition in the lens. Treatment with transforming growth 
factor-beta resulted in myofibroblastic transdifferentiation and production of aberrant 
extracellular matrix in both rat (de Iongh et al., 2005) and human lens epithelial explant systems 
(Wormstone et al., 2002). In vivo models including intravitreal injection of active transforming 
growth factor-beta into rodent eyes (Hales et al., 1999), ectopic overexpression of mature 
transforming growth factor-beta-1 in transgenic mouse lenses (Lovicu et al., 2002) and 
adenoviral gene delivery of transforming growth factor-beta into the mouse anterior chamber 
(Robertson et al., 2007) have all induced anterior subcapsular cataract with characteristic 
epithelial-mesenchymal transition features. Transforming growth factor-beta has also been 
implicated in the pathogenesis of another fibrotic lens event, posterior capsular opacification 
that arises from the transdifferentiation of residual lens epithelial cells across the capsular bag 
following cataract surgery (Wormstone et al., 2002).  Accompanying this are elevated levels 
of active transforming growth factor-beta-2 and its receptors that have been detected in donor 
human post-mortem capsular bag tissue (Wormstone et al., 2002). 
It has been postulated that anterior subcapsular cataract development in patients with atopic 
dermatitis may be directly related to constant trauma secondary to eye rubbing (Bair et al., 
2011). Both transforming growth factor-beta-1 and transforming growth factor-beta-2 isoforms 
are constitutively expressed by lens epithelial cells and exist in the ocular media in their latent, 
inactive forms (Gordon-Thomson et al., 1998). Following trauma, active levels of transforming 
growth factor-beta isoforms become dramatically elevated (Saika et al., 2004b). In a mouse 
lens injury model of anterior subcapsular cataract, capsular puncture has been found to 
upregulate the transforming growth factor-beta/Smad signalling pathway and induce 
myofibroblastic transdifferentiation of lens epithelial cells (Saika et al., 2004b). Smad proteins 
are intracellular molecules involved in transforming growth factor-beta signal transduction (de 
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Iongh et al., 2005). Once activated, transforming growth factor-beta receptors phosphorylate 
receptor-regulated Smad2 and Smad3 that associate with the common Smad (Smad4) to form 
a heteromeric complex (de Iongh et al., 2005). This complex translocates into the nucleus to 
regulate transcription of transforming growth factor-beta-responsive genes (de Iongh et al., 
2005). Pre-treatment with transforming growth factor-beta-neutralising antibodies prior to 
puncture wound injury inhibited the nuclear translocation of Smad3 and Smad4 and subsequent 
lens fibrosis (Saika et al., 2004b). Moreover, injury-induced epithelial-mesenchymal transition 
was inhibited in Smad3 knockout transgenic mice, supporting the role of Smad signalling in 
lens fibrosis (Saika et al., 2004b). However, some alpha-smooth muscle actin expression was 
still detected in lenses of Smad3 null mice overexpressing transforming growth factor-beta-1 
suggesting that alternative transforming growth factor-beta-signalling pathways may be 
involved in this lens fibrosis (Banh et al., 2006). 
While the Smad signalling pathway represents the canonical signalling pathway for 
transforming growth factor-beta, several non-Smad intracellular signalling cascades have been 
implicated in regulating epithelial-mesenchymal transition in the lens (de Iongh et al., 2005). 
The mitogen activated protein kinase pathways including extracellular-signal-regulated kinase, 
stress-activated p38 and Jun N-terminal Kinase are involved in transforming growth factor-
beta-induced epithelial-mesenchymal transition in the lens (de Iongh et al., 2005). Recently, 
Sprouty, an antagonist of mitogen activated protein kinase, has been identified as a negative 
regulator of transforming growth factor-beta signalling in the lens (Lovicu et al., 2015). 
Conditional knockout of Sprouty from the lens of mice resulted in anterior subcapsular cataract 
with subpopulations expressing alpha-smooth muscle actin and a concomitant loss of E-
cadherin indicating loss of the epithelial phenotype (Shin et al., 2012). Interestingly, 
overexpression of Sprouty in lens epithelial cells rendered the cells less responsive to 
transforming growth factor-beta signalling and maintained lens transparency (Zhao et al., 
2015). Moreover, the Rho/Rho kinase pathway has been shown to relay transforming growth 
factor-beta signals leading to cytoskeletal reorganisation, cell motility and invasion in the lens 
(Cho and Yoo, 2007). Transforming growth factor-beta also signals through the mTOR (Q. 
Meng et al., 2013) and the phosphoinositide 3-kinase/Akt pathway (Yao et al., 2008) to regulate 
cell growth inhibition and induction of epithelial-mesenchymal transition. Wnt signalling has 
also been found to promote transdifferentiation in the lens of transgenic mice overexpressing 
transforming growth factor-beta-1 with increased nuclear β-catenin detected in anterior 
Chapter Six: Results (Part IV) 
167 
subcapsular cataract plaques (Chong et al., 2009). More research is required to characterise the 
signalling pathways involved in transforming growth factor-beta-induced epithelial-
mesenchymal transition to develop potential therapeutic agents for the prevention of anterior 
subcapsular cataract and posterior capsular opacification. 
It is interesting to note that elevated levels of transforming growth factor-beta have been 
implicated in other ocular pathologies, including corneal opacification, proliferative 
vitreoretinopathy and primary open angle glaucoma (Saika, 2006). However, these pathologies 
are not typically associated with a corresponding anterior subcapsular cataract. This may be 
because the lens normally has protective mechanisms such as Sprouty that may prevent the 
initiation of the epithelial-mesenchymal transition process, even if transforming growth factor-
beta signals are transduced in surrounding ocular tissues (Shin et al., 2012). It is likely that a 
dysregulation of such protective mechanisms within the lens may render it susceptible to 
undergoing epithelial-mesenchymal transition with resultant anterior subcapsular cataract. 
In the present case, cells of the human anterior subcapsular cataract plaque were strongly 
immunoreactive for alpha-smooth muscle actin. Although alpha-smooth muscle actin is an 
established myofibroblastic marker (Kalluri and Weinberg, 2009), its role in lens fibrosis 
appears to conflict in animal and human studies. In bovine and rat lens epithelial-mesenchymal 
transition models, the expression of alpha-smooth muscle actin has been found to correlate 
with increased matrix contraction and consequent capsular wrinkling (de Iongh et al., 2005). 
In contrast, Dawes et al. found that alpha-smooth muscle actin expression did not correlate 
with matrix contractility and surprisingly, alpha-smooth muscle actin knockdown using small 
interfering RNA technology enhanced matrix contraction (Dawes et al., 2008). This species 
difference should be an important consideration when modelling human disease and evaluating 
putative therapeutic agents. Future studies should be aimed at further elucidating the functional 
differences in alpha-smooth muscle actin between species and characterising the proteins 
involved in matrix contractility in various experimental systems. 
With all case reports, we are hindered by the limited tissue and hence restricted in making 
major conclusions relating to the general molecular and morphologic phenotype of human 
anterior subcapsular cataract. The use of immunolabelling of a wholemount anterior 
subcapsular cataract proved beneficial in examining a large surface area to obtain valuable 
information regarding regional diversity between the plaque and surrounding intact lens 
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epithelia; however, this manipulation was detrimental to the structural integrity of the anterior 
subcapsular cataractous tissue, and we were reluctant to further characterise the anterior 
subcapsular cataract histologically by subsequently embedding and sectioning tissue that may 
not be reflective of its native state. This will be taken into account for future studies with the 
objective of correlating both wholemount and corresponding sectioned material for further 
analysis. Although the use of a non-cataractous tissue was important in establishing the validity 
of the alpha-smooth muscle actin antibody, it should be noted that although the lens epithelial 
cells appear similar in appearance, the control specimen is from a much older patient due to 
the limited availability of ‘normal’ lens tissue from younger age-matched patients. 
1.5 Conclusions 
The process of epithelial-mesenchymal transition is complex, involving not only 
morphological and cytoskeletal reorganisation but also extensive biochemical and genetic 
changes. Here we highlight some of these morphologic and molecular traits accompanying 
epithelial-mesenchymal transition in human anterior subcapsular cataract, traits that have also 
been well characterised in animal models of epithelial-mesenchymal transition-driven cataract. 
While we have shown some of this cellular heterogeneity, further characterization of human 
anterior subcapsular cataract cases is required in patients with atopic dermatitis. By translating 
the morphologic and molecular events mediating epithelial-mesenchymal transition from 
animal research to the human lens, novel pharmaceutical alternatives can be developed for the 
treatment of anterior subcapsular cataract and potentially posterior capsular opacification. 
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2 Myofibroblast transdifferentiation: the dark force in ocular 
wound healing and fibrosis 
Daisy Y. Shu,1,2 Frank J. Lovicu1,2 
1Discipline of Anatomy and Histology, Bosch Institute, The University of Sydney, NSW, 
Australia 
2Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, The University 
of Sydney, NSW, Australia 
 
Although animal models have played an essential role in elucidating the growth factor 
signalling pathways regulating cataractogenesis, human models need to be developed further 
in order to translate these findings into human applications. Based on our established rat lens 
epithelial explant model, we have developed a human lens explant system by culturing 
anterior capsulorhexis flaps obtained during cataract surgery. Similar to the rat lens epithelial 
explant model, the anterior monolayer of LECs remain adherent to the lens capsule of the 
capsulorhexis, thus enabling the observation of changes in morphology of the LECs whilst on 
their native basement membrane. In our rat explant system, treatment of LECs obtained from 
21-day-old Wistar rats with 200 pg/ml TGFβ2 induced myofibroblastic transdifferentiation 
(Das et al., 2016; Shu et al., 2017). Anterior capsulorhexis specimens obtained from patients 
aged 59 to 76 years undergoing routine surgery for age-related nuclear and/or cortical 
cataract were subsequently pinned down onto a culture dish in a similar manner to rat lens 
epithelial explants. Throughout the culture period, the human lens epithelial explants are 
maintained in the same serum-free media that we use for our rat lens epithelial explants. 
Treatment with a higher dose of TGFβ2 (10 ng/ml) was required to induce 
transdifferentiation of the normal human LECs into spindle-shaped myofibroblastic cells, 
with loss of membranous β-catenin labelling and acquisition of α-SMA stress fibres (Fig. 4) 
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and these cells undergo cell death over the culture period (Fig. 5) similar to the rat lens 
epithelial explant system (Das et al., 2016; Shu et al., 2017). This in vitro human model will 
enable the translation of animal-based EMT research to the human lens and may contribute to 
the development of novel pharmaceutical alternatives for the treatment of ASC and PCO. 
 
Figure 4. A human lens epithelial explant model for studying cataractogenesis. 
Following 10 days of culture, phase contrast microscopy shows that untreated human lens epithelial 
explants (A, anterior capsulorhexis tissue obtained in surgery) remain as a normal cuboidal layer of 
epithelial cells, with membranous localisation of β-catenin and minimal α-SMA (B) viewed with confocal 
microscopy. Immunofluorescence labelling was performed as described previously (Shu et al., 2017). 
Treatment with 10 ng/ml TGFβ2 displayed an elongate, spindle-shaped morphology (C). Although β-
catenin remained localised to the membrane in TGFβ2-treated explants, the label no longer highlighted 
the normal cobblestone-packed arrangement as in control explants (D). TGFβ-treated explants 
exhibited strong immunoreactivity for α-SMA, co-labelling to stress fibres (D). Scale bar: 100 µm (A, C), 
25 µm (B, D). 
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Figure 5. TGFβ2 treatment of human lens epithelial cell explants induced cell death over 12 
days culture. 
Phase contrast microscopy shows morphological changes of human lens epithelial cells following 
treatment with 10 ng/ml TGFβ2 at Day 0 (A), Day 2 (B), Day 5 (C), Day 7 (D), Day 10 (E), Day 12 (F) 
and untreated human lens epithelial cell explants at Day 12 (G). TGFβ2 appears to induce cell 
elongation into spindle-shaped myofibroblastic cells at Day 5 and eventually leads to cell loss by Day 
12. Untreated cells remain as an epithelial monolayer with no signs of cell loss at Day 12. Scale bar: 
100 µm. 
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General Discussion 
“It is not the answer that enlightens, but the question.” - Eugène Ionesco 
 
1 Navigating the TGFβ-signalling network: more than one way to 
cure cataract? 
TGFβ activates an integrative network of canonical and non-canonical signalling pathways 
during lens EMT. While this thesis has shown key roles for Smad2/3-, ERK1/2- and EGFR-
signalling pathways, several other signalling pathways have also been implicated in the 
pathogenesis of fibrotic cataract including JNK, p38 MAPK, PI3K/Akt/mTOR, JAK/STAT, 
Rho/ROCK, integrin and oxidative stress signalling pathways. Inhibition of any one of these 
signalling pathways appears to block a key aspect of the EMT process, leading to partial or 
complete suppression of TGFβ-induced lens EMT. 
The canonical Smad pathway plays a pivotal role in TGFβ-induced lens EMT. We showed that 
TGFβ activates Smad2/3 signalling as early as 15 minutes and up to 18 hours through Western 
blotting, and validated these findings by showing the translocation of Smad2/3 proteins from 
the cytoplasm into the nucleus upon treatment with TGFβ using the rat lens epithelial explant 
system. As introduced in Chapter 1, many studies have highlighted the importance of 
TGFβ/Smad signalling using various models including the mouse lens injury model (Saika et 
al., 2004b, 2004a, 2001), post-cataract surgery human lens specimens (Saika, 2002) and human 
lens cell lines FHL124 (Dawes et al., 2009; Wormstone et al., 2004) and HLE-B3 (Li et al., 
2011). 
BMP-7, another member of the TGFβ superfamily also activates Smad proteins as part of its 
canonical signalling pathway; however, its activity opposes that of TGFβ (see Figure 1). In 
Chapter 3, we show that BMP-7 blocks TGFβ-induced EMT in rat lens epithelial explants by 
upregulating Smad1/5 proteins and concurrently downregulating TGFβ-mediated Smad2/3 
proteins (Shu et al., 2017). While BMP and TGFβ use different R-Smads, they both require the 
co-Smad, Smad4 to translocate into the nucleus to initiate gene transcription. Whether the 
inhibitory effect of BMP-7 on TGFβ in LECs may be due to competition for a finite supply of 
the shared component, Smad4 remains to be explored. Competition for Smad4 has been shown 
between other members of the TGFβ superfamily, that is, BMP-2/4 and activin signalling, that 
activate Smad1 and Smad2, respectively (Candia et al., 1997). In an elegant study using 
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Xenopus embryos, Smad4 was found to interact with both Smad1 and Smad2 and by adding a 
dominant negative Smad4 mutant, activin and BMP-2/4 signalling were both inhibited (Candia 
et al., 1997). Activation of two TGFβ superfamily members may result in competition for 
Smad4 and the outcome of this competition may determine the relative strengths of the 
opposing signals, thus favouring a particular cellular response. It appears that Smad4 may act 
as a focal point for Smad action and function, thereby regulating the intracellular interplay 
amongst members of the TGFβ superfamily. 
 
Figure 1. Schematic of canonical TGFβ and BMP signalling. 
 
Notably, in our study, exogenous BMP-7 only induced a modest two-fold activation of 
Smad1/5 compared to the robust five-fold activation of Smad2/3 by TGFβ. There is little in the 
literature analysing the potency of the R-Smads (can small changes in Smad1/5 levels be potent 
enough to induce functional changes in lens epithelial cells?) nor are there studies comparing 
the binding affinities of Smad1/5 or Smad2/3 to Smad4; but one may assume that the low levels 
of Smad1/5 conferred by adding BMP-7 may not be enough to outcompete Smad2/3 for 
binding to Smad4.  
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There are several other possible mechanisms by which BMP-7 may be antagonising TGFβ. It 
is possible that BMP-7 may be interfering with TGFβ-induced EMT through the inhibitors of 
differentiation (Id). The BMP-7 target genes, Id2/3, were found to be suppressed by TGFβ 
whereas co-treatment with BMP-7 and TGFβ maintained Id2/3 at basal levels. 
Another model of BMP-induced suppression of TGFβ-induced EMT may involve the 
inhibitory Smad, Smad6. In a model of renal fibrosis, BMP-7 induced the upregulation of 
Smad6 through Smad5 which prevented TGFβ-induced upregulation of plasminogen activator 
inhibitor (PAI)-1, a key marker of tissue fibrosis (Wang and Hirshberg, 2004). 
Building upon the Smad6 mechanism, Wang et al., (2012) showed that BMP-2 blocks TGFβ 
induced cardiac fibrosis by activating Smad ubiquitin regulatory factor 1 (Smurf1), a member 
of the family of E3 ubiquitin ligases. The authors showed that the anti-fibrotic activity of BMP-
2 was linked to Smad6 activation which was able to reduce phosphorylation of Smad3 (Wang 
et al., 2012). They further showed that Smad6 activation was dependent on Smurf1 and that 
the Smurf1/Smad6 complex was capable of regulating receptor degradation of TGFβ receptor 
type I. While these experiments were shown for BMP-2, a similar mechanism may be involved 
for the anti-fibrotic effect that we observed for BMP-7 in LECs. 
The mammalian MAPK superfamily consists of three main protein kinase families: ERK1/2, 
JNK/SAPK and p38 MAPK (Kim and Choi, 2010). Work in our laboratory has shown that 
blockade of ERK1/2 phosphorylation using U0126 was effective in suppressing EMT when 
administered to LECs for up to 6 hours after TGFβ treatment (Wojciechowski et al., 2017); 
however, adding U0126 at 24 or 48 hours following TGFβ treatment was unable to block EMT, 
suggesting that ERK1/2 is required for the initiation but not the progression of EMT 
(Wojciechowski et al., 2017). Further, we also showed that Sprouty, an antagonist of receptor 
tyrosine kinases and ERK1/2-signalling, is a negative regulator of TGFβ-signalling in the lens 
(Shin et al., 2012). Conditional knockout of Sprouty from mice lenses induced ASC plaques, 
with subpopulations of cells expressing α-SMA with concomitant loss of E-cadherin, 
indicating myofibroblast transdifferentiation (Shin et al., 2012). Overexpression of Sprouty in 
LECs rendered cells less responsive to TGFβ-signalling by suppressing α-SMA levels both in 
vivo (Shin et al., 2012) and in vitro (Zhao et al., 2015). 
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In Chapter 4, we highlighted a role for ERK1/2-driven EGFR-signalling in TGFβ-induced 
EMT in rat lens epithelial explants. We showed that treatment with TGFβ2 alone is capable of 
transactivating EGFR-signalling (Shu et al., 2018). Blockade of EGFR-signalling with 
PD153035 inhibited TGFβ2-induced EMT indicating that TGFβ-induced EGFR signalling is 
required for EMT (Shu et al., 2018). We showed that the transactivation of EGFR-signalling 
by TGFβ occurred at 18 hours compared to the rapid activation of EGFR-signalling by EGF at 
15 minutes. This suggested that TGFβ may activate EGFR-signalling in an indirect manner 
rather than directly activating the EGFR. Traditionally, growth factors were believed to 
recognise and directly bind to a highly selective binding site on their cognate receptor; 
however, accumulating evidence has revealed that the EGF receptor may be activated by 
ligands of other membrane receptors (Forrester et al., 2016). This phenomenon was first termed 
“transactivation” by Axel Ullrich’s group following the discovery that various G-protein 
coupled receptor (GPCR) agonists could stimulate activation of the EGF receptor (Daub et al., 
1996). Since then, this phenomenon has now been extended to a wide variety of GPCR 
agonists, including angiotensin II (AngII), carbachol, thrombin and lysophosphatidic acid 
(LPA) (Gschwind et al., 2001). Note that this event is different from the “transactivation” of 
genes by an intermediate transactivator protein such as a transcription factor or retrovirus 
(Calendar, 1986). 
The mechanism by which TGFβ indirectly transactivates EGFR may occur through 
“sheddases” called Adam proteins, a subgroup within the matrix metalloprotease (MMP) 
family. Adams proteins induce ectodomain “shedding” (cleaving) of EGF ligands to enable the 
release of soluble functional factors into the extracellular space (Prenzel et al., 1999). The EGF 
ligands (such as EGF, HB-EGF, TGFα, neuregulins) are then able to bind directly to the EGFR 
to promote dimerisation and activation of the EGFR, thereby activating a cascade of signalling 
pathways including ERK1/2 and PI3K/Akt, to elicit downstream cellular responses (Pierce et 
al., 2001; Zhang et al., 2006). Adam family members including Adam10 (Lemjabbar and 
Basbaum, 2002; Yan et al., 2002), Adam12 (Asakura et al., 2002) and Adam17 (or TACE, 
tumour necrosis factor-α-converting enzyme) (Gschwind et al., 2003; Lemjabbar et al., 2003; 
Ohtsu et al., 2006) have been implicated in various models of cancer, cystic fibrosis and cardiac 
hypertrophy. In Chapter 4, we showed that TGFβ upregulated Adam19 and Hb-egf gene 
expression and that this was dependent on EGFR-signalling (Shu et al., 2018). We propose that 
TGFβ upregulates Adam19 that then cleaves HB-EGF to release the soluble functional form 
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of HB-EGF into the extracellular space to bind onto the EGFR, thus activating EGFR-
signalling (see Figure 2). While most of the literature has been focused on the role of ADAM17 
in shedding HB-EGF, there have been conflicting reports of a similar role for ADAM19. 
Horiuchi et al. (2005) showed that Adam19 does contribute to HB-EGF shedding but only in 
the absence of the major HB-EGF sheddase Adam17 in a mouse model studying heart 
development. In contrast, Sahin et al., (2004) and Zhou et al., (2004) reported that ADAM19 
is not involved in HB-EGF shedding using mouse embryonic fibroblasts isolated from Adam19 
knockout and wild-type mice. Further studies are required to clarify the role of ADAM19 in 
shedding HB-EGF in lens epithelial cells. 
 
Figure 2. Schematic of the proposed mechanism of TGFβ-driven transactivation of EGFR-
signalling through cleavage of HB-EGF ligands by Adam19. 
 
MMPs also play a role in TGFβ-induced EMT by remodelling tissue architecture through ECM 
protein degradation (Sivak and Fini, 2002). Both MMP-2 and MMP-9 were upregulated during 
TGFβ-induced EMT in rat lenses (Dwivedi et al., 2006) and the human lens capsular bag 
(Wormstone et al., 2002). It was shown that MMP-2 and MMP-9 were required for epithelial 
cell migration and contraction of the lens capsule in a sham cataract surgery model on donor 
human lenses (Wong et al., 2004). Treatment of rat lenses with TGFβ2 and a broad-spectrum 
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MMP inhibitor (GM6001) or an MMP-2/MMP-9 selective inhibitor blocked TGFβ-induced 
lens opacities, with reduced α-SMA and cellular multilayering (Dwivedi et al., 2006). The lens 
capsule is thought to be a store for growth factors including TGFβ2 (Wormstone et al., 2006) 
and FGF (Tholozan et al., 2007). Hence, it is hypothesised that MMPs may also function to 
release growth factors from the ECM to enable a sustained release of growth factor activity for 
LECs over extended periods, thereby linking short-term inflammation to long-term progressive 
fibrosis (Eldred et al., 2011). 
The ECM microenvironment also plays a key role in dictating lens cellular behaviour during 
TGFβ-induced EMT (Mamuya and Duncan, 2012). Integrins are heterodimeric ECM receptors 
that mediate interactions between cells and the surrounding ECM to facilitate cellular processes 
including proliferation, differentiation, migration and adhesion (Mamuya and Duncan, 2012). 
ECM remodelling can trigger integrins to change from an inactive low affinity state to a high-
affinity ligand binding state (Boudreau and Jones, 1999). Using a mouse cataract surgery 
model, αV integrin subunit was present at modest levels in LECs during surgery and 
dramatically upregulated by 48 hours after surgery in cells, displaying multilayering and 
increased α-SMA expression (Mamuya et al., 2014). It is thought that αV integrin may interact 
with MMPs, such as MT1-MMP (also known as MMP14), tethering them to the cell surface 
(Mu et al., 2002). This brings MMPs into close proximity with latent TGFβ, thus facilitating 
proteolysis of either the latency associated peptide (LAP) or the latent TGFβ binding protein 
(LTBP) so as to release the active form of TGFβ (Mu et al., 2002). Cross-talk between TGFβ 
and αV integrin signalling can occur through integrin-associated adaptor proteins such as Src, 
integrin-linked kinase (ILK) and focal adhesion kinase (FAK) that subsequently activate other 
downstream TGFβ signalling pathways including MAPK, Rho, small GTPases and PI3K/Akt 
(Mamuya and Duncan, 2012). 
TGFβ upregulated the phosphorylation of JNK/SAPK in HLE-B3 and SRA01/04 human lens 
epithelial cell lines (Choi et al., 2007). Slug (also known as Snail2), a transcriptional repressor 
of E-cadherin, was also upregulated upon treatment with TGFβ1 (Choi et al., 2007). Inhibitors 
of MEK- or JNK/SAPK, but not Smad or small GTPase Rho proteins, significantly blocked 
TGFβ1-induced Slug expression, thus indicating that MAPK pathways may be involved in the 
breakdown of adherens junctions during EMT (Choi et al., 2007). In contrast, Dawes et al., 
(2009) showed no significant change in phospho-JNK levels when FHL-124 human epithelial 
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cells were treated with TGFβ2, thereby highlighting differences in lens cell behaviour with 
different cell lines. Instead, they showed that TGFβ2 significantly increased phospho-ERK1/2 
and p38/MAPK levels (Dawes et al., 2009). The upregulation of p38/MAPK pathway was also 
found in α-TN4 murine LECs, and TGFβ2-induced upregulation of p38 was blocked by 
genipin, the main bio-active compound in the herbal medicine, inchin-ko-to (Kitano et al., 
2006). The p38/MAPK pathway has also been implicated in cell migration during TGFβ-
induced EMT in embryonic chick LECs (Boswell et al., 2017). 
TGFβ-induced PI3K/Akt phosphorylation is also required for lens EMT given the addition of 
the PI3K inhibitor, LY294002, blocked TGFβ-induced EMT. More recently, the importance 
of PI3K/Akt-signalling was further highlighted in an in vivo diabetic rat model of TGFβ2-
induced EMT (Du et al., 2017). The authors showed that quercetin, a naturally occurring plant 
flavonoid found in the human diet, blocked EMT in diabetic rats through TGFβ2/PI3K/Akt-
signalling and reduction of oxidative stress (Du et al., 2017). mTOR-signalling is also activated 
during TGFβ-induced lens EMT and inhibition of phospho-mTOR abrogated the EMT 
response and cell motility (Q. Meng et al., 2013). More recently, the PI3K/Akt/mTOR 
signalling axis has been implicated in TGFβ2-induced EMT in HLE-B3 human LECs (Guo et 
al., 2016). 
The Rho/ROCK pathway has also been shown to promote TGFβ activity through cytoskeletal 
reorganisation and cell motility in LECs (Maddala et al., 2003). TGFβ induced a biphasic 
activation in Rho activity, peaking at both 5 minutes and 48 hours in α-TN4 murine LECs (Cho 
and Yoo, 2007). Pre-treatment of LECs with C3-exoenzyme (an irreversible inhibitor of Rho-
GTPase) or the ROCK inhibitor, Y-27632 blocked TGFβ-induced EMT by abolishing the 
formation of actin stress fibres and focal adhesions (Maddala et al., 2003). TGFβ stimulated 
nuclear accumulation of the actin-binding protein, myocardin-related transcription factor A 
(MRTF-A), thereby enabling the upregulation of α-SMA expression during lens EMT (Gupta 
et al., 2013) and this process was ROCK-dependent (Korol et al., 2016). 
TGFβ has also been reported to stimulate the production of reactive oxygen species (ROS) 
during EMT of LECs (Das et al., 2016; Yao et al., 2007). Glutathione (GSH), an important 
antioxidant in the lens, has been shown to block TGFβ-induced EMT in cultured rat whole 
lenses and lens epithelial explants (Chamberlain et al., 2009). Work in our laboratory identified 
a role for the ROS-producing enzyme, Nox4 in mediating TGFβ-induced EMT in the lens (Das 
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et al., 2016). Inhibition of Nox4 expression and its production of ROS using a pan-NADPH 
oxidase inhibitor, VAS2870, suppressed the progression of EMT (Das et al., 2016). ROS also 
plays a role in mediating TGFβ-induced apoptosis in HLE-B3 human LECs (Yao et al., 2007). 
Treatment of cells with radical scavengers (e.g. N-acetyl-Lcysteine, NAC and pyrrolidine 
carbodithioic acid, PDTC) reduced the production of ROS and partially blocked cell death by 
TGFβ (Yao et al., 2007). 
More recently, an elegant study by Jiang et al., (2018) shed light on the timing at which 
different genes and proteins are upregulated with respect to TGFβ signalling (Jiang et al., 
2018). Using an in vivo mouse model of cataract surgery, the upregulation of mRNAs encoding 
fibrotic markers including fibronectin and α-SMA were upregulated within 24 hours while the 
protein levels were not seen until 48 hours (Jiang et al., 2018). In this model, phosphorylated 
Smad2/3 levels are first seen at 48 hours; however, the peak upregulation is not observed until 
5 days. This lag between the onset of surgery and activation of the TGFβ pathway enabled the 
study of gene changes that occur in the interim (Mamuya et al., 2014). Inflammatory mediators 
such as COX-2, CCL2 and CXCL1 were upregulated in LECs from 1 hour, peaking at 24 hours 
and subsequently sharply attenuated by 3 days. This dramatic upregulation of inflammatory 
mediators preceded neutrophil infiltration into the eye at 18 hours, the first upregulation of 
canonical TGFβ signalling at 48 hours and macrophage infiltration at 3 days (Jiang et al., 2018). 
Based on this, the residual LECs that remain after cataract surgery appear to serve as 
“signalling centres” that promote inflammation following cataract surgery by triggering the 
innate immune system (Jiang et al., 2018). 
While we have consolidated a vast body of literature dedicated to TGFβ-induced lens EMT, 
more research is required to understand how the various downstream TGFβ signalling 
pathways are integrated into a cohesive network of lens cellular communication. Does each 
individual pathway serve a specific role in modulating one or more aspects of the EMT 
response? Given that some of these pathways e.g. ERK1/2 are essential for lens homeostasis, 
how does their activation during TGFβ-induced EMT differ from their activation during normal 
lens cellular process? Perhaps, in order for ERK1/2 to initiate fibrotic activity, the cells also 
need to be exposed to the canonical Smad-signalling pathway or even undergo oxidative stress? 
The additive effects of signalling pathways is an area yet to be determined. Moving forward, 
our aim is to specifically antagonise the pathways responsible for the fibrotic and vision-
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impairing effects of TGFβ, including myofibroblast contraction and aberrant ECM 
accumulation, while preserving and promoting the TGFβ signalling pathways required for 
homeostasis and normal healing. To do this, we need a more precise understanding of the 
timing of events during EMT, in parallel with a comprehensive understanding of the spatial 
and temporal activation of genes, proteins and signalling pathways. 
2 Role of growth factors in fibrotic cataract: a delicate balancing 
act in situ 
LECs are constantly exposed to a cocktail of growth factors that differentially influence cellular 
behaviour. TGFβ isoforms are constitutively expressed by LECs and exist in the aqueous 
humour in their latent, inactive forms (Gordon-Thomson et al., 1998). Following ocular trauma 
(e.g. cataract surgery), TGFβ becomes activated and induces LECs to undergo EMT leading to 
the formation of fibrotic cataract (Eldred et al., 2011). While an extensive body of literature 
explores the role of TGFβ in lens EMT, this thesis highlights how other growth factors in the 
ocular media may impact on the ability of TGFβ to induce lens EMT. We show that different 
growth factors can have opposing effects on TGFβ. On the one hand, BMP-7 suppresses the 
fibrogenic capability of TGFβ, thereby blocking the subsequent EMT response and, on the 
other hand, EGF augments the effects of TGFβ leading to a more pronounced EMT response. 
The opposing effects of BMP-7 and EGF lead to the question of whether the protective effects 
of BMP-7 can counteract the EMT-potentiating effects of EGF. In a model of liver fibrosis in 
mice, Wang et al., (2014) showed that BMP-7 reduced the expression of TGFβ1, α-SMA and 
protected against liver damage resulting from exposure to carbon tetrachloride (L.-P. Wang et 
al., 2014). Interestingly, in this same study, BMP-7 also suppressed the expression of 
phosphorylated EGFR in a dose-dependent manner (L.-P. Wang et al., 2014). Whether BMP-
7 also blocks TGFβ-induced EGFR-signalling during lens EMT remains to be explored. 
Inversely, whether inhibition of EGFR-signalling promotes basal levels of BMP-associated 
Smad1/5-signalling is another area of future investigation. In Chapter 4, we showed that 
blocking EGFR using PD153035 does not impact on the BMP-associated target genes Id2/3, 
suggesting that their inhibitory effects against TGFβ may be distinct. Further experiments are 
required to better understand whether there is any crosstalk between BMP- and EGFR-
signalling. 
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Studies in our laboratory have shown that data from our in vitro rat lens epithelial explants 
translates to in situ data for growth factors such as FGF (Lovicu and Overbeek, 1998; McAvoy 
and Chamberlain, 1989) and TGFβ (Liu et al., 1994; Srinivasan et al., 1998). However, it 
should be noted that the near complete cell death that is observed in our culture system over 5 
days following treatment with 200 pg/ml TGFβ2 is not observed to the same extent in in vivo 
models where lens epithelial cells are exposed to a myriad of growth factors. Aside from BMPs 
and EGF, other growth factors present in the aqueous humour (e.g. FGF, IGF, PDGF and 
VEGF) may also impact on TGFβ activity (Iyengar et al., 2009). Earlier studies showed that 
FGF exacerbates the cataractogenic effects of TGFβ in cultured rat whole lenses (Cerra et al., 
2003). Only FGF-2 but not EGF, PDGF, IGF or HGF promoted the survival of TGFβ-treated 
cells in a rat lens epithelial explant model with cells remaining viable for up to 31 days of 
culture compared to TGFβ-treated cells, where only a few cells remained on the lens capsule 
by day 5 (Mansfield et al., 2004). While FGF-2 blocked TGFβ-induced apoptosis of LECs, the 
cells still underwent EMT with a loss of the lens epithelial marker, Pax6 and acquired 
immunoreactivity for EMT markers (α-SMA, type I collagen, fibronectin). Perhaps higher 
concentrations of BMP-7 may be required to overcome the EMT-enhancing capabilities of 
EGF and FGF in vivo. Since our rat lens epithelial explant system is serum-free, it enables the 
controlled study of how growth factors impact on cellular behaviour in vitro. 
While we have focused on how BMP-7 or EGF impact on TGFβ activity, future studies should 
be directed towards how they impact on other growth factors present in the aqueous humour 
and their subsequent combined influence on lens cell behaviour. For example, synergistic 
effects have been observed between BMP-7 and IGF-1 in stimulating osteoblastic cell 
differentiation (Yeh et al., 2010), articular cartilage repair (Peng et al., 2018) and 
chondrogenesis (Gokce et al., 2012). Further adding to the complexity of growth factor 
interactions, there are also studies showing synergistic effects between EGF and IGF-1 in 
stimulating proliferation of keratinocytes (Krane et al., 1991), intestinal epithelial cells 
(Duncan et al., 1994) and human oesophageal epithelial cells (Qureshi et al., 1997). Whether 
IGF synergises with the activity of BMP-7 and/or EGF in LECs remains to be explored. 
Moreover, other growth factors in the ocular media may exhibit synergistic activity with 
different growth factor pairing preferences. How do these different growth factor combinations 
impact on TGFβ activity and the subsequent EMT response? A thorough exploration of how 
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different combinations of growth factors in the eye impact on cellular behaviour is clearly 
warranted. 
Endogenous antagonists of growth factors add yet another layer of complexity to translating 
our findings to the in vivo situation. BMP signalling is regulated by several secreted 
extracellular BMP antagonists including gremlin, noggin, chordin and DAN/Cerberus 
(Yanagita, 2005). Gremlin, an extracellular and intracellular BMP antagonist, has been shown 
to increase ECM synthesis in trabecular meshwork cells (Sethi et al., 2011; Wordinger et al., 
2007). In human LECs, silencing gremlin effectively inhibited TGFβ2-induced EMT and ECM 
synthesis (Ma et al., 2014). Recent work in our laboratory has shown that TGFβ2 upregulates 
gremlin-1 during EMT in our rat lens epithelial explant system (Flokis and Lovicu, unpublished 
data). Will exogenous addition of BMP-7 in vivo impact on the expression of its associated 
antagonists via a controlled feedback mechanism? The expression levels of BMP antagonists 
may influence the efficacy of BMP-7 as a therapeutic target and hence, further research is 
required to elucidate the complex regulation and feedback mechanisms underlying BMP-
signalling. 
Translation of data from animal models to humans is an important step towards developing a 
clinical treatment for fibrotic cataract. In Chapter 6, we describe features of an ASC plaque 
obtained from a patient during cataract surgery, bearing similarities to TGFβ-treated rat lens 
epithelial explants. We further show that normal human anterior lens capsules that were 
removed during cataract surgery (anterior capsulorhexis) can serve as human lens epithelial 
explants. These explants can be cultured and treated with growth factors similar to our rat lens 
epithelial explant model. We found that a higher dose and longer period of exposure to TGFβ 
was required to induce an EMT response in our human anterior lens capsules. While these 
observations are in their initial stages and require further characterisation, the plan is to 
translate our data on the roles of BMP-7 and EGFR-signalling, as well as other novel pathways 
and drug targets found in animal models, to this human model. 
While this thesis provides a detailed analysis of how growth factors and their downstream 
signalling pathways interact during lens EMT, it is only the proverbial “tip of the iceberg". The 
in vivo situation is the ultimate balancing act, comprising layers of complexity including the 
myriad of growth factors and their associated antagonists, but also potential 
synergistic/antagonistic effects of different growth factor combinations and compensatory 
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positive/negative feedback loops. It would not be surprising to discover that a cocktail of 
growth factors or inhibitors may be required to block lens EMT in vivo.  
3 Developing a drug-based approach to treat fibrotic cataract: 
from bench to bedside 
Given the rapid and extensive progress in growth factor signalling pathways underlying fibrotic 
forms of cataract, the development of a non-invasive, drug-based alternative to cataract surgery 
and laser capsulotomy is promising. Currently, the primary focus is on developing a drug to 
prevent PCO following cataract surgery with the hope of extending these findings to treating 
ASC plaques in the future. There is growing interest in the concept that partial inhibition of 
multiple targets may be more effective at treating a disease than the complete arrest of a single 
target (Csermely et al., 2005). Multi-kinase inhibitors have been found to result in stronger and 
more durable clinical outcomes compared to monotherapy in cancer patients (Mirantes et al., 
2016; Wilhelm et al., 2006). A similar approach can be applied to treating fibrotic cataract 
given the diversity of signalling pathways involved. 
There are many benefits to a multi-target drug approach. Single target drugs may activate 
inherent redundancy systems that may not respond to the same drug. Hence, blocking multiple 
signalling pathways may overcome these “back-up” systems. One would suppose that a multi-
target inhibitor might result in more side effects; however, it is believed that multi-target 
inhibitors are likely to interact with lower affinity compared to a single-target drug since it will 
bind to several different targets with equal affinity (Csermely et al., 2005). One such example 
is memantine, a multi-target non-competitive NMDA receptor antagonist used to treat 
Alzheimer’s disease, that binds with low affinity but has a reduced range of side effects 
compared to the high-affinity, single-target drugs (Rogawski, 2000). In the context of treating 
lens fibrosis, Boswell et al. (2017) showed that rebastinib, a drug that targets multiple kinases 
in the p38 signalling pathway, blocked TGFβ-induced EMT in embryonic chick LECs 
(Boswell et al., 2017). Thus, there are good prospects for the development of a multi-target 
drug to treat fibrotic cataract and future studies should be directed towards developing a drug 
that targets multiple kinases in the TGFβ-signalling pathway. 
Should such a drug be developed, what would be the best possible mode of delivery in clinical 
practice? To combat PCO, the drug could be either administered as an eye-drop, injected into 
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the anterior chamber, incorporated into the viscoelastic solution or irrigating solution used 
during cataract surgery, or even loaded onto the intraocular lens implant with a sustained slow-
release mechanism (Wormstone et al., 2009). Given the findings in this thesis showing that 
EGFR inhibition blocks TGFβ-induced EMT, it is promising to discover that Wertheimer et 
al., (2018) showed that intraocular lenses soaked in Erlotinib, an EGFR inhibitor, blocked 
proliferation of cells in a human capsular bag organ culture model (Wertheimer et al., 2018). 
A major concern with introducing pharmacological agents during cataract surgery is the risk 
of damage to other ocular tissues, such as the corneal endothelial cells. These cells cannot 
regenerate after damage, and a significant reduction in corneal endothelial cell number may 
result in corneal oedema and subsequent visual impairment (Rosado-Adames and Afshari, 
2012). In this context, Erlotinib did not show any toxicity to corneal endothelial cells 
(Wertheimer et al., 2018). Another important consideration is the impact of the drug on the 
trabecular meshwork, retina and optic nerve, as TGFβ-mediated myofibroblast 
transdifferentiation has been implicated in fibrosis of these other ocular tissues (Shu and 
Lovicu, 2017). 
Paediatric patients and diabetics are more at risk of developing severe PCO, and at a faster rate 
(Ebihara et al., 2006; Vasavada et al., 2011). By better understanding the unique susceptibility 
biomarkers present in such patients, a more tailored approach can be utilised to combat PCO, 
thereby maximising the anti-fibrotic efficacy of the treatment for each distinct group of 
patients. High-throughput screening of possible multi-kinase inhibitor combinations may be 
required to efficiently develop the most effective, personalised treatment for patients.  
Conclusion 
As William Shakespeare said, “In nature’s infinite book of secrets, a little I can read” and this 
thesis has, hopefully, enabled us to appreciate a few of her secrets. By unravelling the intricate 
connections between growth factor signalling pathways, we can begin to gain a clearer picture 
of how fibrotic cataracts develop. In coming years, continued advances in technology and 
dedicated research in this field will ultimately provide a more complete narrative of the signal 
transduction networks that govern lens cellular behaviour. An exciting road lies ahead in 
further discovering and assembling the complex mosaic of secrets underlying the development 
of cataract. 
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